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Patiënten met chronisch hartfalen worden vaak 
beperkt in hun dagelijkse activiteiten door kortade­
mig heid en een verminderd inspanningsvermogen. 
Een deel van deze klachten kan echter ook het gevolg 
zijn van een bijkomende longaandoening, zoals 
chronisch obstructieve longziekte (COPD). Ook 
kunnen andere longfunctiestoornissen bijdragen aan 
de beperkingen die deze groep patiënten ervaart. 
In dit proefschrift beschrijft Armine Minasian hoe 
vaak COPD en longfunctiestoornissen nu eigenlijk 
voorkomen bij patiënten met chronisch hartfalen 
waarbij ze verschillende definities van COPD en 
longfunctiestoornissen met elkaar vergelijkt. Ook 
een aantal andere belangrijke vraagstukken komen 
aan bod. Wordt de diagnose COPD wel correct 
gesteld en is het noodzakelijk om hiervoor long­
functietesten te herhalen? Wat zijn voorspellers 
van longfunctiestoornissen en heeft de gebruikte 
 definitie van deze stoornissen daarop invloed? Zijn 
patiënten met chronisch hartfalen gebaat bij het 
inhaleren van luchtwegverwijdende medicijnen? 
De auteur hoopt met dit proefschrift meer aan­
dacht te vestigen op de gelijktijdige aanwezigheid 
van zowel long­ als hartaandoeningen en pleit voor 
een meer geïntegreerde aanpak van diagnostiek 
en behandeling van COPD en hartfalen.
Armine Minasian (1983) is geboren in Armenië en 
verblijft sinds haar elfde in Nederland. Ze is sinds 
2012 in opleiding tot longarts in het Rijnstate 
 ziekenhuis te Arnhem.
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1.1 Chronic Obstructive Pulmonary Disease 
Chronic Obstructive Pulmonary Disease (COPD), a common preventable and treatable 
disease, is one of the leading causes of morbidity and mortality in adults all over the 
world resulting in a substantial socioeconomic burden.1 According to predictions of 
the World Health Organization, COPD will become the third leading cause of death, 
exceeded only by ischemic heart disease and cerebrovascular disease, and the fifth 
leading cause of disability worldwide by the year 2020.2 Estimates of COPD prevalence 
in the general population vary substantially across studies due to geographical 
variations, differences in survey methods, study population, and collection of 
spirometric data.3 Moreover, different diagnostic criteria have been applied, yielding 
varying  COPD prevalence rates.3 A systematic review and meta-analyses of studies 
carried out in 28 countries between 1990 and 2004 reported a pooled prevalence of 
“patient-reported and physician diagnosed COPD” of ~ 5%, reflecting the widespread 
underrecognition and underdiagnosis of COPD.3 The pooled prevalence from 26 
“spirometric estimates” was ~ 9%, with the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) being the most common spirometric definition used.3 
Prevalence rates were higher in elderly (≥ 40 years), smokers, males, and urban 
residents.3 The Burden of Obstructive Lung Disease (BOLD) study, including 9425 
participants ≥ 40 years old from 12 sites worldwide, has documented higher COPD 
prevalence rates (11 – 26%) and more advanced staging of “spirometrically confirmed 
COPD” (GOLD criteria) than previously reported (GOLD stage  ≥ II = overall 10%).4 
Using the lower limit of normal (LLN) to define COPD, however, resulted in lower 
prevalence rates of COPD (~ 8-19%) than the GOLD criteria.5 Globally, the burden 
and mortality of COPD is projected to increase in coming decades because of 
continued exposure to COPD risk factors, ageing of the population, and a decrease 
of mortality due to other diseases like cardiovascular disease in industrialized 
countries and infectious disease in developing countries.6, 7 
COPD is a heterogeneous disease process that varies greatly from person to person 
with respect to lung pathology, natural history of disease, and co-morbidity.6 It is 
characterized by persistent airflow limitation that is usually progressive and associated 
with an enhanced chronic inflammatory response in the airways and the lung to 
cumulative exposures over decades to noxious particles or gases.1 Tobacco smoking 
is the main risk factor for the development of COPD. However, other factors, such as 
genetic factors, exposure to indoor and outdoor air pollution, occupational hazards, 
infections, and chronic asthma are also important.6, 8 The inflammatory process 
results in hypersecretion of mucus, structural changes and narrowing of the small 
airways (chronic obstructive bronchiolitis), and enlargement of air spaces, destruction 
of lung parenchyma, loss of elasticity, and closure of small airways (emphysema).1, 9 
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The characteristic symptoms of COPD are chronic and progressive dyspnea, cough, 
and sputum production that can be variable from day-to-day. Additional symptoms 
may include wheezing, chest tightness, fatigue, weight loss, anorexia, and symptoms 
of depression/anxiety and cor pulmonale.1 With increasing severity of disease, 
patients experience acute exacerbations of COPD, characterized by acute worsening 
of respiratory symptoms that is beyond normal day-to-day variations and requires 
change in medication.1 Exacerbations can be precipitated by several factors, 
including respiratory tract infections (viral or bacterial), exposure to pollutants, and 
interruption of maintenance therapy. However, the cause of about one-third of severe 
COPD exacerbation cannot be identified.1 Importantly, exacerbations can negatively 
affect a patient’s quality of life, accelerate the rate of lung function decline, and are 
associated with significant mortality and high socioeconomic costs. One of the 
treatment goals of COPD is therefore to reduce the frequency and severity of 
exacerbations.1
Spirometry is required for the diagnosis of COPD by measuring persistent airflow 
limitation. However, there is no consensus on how to define airflow limitation.10-20 
This is further elaborated in subsection 1.5 of the introduction of this thesis.
 
It is increasingly recognized that COPD is a complex multi-component disease that 
extends beyond the lungs. Many patients have systemic manifestations and 
co-morbidities that can further impair functional capacity and health-related quality 
of life and can increase the risk of hospitalization, mortality, and costs.21, 22 Indeed, 
patients with COPD more frequently die from other causes than COPD,23 with 
cardiovascular disease and lung cancer being the commonest causes of death,24-27 
especially in those with mild to moderate COPD.28 Moreover, co-morbidities may 
interfere with COPD management.1 Co-morbidities and extra-pulmonary effects of 
COPD include cardiovascular disease, skeletal muscle dysfunction, cachexia, pulmonary 
hypertension, metabolic syndrome, lung cancer, osteoporosis, depression, anemia, 
and obstructive sleep apnea.21 Co-morbidities are more commonly seen in association 
with severe COPD, but they may also be associated with milder disease.22 Although 
the mechanism linking COPD to systemic manifestations and co-morbidities is not yet 
certain, it is though that systemic inflammation is crucial in the pathogenesis.21, 22, 29, 30 
Other possible mechanisms include shared genetic predispositions, cigarette 
smoking, accelerated ageing, physical inactivity, and chronic hypoxia.21, 22  
The cornerstone of COPD treatment is smoking cessation which has the greatest 
capacity to influence the natural history of COPD.31 Other non-pharmacological 
therapeutic options are rehabilitation, nutritional advice, oxygen therapy, ventilatory 
support, lung volume reduction therapies such as bullectomy and valve placement, 
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lung transplantation, and palliative care. Pharmacological treatment of COPD 
includes bronchodilators, corticosteroids, phosfodiesterase-4 inhibitors, vaccines, 
alpha-1 antitrypsin augmentation therapy, antibiotics, mucolytic and antioxidant 
agents, antitussives, and narcotics (morphine).1 
1.2 Heart failure
Heart failure (HF) is defined according to the European Society of Cardiology (ESC) 
guidelines32 as a clinical syndrome in which patients have typical symptoms and 
signs resulting from an abnormality of cardiac structure or function. HF often results 
in diminished quality of life, declining functional capacity, episodes of decompensation 
leading to hospital admission, and premature death, usually due to pump failure or a 
ventricular arrhythmia.32, 33 Typical symptoms of HF include breathlessness, 
orthopnea, paroxysmal nocturnal dyspnea, reduced exercise tolerance, ankle 
swelling, and fatigue. Less typical symptoms are nocturnal cough, wheezing, weight 
gain or loss, bloated feeling, loss of appetite, confusion, depression, palpitations, 
and syncope.32 There is a poor relationship between symptoms and the severity of 
cardiac dysfunction. Symptoms do relate more closely to prognosis if persistent after 
therapy and can be used to classify the severity of HF (New York Heart Association 
(NYHA) class) and to monitor the effects of therapy.32 Signs of HF may include 
elevated jugular venous pressure, hepatojugular reflux, third heart sound, laterally 
displaced apex beat, cardiac murmur, peripheral edema, pulmonary crackles, 
reduced air entry and dullness to percussion at lung bases, tachycardia, irregular 
pulse, tachypnea, hepatomegaly, ascites, and cachexia.32 Many of the symptoms 
and signs of HF are not specific and, therefore, of limited diagnostic value. 
Demonstration of an underlying cardiac cause for these symptoms and signs by 
obtaining objective evidence of a structural or functional cardiac abnormality is 
therefore central to the diagnosis of HF.32 This is usually myocardial disease causing 
systolic ventricular dysfunction. However, abnormalities of ventricular diastolic 
function or of the valves, pericardium, endocardium, heart rhythm, and conduction 
can also cause HF and more than one abnormality can be present.32 
Approximately 1–2% of the adult population in developed countries has HF, with the 
prevalence rising to ≥ 10% among persons 70 years of age or older, while persons 
younger than 50 years are hardly ever found to have HF.32, 33 The life time risk of 
developing HF is approximately 20% for all individuals older than 40 years.34 The 
number of patients with HF is predicted to increase due to the ageing of the population, 
improvements in the treatment of acute coronary syndromes, and a longer survival of 
patients with HF.33 
14
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Two types of HF related to the measured ejection fraction (EF) have been recognized, 
i.e. HF with a reduced EF (HF-REF), or ‘systolic HF’, and HF with a preserved EF 
(HF-PEF), or ‘diastolic HF’.32 Approximately half of patients with HF have preserved 
EF.35, 36 Whether HF-PEF and HF-REF are two distinct entities or two ends of a 
common spectrum remains a matter of debate.36, 37 Amongst many causes of HF-REF, 
coronary artery disease is the cause of approximately two-thirds of cases of HF-REF.32 
Patients with HF-PEF, on the contrary, are less likely to have coronary heart disease 
and more likely to have hypertension and atrial fibrillation (AF).35, 38, 39 Moreover, 
patients with HF-PEF are older, more often female and obese, and seem to have a 
better prognosis than those with HF-REF,33, 35, 39  although not all studies could confirm 
this latter finding.38, 40, 41 Also, the diagnosis of HF-PEF is more challenging than the 
diagnosis of HF-REF, because it is largely one of exclusion; potential non-cardiac 
causes of the patient’s symptoms, such as anemia or chronic lung disease, must first 
be discounted.32 Moreover, there is no universally agreed upon definition to diagnose 
HF-PEF.41 The left ventricular EF (LVEF) is normal or only mildly reduced in HF-PEF.32 
A cutoff point of 50% LVEF was used in the consensus statement on the diagnosis of 
HF with normal LVEF by the HF and echocardiography associations of the ESC.42 
Patients with a LVEF in the range 35–50% represent a ‘grey area’ and most probably 
have primarily mild systolic dysfunction.32 Usually, patients with HF-PEF do not have 
a dilated heart and many have an increase in LV wall thickness and increased left 
atrial size. Most have evidence of diastolic dysfunction, which is generally accepted 
as the likely cause of HF in these patients.32 Diastolic LV dysfunction, however, is not 
unique to patients with HF-PEF, but also occurs in patients with HF-REF, in whom it 
even correlates better to symptoms than LVEF.42  
It is important to identify the underlying cardiac problem, as the precise pathology 
determines the specific treatment used.32 The goals of treatment are to relieve 
symptoms and signs, prevent hospital admission, and improve survival.32 Although 
several pharmacological treatment options exist for patients with chronic HF-REF, 
such as diuretics, angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin 
receptor blockers (ARBs) in case of intolerance, beta-blockers, and mineralocorti-
coid/aldosterone receptor antagonists, no effective treatment has been identified in 
patients with HF-PEF in order to reduce morbidity and mortality.32, 36, 43 Diuretics are 
used to relieve symptoms and signs in patients with HF-PEF. Also, adequate treatment 
of hypertension, myocardial ischemia, and AF is considered to be important for 
which calcium-channel blockers may be used, contrary to patients with HF-REF, in 
whom their negative inotropic action can be dangerous.32 Other treatment modalities 
for HF are described elsewhere in detail,32  including treatment of acute HF/
cardiogenic shock, exercise training, implantable cardioverter-defibrillator, cardiac 
resynchronization therapy, treatment of arrhythmia or severe bradycardia/conduction 
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disturbances, coronary revascularization, surgery (valve surgery, ventricular assist 
devices, transplantation), and palliative care. Finally, management of co-morbidities 
such as COPD is important, as they may influence treatment and prognosis of HF.44, 45 
1.3 COPD in HF and vice versa
COPD and HF are both common diseases with significant morbidity, mortality, and 
health care use.44, 45 Moreover, COPD and HF seem to coexist more frequently than 
expected from their separate population prevalences.46 Several factors might explain 
the high coexistence of these two diseases, including sharing of environmental 
(mainly smoking) or genetic risk factors, advanced age, systemic inflammation,45, 47-53 
and a relationship between a reduction in pulmonary and heart function.54-58 Also, 
COPD patients are at an increased risk of co-morbidities, such as metabolic syndrome, 
which in turn are an important risk for cardiovascular disease.59 Furthermore, factors 
that increase stress on the cardiovascular system or precipitate arrhythmic events 
can also explain the association between COPD and cardiovascular disease, 
including hypoxemia, hyperinflation, hyperventilation, neurohumoral disturbances, 
increased work of breathing and oxygen consumption, pulmonary hypertension, and 
the use of pulmonary medication.48, 53, 60-65 Finally, other factors, such as oxidative 
stress, endothelial dysfunction, arterial stiffness, hypercoagulable state, and 
connective tissue degradation have also been suggested to play a role.48, 60, 62, 66 
The combination of both diseases presents many diagnostic and therapeutic challenges 
as well as adverse prognostic implications.44-47, 67-75 Several difficulties in diagnosing 
COPD in patients with HF and vice versa have been put forward, all of which may lead 
to misdiagnosis or delay in the diagnosis. These include the overlap in symptoms, 
signs, and risk factors, misinterpretation of radiological evidence of HF due to chest 
hyperinflation and pulmonary vascular remodeling, poor acoustic windows of 
transthoracic echocardiography due to air trapping, lower diagnostic accuracy of 
B-type natriuretic peptide (BNP) in stable patients with COPD and chronic HF (CHF), 
even more challenging diagnosis of HF-PEF in patients with COPD, the underuse of 
spirometry, and difficulties with interpreting spirometry results, especially in patients 
with decompensated HF, who may have both restrictive and obstructive ventilatory 
defects.44, 72, 76, 77 
Therapeutic challenges have been stressed as well. COPD may interfere with 
treatment and clinical course of HF and oppositely. Especially the opposite pharma-
cological effects of beta-blockers for HF and beta-agonists for COPD have been a 
reason for concern leading to underuse of beta-blockers.78-81 Although cardioselective 
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beta1-blockers are considered to be safe,82-85 even during hospitalization for COPD,86 
and therefore should not be withheld from patients with COPD and coexisting 
cardiovascular diseases, the safety profile of non-selective beta-blockers is not as 
well-established.82, 85-97 In addition, the cardiovascular safety of beta2-agonists is 
disputable.82 Beta2-agonists have been reported to increase the risk of adverse 
cardiovascular events in patients with obstructive airway disease,98 with a significant 
increase in sinus tachycardia and a non-significant trend toward an increase in major 
cardiovascular events, including ventricular tachycardia, AF, syncope, congestive 
HF, myocardial infarction, cardiac arrest, and sudden death.99 On the other hand, a 
pooled analysis of cardiovascular safety data including 17 randomized clinical trials 
did not find an increased risk of cardiovascular adverse events as well as deaths 
comparing salmeterol treatment to placebo in patients with COPD.100 Similar findings 
were reported when patients were stratified for age of > 65 years or the presence of 
known cardiovascular disease.100 Similarly, cardiovascular mortality and cardio-
vascular related adverse events were not greater in the salmeterol (+/- fluticasone) 
group compared to placebo in more than 6000 patients with COPD in the TORCH 
trial.25, 101 Observational studies have shown worse outcomes with bronchodilator use 
in patients with HF, including increased risk of HF hospitalization, increased mortality 
rates, in-hospital mechanical ventilation, intravenous vasodilator use, and major 
cardiovascular events associated with the use of beta-agonists,82, 102-104 although not 
all could confirm these findings.105 Possible mechanisms for adverse cardiovascular 
outcomes are arrythmogenesis, ischemia, hypoxemia, inflammation, cardiac remodeling, 
QTc prolongation, metabolic alterations (hypokalemia), and/or attenuation of beta- 
blocker benefits.82, 98, 103 In addition, hepatic metabolism of beta2-agonists may be 
diminished in patients with HF, leading to prolonged plasma half-life and accumulation 
with repeated doses.106 
Inhaled anticholinergics have also been reported to be associated with adverse 
cardiovascular effects among patients with COPD, including an increased risk of 
cardio vascular death, myocardial infarction, or stroke,107-116 although recently reassuring 
cardiovascular safety data have been reported on the long-acting anticholinergic 
bronchodilator tiotropium HandiHaler110, 115, 117-123 as well as Respimat.124 However, HF 
patients are usually excluded from clinical trials and the impact of bronchodilators on 
outcomes has never been prospectively evaluated in patients with HF.103 Furthermore, 
methodological limitations of most studies require further investigation of reported 
adverse events.82, 103 Until then, bronchodilators, in particular beta-agonists, must be 
used with caution in patients with underlying cardiac condition such as HF, given the 
paucity of data in such patients. 
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Similarly, other medications prescribed for one disease may have detrimental effects 
on the other. High dosages of diuretics can cause metabolic alkalosis which may 
blunt the respiratory drive of COPD patients, causing hypoventilation with subsequent 
worsening of hypercapnia.75 Moreover, in HF patients with diuretic medication the 
potassium lowering effect of additive administration of beta2-agonists has to be 
considered, as it can provoke arrhythmias.51 Digitalis can cause pulmonary vasocon-
striction, reduced venous return and cardiac output, and cardiac arrhythmias due to 
hypoxia and acidosis in patients with COPD.75 Also, it has the potential to increase 
airway obstruction.68 ACE-I are associated with side-effects such as cough, although 
according to the review of Packard et. al125 patients with asthma or COPD were not at 
an increased risk of developing cough and bronchoconstriction as a result of therapy 
with ACE-I. Theofylline can predispose to tachyarrhythmias even in the absence of 
elevated serum drug levels.126 Finally, oral corticosteroids cause sodium and water 
retention, potentially leading to worsening of HF, but this is not believed to be a 
problem with inhaled corticosteroids.32, 127 Moreover, systemic corticosteroids, unlike 
inhaled corticosteroids, have been associated with the development of atrial 
fibrillation and ventricular arrhythmias,126, 128 possibly due to local potassium efflux, 
mineralocorticosteroid effect leading to hypertension, development of late potentials, 
vasodilation, and possible anaphylaxis.129 
On the other hand, cardiovascular drugs, including statins and ACE-I/ARBs, could 
have beneficial effects in patients with COPD;130-135 statins due to their anti-inflammatory, 
anti-oxidative, and immunomodulatory pleiotropic effects,131, 132, 136-140 as well as their 
potential to inhibit smoke-induced airway epithelial injury,141 and ACE-I/ARBs due to 
their anti-inflammatory and vasodilator effects as well as their effects on alveolar 
epithelial cell apoptosis and lung fibroblast growth.131, 140 However, a recent large 
multicenter randomized controlled trial (RCT) of 885 moderate to severe COPD 
patients at high risk for exacerbations and without an indication for statin use did not 
show beneficial effects of daily treatment with 40 mg simvastatin during 12-36 months 
versus placebo on exacerbation rate, time to the first exacerbation, or the severity of 
exacerbations.142 Simvastatin also had no effect on lung function, general or disease 
specific quality of life, serious adverse events, or the number of deaths.142 The 
underuse of statins in persons with cardiac risk factors who have been included in 
prior retrospective studies may account in part for the differences in findings. 
Beta-blockers could theoretically exert beneficial effects in patients with COPD by 
tempering the sympathetic nervous system or by reducing the ischemic burden.65, 131 
Moreover, chronic use of beta-blockers may decrease airway hyperresponsiveness 
and inflammation as suggested by animal data and a small pilot study in humans.131 
Recently, long-term treatment with beta-blockers has been shown to reduce the risk 
of exacerbations and improve survival in patients with COPD, even in the absence of 
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overt cardiovascular disease, possibly as a result of dual cardiopulmonary protective 
properties.143, 144 Furthermore, thrombocytosis is associated with increased short- 
and long-term mortality after exacerbation of COPD and antiplatelet therapy may 
have a protective role by lowering 1-year mortality after COPD exacerbation.145, 146 
Similarly, bronchodilation may have positive effects on cardiovascular function by 
alleviating dynamic hyperinflation,147 which reduces intrathoracic pressure, thus 
improving venous return and cardiac output, and lessens the effort of breathing by 
unloading respiratory muscles.148 Finally, corticosteroids may play a role in improving 
cardiovascular outcomes in COPD due to their anti-inflammatory properties,149-153 
although a recent systematic review and meta-analysis of 23 RCTs did not show 
significant association between the use of inhaled corticosteroids with the reduction 
in risk of myocardial infarction, cardiovascular death, or mortality.154 In the observational 
studies, on the other hand, inhaled corticosteroids were associated with a significant 
reduction in cardiovascular death and mortality, most probably due to methodological 
issues.154  
Patients with concurrent COPD and CHF may benefit from higher levels of positive 
end-expiratory pressure (PEEP) when managed with supported invasive mechanical 
ventilation. On the other hand, PEEP levels of 10 cm H2O or greater should be used 
cautiously in patients with COPD alone, since this can lead to increased dead space 
ventilation and work of breathing and as a consequence a decrease in minute alveolar 
ventilation and increased PaCO2 levels.
155  
The prognosis of coexistent COPD and HF is poorer than that in either disease alone. 
COPD is an independent predictor of death and HF hospitalization in patients with 
HF,44, 88, 156-168 although not all studies could confirm this.169-172 A recent study found 
COPD to be associated with increased risk of HF hospi talization and major adverse 
cardiovascular events, but not with 24 months survival in ambulatory HF patients.173 
Similarly, after adjustment for prognostic risk factors, beta-blocker use, and 
randomized treatment (ivabradine/placebo), coexistent COPD was associated with 
all-cause hospitalization and hospitalization for worsening HF, but not with all-cause 
or cardiovascular mortality in ambulatory patients with stable systolic HF in another 
study.174 Higher GOLD stage is a predictor of worse prognosis.175 Long-term prognosis 
of patients with coexistent HF and COPD is similar in patients with HF-REF compared 
to those with HF-PEF,175 although mortality risk has been shown to be higher in 
patients with HF-PEF in another study.160 Furthermore, having COPD is associated 
with decreased functional capacity as measured by the 6-minute walking test176 and 
cardiopulmonary exercise testing.177 Similarly, concurrent HF is an independent 
predictor of mortality in patients with both stable and exacerbated COPD.178-182 
Furthermore, congestive HF has been found to be associated with a higher risk for 
19
Introduction and outline of this thesis
1
COPD related emergency department visit,183 hospitalization,183 and worse self-rated 
health.184 Finally, healthcare utilization and costs for concomitant COPD and HF are 
greater than that in patients with either condition alone.80, 185, 186 
Despite the close relationship between lung and heart diseases, pulmonologists and 
cardiologists often focus on their own field of specialization.70 Meanwhile, HF and 
COPD often remain an ignored combination73 and the degree of awareness is low 
among both cardiologists as well as pulmonologists.170 In view of diagnostic, 
therapeutic, and prognostic implications of the coexistence of COPD and HF, more 
attention should be paid to the concomitant presence of both diseases in clinical 
practice and research.73 Moreover, knowledge about the concomitant prevalence 
facilitates the decision on additional testing in daily practice.46 Although the occurrence 
of HF in patients with COPD has been assessed extensively in prior research, the 
occurrence of COPD in patients with HF has received much less attention.46 
The prevalence of unrecognized HF has been reported to be 21% in both stable 
COPD patients from a general practice (54% systolic, 46% isolated diastolic, 0% 
right-sided HF),187 as well as patients with a history of COPD or asthma presenting to 
the emergency department with acute dyspnea.188 A history of ischemic heart 
disease, a laterally displaced apex beat, a body mass index > 30 kg/m2, and a raised 
heart rate (> 90 beats/min) were independent clinical indicators of the presence of 
concomitant HF in elderly patients with stable COPD. Raised N-terminal-pro-BNP 
(> 14.75 pmol/l) and abnormalities on electrocardiography further improved the 
diagnostic accuracy.189 The prevalence of LV systolic dysfunction (LVSD, i.e. LVEF 
< 40-50%) in stable COPD patients without known coronary artery disease (CAD) 
varied between 0% and 16% (4 out of 9 studies found a prevalence of 0%).73 When 
LVSD was found, it was generally mild and mainly in patients with a history of cor 
pulmonale.46 In patients without known CAD who were experiencing COPD 
exacerbation, prevalence varied between 0% and 32%.73 In groups without exclusion 
of patients with known CAD, prevalence rates of LVSD ranged from 0% to 46%.73, 170, 190 
In another study, echocardiographic LV dysfunction was found in 51% of patients 
admitted for a severe acute exacerbation of COPD without an obvious cause, of 
which 64% was systolic, 23% diastolic, and 13% both. After discharge, an expert 
panel could confirm in 31% of the acute exacerbations a definite association with LV 
dysfunction.191 In a recent study,192 echocardiography was performed in 342 patients 
with COPD 3 months after discharge from their first hospital admission for COPD 
exacerbation. Significant cardiac alterations were present in 64% of the patients; 27% 
left- and 48% right-heart disorders. The most common were right ventricle enlargement 
(30%) and pulmonary hypertension (19%; 33% in severe disease and 7% in mild 
disease). The magnitude of pulmonary hypertension was mild in the majority of 
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patients and only 3% of patients had systolic pulmonary artery pressures close to 
out-of-proportion pulmonary hypertension in COPD. Left ventricle enlargement was 
present in 6%, LV systolic dysfunction in 13% (9% LVEF 40-50%, 4% LVEF 30-40%), 
LV diastolic impairment in 12%, and left atrial dilatation in 29%. Echocardiographic 
abnormalities were unrelated to COPD severity and they were also observed in 63% 
of patients without known cardiac disease or cardiovascular risk factors other than 
smoking, although left heart abnormalities were more frequent in patients with 
previous cardiac disease compared to those without known cardiac disease (47% 
versus 27%).192 Finally, LV diastolic dysfunction has been found to be highly prevalent 
(48-88%) in patients with COPD in other studies.193-198 Interestingly, a recent study 
found 50% of advanced COPD patients with diastolic dysfunction but without known 
risk factors for diastolic dysfunction (hypertension, diabetes, ischemic heart disease, 
and hypothyroidism) to have reversible perfusion defect on stress SPECT myocardial 
perfusion imaging that were not apparent with stress electrocardiography.195 This 
observation suggests that myocardial ischemia is a possible cause of diastolic 
dysfunction in patients with advanced COPD without risk factors for LV relaxation 
abnormalities.195 Several other mechanisms of diastolic dysfunction in COPD have 
been put forward in the literature, including co-morbidities leading to impaired 
diastolic relaxation, interventricular dependence with impaired LV filling, hypoxia, 
prolonged use of beta2-agonists, pericardial restriction due to hyperinflation,195, 199 
accelerated ageing,200 myocardial fibrosis,200 and LV hypertrophy which is present in 
30% of COPD patients, even when normotensive and normoxemic.201      
Pulmonary hypertension is a frequent complication of COPD, especially in those with 
advanced disease and hypoxemia.202 Estimates of the prevalence of pulmonary 
hypertension vary widely between 30% and 70% due to differences in definitions of 
pulmonary hypertension, study population, and methods used to determine 
pulmonary pressures.202 The true prevalence of pulmonary hypertension in patients 
with mild to moderate COPD is unknown because of the absence of large-scale 
epidemiologic studies.202 Severe pulmonary hypertension, defined as mean 
pulmonary artery pressure > 40 mmHg, is uncommon (< 5%) and is typically 
associated with less severe airflow limitation on the one hand, but more severe 
hypoxemia and diffusion impairment on the other hand.202 The pathophysiology of 
pulmonary hypertension is likely multifactorial: destruction of lung parenchyma with 
accompanying loss of vascular surface area, hypoxic vasoconstriction and 
inflammation leading to pulmonary vascular remodeling, and genetic susceptibility.202 
Finally, other co-morbid conditions, such as left-sided heart disease, may 
contribute.202 Increase in the pulmonary vascular resistance and pulmonary artery 
pressure presents an increased afterload to the right ventricle which may eventually 
lead to ventricular remodeling with hypertrophy and later dilatation of the right 
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ventricle (cor pulmonale) with subsequent dysfunction.68, 202, 203 Also, pressure 
overload of the right ventricle and hypoxemia may lead to right ventricle ischemia, 
which may further aggravate ventricular dysfunction.202, 203 Finally, decreased right 
ventricular preload due to decreased venous return associated with hyperinflation 
may contribute to right ventricular dysfunction.54, 57, 202, 204 The same is true for the LV.57, 
200, 204 On the other hand, the increase in the end-diastolic volume (preload) of the 
right ventricle due to dilatation maintains the cardiac output even as the right ventricle 
EF decreases.68 Most patients with COPD-associated pulmonary hypertension have 
preserved right ventricular contractility during stable conditions, while right ventricular 
systolic failure may be present in the acutely decompensated state.202 However, 
subclinical right ventricular dysfunction may be present in patients with mild airflow 
obstruction205 and without pulmonary hypertension,206 while right ventricular 
hypertrophy has been shown in patients with mild to moderate COPD196 and in those 
without pulmonary hypertension206 and without hypoxemia,207 suggesting that right 
ventricular morphological and functional changes could be early signs of pressure 
overload developing in the initial disease stages.208 Right ventricular dysfunction may 
ultimately lead to deterioration of LV function due to interventricular dependence.68, 202, 
203 As the two ventricles are in series, the reduced right ventricular output reduces the 
LV preload.55, 68, 202 Moreover, a dilatation of the right ventricle shifts the interventricular 
septum into the left, changing LV geometry and thereby reducing LV diastolic 
compliance and end-diastolic volume.68, 202, 203, 209 On the other hand, the increased 
right ventricular end-systolic pressure also serves to augment the LV emptying.68, 210 
Due to this complex interplay of opposite forces the LVEF is relatively preserved, even 
in advanced emphysema.68 
Estimates of COPD prevalence in patients with HF vary substantially between 9% and 
52% in earlier reports that relied on clinical data, disease codes, or self-reported 
COPD, which is a very inaccurate method for establishing the diagnosis.44 Indeed, 
relying on self-report or physician diagnosis of COPD results in approximately 
one-third to one-half of patients being labeled as having COPD who actually do not 
fulfill the GOLD criteria for COPD.77, 187, 211, 212 Although spirometry is considered to be 
the gold standard for the diagnosis of COPD, data on the prevalence of COPD based 
on spirometry in patients with HF are scarce and spirometry is widely underused, 
even in a tertiary care setting.77 Fortunately, during the past six years more spirometric 
data on the prevalence of COPD in HF has become available. Nevertheless, 
prevalence rates of COPD still vary considerably between 9% and 44%, depending 
on study design, population, and diagnostic criteria used (Table 1). Also, a great 
number of patients is either under- or overdiagnosed with COPD, although exact 
figures vary across the studies (Table 1). Since airway obstruction is a dynamic 
phenomenon in HF, as it may be present in congestive HF and may disappear with 
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Table 1   COPD prevalence, under- and overdiagnosis in patients with HF.
Author, yr Study 
type
No. Population Definition of  
HF stability
Age,
yrs
Men,
%
NYHA LVEF,
%
FS/CS, 
%
Definition  
of COPD
COPD 
prevalence,  
%
Severity of  
COPD, 
%
COPD under-/  
overdiagnosis, 
%
Beghé et al.,
2013190
P 124 Stable CHF, ≥ 50 yrs, 
≥ 10 PY
On stable 
medication  
for 3m
72 ± 7 86 I-IV 40 ± 12 100 GOLD (?) 34 GOLD I/II: 52/40
GOLD III: 8
24*
Brenner et al.,
2013157
P 619 6m after hospitalization for HF, 
LVEF ≤ 40%
- 65 ± 12 76 II-IV 42 ± 11 54 GOLD 9 NA NA /
78
Miniati et al.,
2013213
P 260 Hospitalized for systolic HF 
(LVEF < 50%), evaluation under 
stable clinical conditions shortly 
before hospital discharge
- 68 (58-75)^ 80 III/IV 
32%
32 (25-40)^ CS: 19 LLN + 
clinical 
criteria
25 GOLD I/II: 17/63
GOLD III/IV: 20
NA
Miniati et al.,
2013214
P 439 Hospitalized for systolic HF 
(LVEF < 50%), evaluation under 
stable clinical conditions shortly 
before hospital discharge
- 68 (? - ?)^ 79 NA NA NA LLN + 
clinical 
criteria
27 NA NA
Boschetto et al., 
2013169
P 118 Stable systolic/diastolic CHF  
(< 3m), first outpatient visit,  
≥ 65 yrs, ≥ 10 PY
NA 73 ± 7 86 I-IV 40 ± 11 100 GOLD
LLN
31
29
GOLD I/II: 56/39
GOLD III: 6
64** /
NA
Steinacher et al., 
2012215
P 89 Stable CHF outpatients  
(HF-REF 97%/HF-PEF 3%)
On stable 
diuretic therapy, 
without signs of 
fluid overload, 
acute HF, or 
decompensation 
as worsening 
clinical condition 
67 (59-76)^ 72 I-III 35 (25-40)^ 55 GOLD
LLN
44
25
GOLD I: 32 (LLN), 
77 (LLN -, GOLD+)
68*** /
6***
Arnaudis et al.,
2012159
R 348 Hospitalized for HF,  
LVEF ≤ 45%, spirometry  
< 1w after discharge
- 57 ± 15
(COPD -)
65 ± 11
(COPD +)
76 I-IV 30 ± 10
(COPD -)
33 ± 12
(COPD +) 
68 GOLD 38 GOLD I/II: 52/38
GOLD III/IV: 8/3
81† /
4†
Macchia et al.,
2012170
P 201 Stable CHF outpatients,  
LVEF ≤ 40%, ≥ 60 yrs
NA 75 ± 16 69 NA 32 ± 9 60 GOLD 37 GOLD I/II: 17/48
GOLD III/IV: 33/1
NA
Apostolovic et al., 
2011176
P 174 Stable CHF outpatients  
without known COPD,   
LVEF < 45%, ≥ 65 yrs
No new  
symptoms, no 
change in regular 
therapy, and not 
seeking medical 
help < 2w
73 ± 5
(COPD -)
76 ± 6
(COPD +)
72 I-III 41 ± 10
(COPD -)
38 ± 9
(COPD +)
44 GOLD 28 NA 28 /
NA
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treatment of HF,157 a careful timing and interpretation of pulmonary function tests 
(PFTs) is required to avoid misdiagnosis and inappropriate treatment of COPD.44 
Ideally, PFTs should be used under stable conditions when clinically euvolemic to 
establish a valid diagnosis of COPD. However, data on the need of serial pulmonary 
function measurements to confirm persistent airway obstruction and thus COPD are 
lacking in patients with stable non-congested CHF. It remains therefore unknown 
whether a confirmatory spirometry is necessary for the correct diagnosis of COPD in 
patients with stable non-congested CHF. 
1.4 Pulmonary function impairment in HF
Isolated or combined pulmonary function abnormalities, such as restriction, diffusion 
impairment, and to a lesser extent airway obstruction are common in patients with 
CHF216-223 (Table 2) and can contribute to the perception of dyspnea224 and exercise 
intolerance.224-230 There are only few studies of pulmonary function in patients with 
acute decompensated HF, most likely due to the difficulty involved in studying these 
patients.217 Available data indicates that this group of patients may exhibit obstructive 
and restrictive pulmonary abnormalities, and to a lesser extent diffusion impairment.221-
223, 231 (Table 3) Other abnormalities may also be encountered in patients with HF, 
Table 1   Continued.
Author, yr Study 
type
No. Population Definition of  
HF stability
Age,
yrs
Men,
%
NYHA LVEF,
%
FS/CS, 
%
Definition  
of COPD
COPD 
prevalence,  
%
Severity of  
COPD, 
%
COPD under-/  
overdiagnosis, 
%
Iversen et al.,
2008211
P 527 Hospitalized HF patients, 
HF-REF (59%)/HF-PEF (41%), 
spirometry 24-72h after 
admission
- 72 (71-73)# 64 III-IV 39 (38-40) # 70 GOLD 
≥ 2
35
Diastolic HF: 
41 Systolic 
HF: 31
GOLD II: 51
GOLD III/IV: 39/10
25 /
33
Mascarenhas et al., 
2008166
R 186 Stable HF outpatients,  
LVEF < 45%
NA 67 ± 12 70 I-III NA 49 GOLD 39 GOLD I/II: 26/51
GOLD III/IV: 19/4
NA
Data are presented as mean ± standard deviation (SD) and percentages unless stated otherwise. Underdiagnosis: 
proportion of patients without a history of COPD who had airflow obstruction using spirometry during the study. 
Overdiagnosis: proportion of patients with a history of COPD which was not confirmed by spirometry during the study. 
Abbreviations: CHF, chronic heart failure; COPD, chronic obstructive pulmonary disease; CS, current smokers; FS; 
former smokers; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HF, heart failure; HF-PEF, heart failure 
with preserved ejection function; HF-REF, heart failure with reduced ejection fraction; LLN, lower limit of normal; LVEF; 
left ventricular ejection fraction; m, months; NA, not available; No., number of patients; NYHA, New York Heart Association; 
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such as ventilation-perfusion-mismatch,220, 224, 232 reduced lung compliance,221, 224, 233 
respiratory muscle weakness,228, 234-239 bronchial hyperresponsiveness 223, 240-243 hyper-
ventilation at rest and with exercise and expiratory flow limitation (mainly in supine 
position),216, 219, 237, 244-248 but lie outside the scope of this thesis. 
Reported prevalence rates of pulmonary function abnormalities in patients with CHF 
vary substantially between 41% and 93% for diffusion impairment, 21-55% for 
restriction, and 14-60% for airway obstruction (Table 2). Corresponding figures are 
35%, 17-46%, and 19-61%, respectively, in patients with acute (decompensation of) 
HF and those hospitalized for HF (Table 3).These varying rates across the studies 
can be partly explained by the usually small number of patients included and 
differences in study population as well as diagnostic criteria used to define pulmonary 
function abnormalities. The majority of studies have used conventional cutoff values 
to define an abnormality, failing to diagnose pulmonary function impairment 
according to internationally accepted diagnostic criteria.249 Moreover, some studies 
described a restrictive lung function defect on the basis of reduced forced expiratory 
volume in 1 second (FEV1) and forced vital capacity (FVC) with normal FEV1/FVC 
ratio.250 However, because FEV1 and FVC may also be proportionately reduced with a 
normal ratio in patients with severe COPD and gas trapping, the diagnosis of 
restriction additionally requires detection of reduced total lung capacity (TLC) by 
Table 1   Continued.
Author, yr Study 
type
No. Population Definition of  
HF stability
Age,
yrs
Men,
%
NYHA LVEF,
%
FS/CS, 
%
Definition  
of COPD
COPD 
prevalence,  
%
Severity of  
COPD, 
%
COPD under-/  
overdiagnosis, 
%
Iversen et al.,
2008211
P 527 Hospitalized HF patients, 
HF-REF (59%)/HF-PEF (41%), 
spirometry 24-72h after 
admission
- 72 (71-73)# 64 III-IV 39 (38-40) # 70 GOLD 
≥ 2
35
Diastolic HF: 
41 Systolic 
HF: 31
GOLD II: 51
GOLD III/IV: 39/10
25 /
33
Mascarenhas et al., 
2008166
R 186 Stable HF outpatients,  
LVEF < 45%
NA 67 ± 12 70 I-III NA 49 GOLD 39 GOLD I/II: 26/51
GOLD III/IV: 19/4
NA
P, prospective; PY, pack-years; R, retrospective; w, weeks; yr(s), year(s). # Mean (95% confidence interval). ^ Median 
(interquartile range). * 10 of 40 (24%) patients with both CHF and COPD were aware of airflow limitation and were properly 
treated. ** 23 of 36 (64%) patients with GOLD-COPD were unaware of having any pulmonary disease. *** Among 
patients with irreversible airway obstruction according to the LLN criteria, 68% did not report a history of COPD. Among 
patients without irreversible airway obstruction according to LLN criteria, 6% had a previous diagnosis of COPD. † 81% of 
patients with GOLD-COPD did not have a history of COPD. 4% of patients without GOLD-COPD did have a history of 
COPD.
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plethysmography. Finally, a large number of studies have included (potential) heart 
transplant recipients, who represent one extreme of the HF spectrum.250-256 Therefore, 
it is less known to what extent CHF patients who do not belong to the most severe 
category of HF have pulmonary function abnormalities and which of these abnormalities 
prevail.
Several factors have been implied to play a role in the etiology of pulmonary function 
impairment in patients with HF, including the effects of HF itself on pulmonary function 
in addition to (previously undiagnosed) underlying pulmonary disease and 
confounding influences such as smoking, coronary artery bypass grafting (CABG), 
and obesity.216-223, 232, 257 
Diffusion impairment has been thought to be related to the thickening of alveolar- 
capillary membrane due to hydrostatic mechanical injury, interstitial edema, 
remodeling, and fibrosis.216-218, 221 Pressure or volume overload of the lung micro-
circulation in HF causes structural adaptations of the alveolar-capillary membrane.217, 
218 In acute HF, hydrostatic mechanical injury can cause breaks and discontinuities in 
the endothelial and epithelial layers of the blood-gas barrier, the so-called alveolar- 
capillary stress failure,258 and impair the cellular pathways involved in fluid filtration 
and reabsorption.217, 218 This process, which is generally reversible, leads to resistance 
to gas transfer.217, 218 In CHF, in which sustained neurohormonal activation has a 
significant pathophysiological role, a remodeling process may take place that is 
characterized by fixed extracellular matrix collagen proliferation. These changes may 
be protective against edema development on the one hand and may impair diffusing 
capacity on the other hand.217, 218, 232 Importantly, the damage caused to the alveolar- 
capillary membrane in CHF has been suggested to be permanent and may explain 
why heart transplantation does not affect (or may even worsen) pulmonary diffusing 
capacity despite an improvement in hemodynamic status and lung volumes.251-255, 
259-266 Also, although ultrafiltration reduces lung fluid content, it does not improve 
diffusing capacity in CHF.267 In addition, although cardiac resynchronization therapy 
increases static and dynamic lung volumes, diffusing capacity for carbon monoxide 
remains unchanged.268 Furthermore, a relationship has been established between 
the time course of HF and extent of gas transfer alterations, suggesting that 
reversibility of diffusion impairment might depend on the disease time course.260 
However, infusion of saline in patients with CHF is associated with a reduction in 
diffusing capacity,269-272 suggesting that abnormal pulmonary diffusion in CHF has a 
variable component that could be amenable to therapeutic intervention. Indeed, 
several pharmacological interventions were found to increase diffusing capacity, 
including spironolactone,273 ACE-I enalapril,269, 274-277 and type 5 phosphodiesterase 
inhibitor sildenafil,278 while hydralazine-isosorbide dinitrate,274, 277 ARB losartan,269, 276 
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and  non-selective beta-blocker carvedilol279 did not affect diffusing capacity. 
Furthermore, aerobic exercise training may also favorably affect gas exchange.280 
Little is known about the effects of other diuretics than spironolactone on diffusing 
capacity. Treatment for congestive HF did not result in improvement in diffusing 
capacity in two small studies.281, 282 On the other hand, diffusing capacity did increase 
after 1 year of treatment with diuretics and ACE-I/ARBs in 20 patients with newly 
diagnosed congestive HF.283 However, 87% of the patients were already taking 
diuretics prior to the study and therefore the improvement in diffusing capacity may 
be related to the addition of ACE-I rather than the effect of diuretics. 
Other possible causes of diffusion impairment in HF include reduced lung and pulmonary 
capillary blood volumes, ventilation-perfusion mismatch, recurrent pulmonary emboli, 
smoking, and cardiopulmonary bypass.220-222, 257 
Restriction has been linked to cardiomegaly, pleural effusion, respiratory muscle 
weakness, CABG, fibrosis from chronic congestion, and reduced lung compliance 
due to chronic vascular engorgement, interstitial/alveolar fluid accumulation, and 
chronic remodeling of the pulmonary vasculature due to elevated left atrial pressure.217, 
221, 257, 284-286 This restrictive dysfunction generally improves after treatment of HF either 
by drug therapy,242, 281, 287 ultrafiltration,267, 288, 289 or following cardiac transplantation,252, 
255, 261, 264, 290 most likely due to the reduction in lung water and cardiac size. However, 
other studies could not demonstrate significant improvement in lung volumes after 
pharmacological treatment for HF231, 283 or following cardiac transplantation.254, 291 
Airway obstruction in HF has been attributed to alveolar fluid accumulation, bronchial 
mucosal swelling, peribronchial edema and fibrosis, squamous metaplasia of 
bronchial epithelial cells induces by transforming growth factor-ß from the failing 
heart, geometric decrease in airway size from reduction in lung volume, abnormalities 
of autonomic control, neurohumoral bronchoconstriction, bronchial hyperrespon-
siveness, and smoking.220-223, 257, 292 Airway obstruction generally improves following 
treatment for HF,231, 287, 293 although not all studies could confirm this.242, 281 In addition, 
treatment directed at reversing airway obstruction with bronchodilators may have an 
additional role in the management of HF. There are, however, only few studies 
concerning the beneficial effects of bronchodilators in patients with HF. Improvements 
in pulmonary function,106, 293-298 dyspnea,296 and exercise performance298 have been 
reported. Some investigators have even observed an increase of mean FEV1 greater 
than 200 mL and 12% in patients with HF,293-295 especially in those with airway 
obstruction,295 LVSD,294 and during acute decompensation of HF.293 However, 
contrasting results have also been published. In the study of Witte et al.296 nebulized 
salbutamol (5 mg) and ipratropium bromide (0.5 mg) reduced peripheral airways 
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Table 2   Prevalence of pulmonary function abnormalities in patients with CHF.
Author, 
Yr
No. Population Exclusion of  
pulmonary disease
Age,
yrs
Men,
%
NYHA LVEF,
%
FS/CS, 
%
Definition Prevalence, %
O R D O R D
Khan et al.,
2000295
25 Symptomatic chronic  
CoHF, all had a history 
of repeated hospital 
admissions
Overt pulmonary disease, 
bronchial asthma, COPD 
or history of bronchodilator 
usage 
42 ± 2† 68 II-IV NA 44 ATS (1991) ATS (1991) NA 60 40 NA
Ewert et al., 
1999251
56 CHF, heart transplant 
recipients
History of smoking, 
pulmonary interstitial 
disease on X-ray
50 ± 14 84 NA NA 0 FEV1/VC < 0.75
RV/TLC > 120%
VC < 80%
TLC < 80%
DLCO < 80%
KCO < 80%
41, 43*
43, 29*
43, 36*
27, 21*
46, 95*
59, 96*
Evans et al.,
1996240
37 Stable CHF,  LVSD, no 
change in medication 
<1m, CTR > 0.5, limited 
exercise by breathlessness 
or fatigue, none had 
radiological pulmonary 
edema
A history of asthma, 
chronic airflow limitation, 
or bronchodilator usage, 
recent respiratory infection
61 ± 8 81 II-IV NA 78 FEV1/FVC < 0.7 NA NA 30 NA NA
Bussières et al., 
1995252
14 Male patients undergoing 
cardiac transplantation and 
surviving the 1st year
Severe chronic obstructive 
lung disease or 
bronchodilator agents
47 ± 12 100 NA NA 71 FEV1/FVC < 0.7 TLC < 75% TLCOc < 75% 14 21 93
Egan et al.,
1993254
22 Cardiac transplant 
recipients, severe CoHF
NA 50
(17-60)^
95 III-IV NA 86 NA NA DCOc < 80% 
KCOc < 80% 
NA NA 41 (?) 
23
Niset et al.,
1993255
47 Severe chronic CoHF 
(heart transplant recipients) 
in a compensated state, 
receiving maximal medical 
therapy
NA 49
(17-63)^
89 III-IV 18 ± 9 74 FEV1/VC < 0.7 NA KCOc < 75% 28
21*
NA 2/3rd
Ohar et al.,
1993253
22 Cardiac transplant 
recipients, abstinence from 
tobacco products for at 
least 2m
NA 53 ± 2† 77 NA 23 ± 2† 59 FEV1/FVC < 0.7 TLC < 80% DCOc < 80% 36
27*
55
45*
73
86*
Naum et al., 
1992250
56 Chronic severe CMP 
preceding cardiac 
transplantation, clinically 
stabilized and therapeutic 
regimen optimized before 
testing
NA 49 ± 11 73 III-IV 18 ± 
10
86 FEV1/FVC < 0.7 FVC < 80% 
with
FEV1/FVC ≥ 0.7
DLCO < 80% 21** 54 64
Wright et al., 
1990256
132 Potential heart transplant 
recipients (severe chronic 
CoHF), inpatients
NA 51
(25-68)^
80 Most
III-IV
19 ± 7 83 FEV1/FVC < 0.7 TLC < 80% DCOc < 75%,
provided DCO/
VA was < 
predicted
20 33 67
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recipients, abstinence from 
tobacco products for at 
least 2m
NA 53 ± 2† 77 NA 23 ± 2† 59 FEV1/FVC < 0.7 TLC < 80% DCOc < 80% 36
27*
55
45*
73
86*
Naum et al., 
1992250
56 Chronic severe CMP 
preceding cardiac 
transplantation, clinically 
stabilized and therapeutic 
regimen optimized before 
testing
NA 49 ± 11 73 III-IV 18 ± 
10
86 FEV1/FVC < 0.7 FVC < 80% 
with
FEV1/FVC ≥ 0.7
DLCO < 80% 21** 54 64
Wright et al., 
1990256
132 Potential heart transplant 
recipients (severe chronic 
CoHF), inpatients
NA 51
(25-68)^
80 Most
III-IV
19 ± 7 83 FEV1/FVC < 0.7 TLC < 80% DCOc < 75%,
provided DCO/
VA was < 
predicted
20 33 67
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resistance and breathlessness during exercise in twelve patients with stable CHF and 
increased measures of compliance. However, spirometry was not altered significantly 
and exercise capacity did not improve with bronchodilation. Similarly, treatment with 
three weeks of salbutamol (slow-release 8 mg twice daily) did not improve exercise 
capacity or spirometric measurements in a RCT of twelve CHF patients, although 
respiratory muscle strength did increase.299 Furthermore, there were no improvements 
in symptom scores as measured with the Minnesota living with HF questionnaire and 
fatigue dyspnea index in the same study. In addition, pre-treatment with nebulized 
albuterol (2.5 mg) and ipratropium bromide (0.5 mg) had only minor effects on 
spirometric values at rest and did not influence exercise performance and visual 
analogue score for dyspnea at peak exercise in a randomized, double-blind crossover 
study of nine patients with HF.300 Furthermore, although a small but significant 
increase in maximal exercise capacity and spirometric indices was seen after 
pre-treatment with nebulized salbutamol (5 mg) and with ipratropium bromide (0.5 
mg) in a randomized double-blind study of ten patients with CHF, both bronchodila-
tors had no effect on the perception of dypnea, as measured by a visual analogue 
scale.298 Finally, significant reversibility, defined as more than 400 mL increase in 
FEV1 after inhalation of 0.2 mg fenoterol and 40 μg ipratropium, could not be 
demonstrated in 131 patients admitted with HF in a prospective substudy,211 whereas 
only four of eighteen patients with congestive HF had greater than 10% improvement 
in FEV1 after bronchodilation in another study.
281 Contrasting results across the 
studies might be attributed to the small number of patients studied and to the 
differences in study population, bronchodilators used, and definition of bronchodilator 
responsiveness (BDR). 
Table 2   Continued.
Author, 
Yr
No. Population Exclusion of  
pulmonary disease
Age,
yrs
Men,
%
NYHA LVEF,
%
FS/CS, 
%
Definition Prevalence, %
O R D O R D
Eichacker et al., 
1988304
9 Chronic CoHF, 
hemodynamically stable, 
PCWP ≥ 20 mmHg
A history of asthma 77 ± 7 NA IV 24 ± 6 56 FEV1/FVC < 
0.75
NA NA 33 NA NA
Data are presented as mean ± SD and percentages unless stated otherwise. Abbreviations: ATS, American Thoracic 
Society; CHF, chronic heart failure; CMP, cardiomyopathy; CoHF, congestive heart failure; COPD, chronic obstructive 
pulmonary disease; CS, current smokers; CTR, cardiothoracic ratio; D, diffusion impairment; DLCO(c), diffusing capacity 
of the lung for carbon monoxide (corrected for hemoglobin concentration); FEV1, forced expiratory volume in 1 second; 
FS; former smokers; (F)VC, (forced) vital capacity; KCO(c), transfer coefficient for carbon monoxide (corrected for 
hemoglobin concentration); LVEF; left ventricular ejection fraction; LVSD, left ventricular systolic dysfunction; m, months; 
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Besides the possible etiological factors mentioned above, it should also be 
considered that other conditions may also be related to pulmonary function 
impairment in patients with HF, such as previously undiagnosed pulmonary disease. 
In fact, COPD is frequently unrecognized in patients with HF (Table 1). A careful 
evaluation of the patient and potential treatment options is therefore necessary before 
ascribing pulmonary function impairment only to the effects of HF. 
Irrespective of the causes, pulmonary function abnormalities associated with CHF 
may explain part of the symptoms and functional disability encountered in these 
patients.224-230, 244 Moreover, pulmonary function impairment increases with the 
severity of HF,228, 229, 301 provides important prognostic information,213, 214, 302, 303 and 
may ameliorate or normalize with several treatment modalities, such as pharmaco-
logical and non-pharmacological treatment of HF and anti-obstructive therapy with 
bronchodilators as mentioned above. Pulmonary function might thus be used as a 
guide for the evaluation of patients with CHF, with respect to severity of disease, 
prognosis, and response to treatment. Therefore, it is of great importance to have 
adequate knowledge regarding the occurrence of these pulmonary function 
abnormalities in patients with HF.  
Table 2   Continued.
Author, 
Yr
No. Population Exclusion of  
pulmonary disease
Age,
yrs
Men,
%
NYHA LVEF,
%
FS/CS, 
%
Definition Prevalence, %
O R D O R D
Eichacker et al., 
1988304
9 Chronic CoHF, 
hemodynamically stable, 
PCWP ≥ 20 mmHg
A history of asthma 77 ± 7 NA IV 24 ± 6 56 FEV1/FVC < 
0.75
NA NA 33 NA NA
NA, not available; No., number of patients; NYHA, New York Heart Association; O, airway obstruction; PCWP, pulmonary 
capillary wedge pressure; R, restriction; RV, residual volume; TLC, total lung capacity; TLCO(c), transfer factor of the lung 
for carbon monoxide (corrected for hemoglobin concentration); VA, alveolar volume; yr(s), year(s). † Standard error (SE). 
^ Mean (range). * After heart transplantation. ** Isolated forced expiratory flow (FEF)25-75 reduction (FVC ≥ 80% pred., 
FEV1/FVC ≥ 0.7, FEF25-75 < 60% pred.) = 3.6%.
32
Chapter 1
Table 3   Prevalence of pulmonary function abnormalities in patients with acute  
(decompensation of) HF or hospitalization for HF.
Author, 
Yr
No. Population Exclusion of  
pulmonary disease
Age,
yrs
Men,
%
NYHA LVEF,
%
FS/CS, 
%
Definition Prevalence, %
O R D O R D
Brenner et al., 
2013157
272 Hospitalized for CoHF with 
LVEF ≤ 40%
History of bronchial asthma 66 ± 12 80 II-IV 32 ± 8 58 Post-BD FEV1/
FVC < 0.7
NA NA 19* NA NA
Miniati et al., 
2013213
260 Hospitalized for systolic HF 
(LVEF < 50%), evaluation 
under stable clinical 
conditions shortly before 
hospital discharge
Active cancer, pulmonary 
arterial hypertension
68  
(58-75)^
80 III/IV 
32%
32 
(25-
40)^
CS: 19 - FEV1/SVC >  
5th percentile, 
TLC 
< 5th percentile 
of predicted
NA - 20 NA
Miniati et al., 
2013214
439 Hospitalized for systolic HF 
(LVEF < 50%), evaluation 
under stable clinical 
conditions shortly before 
hospital discharge
Active cancer 68  
(? - ?)^
79 NA NA NA - FEV1/SVC >  
5th percentile, 
TLC 
< 5th percentile 
of predicted
NA - 19 NA
Boni et al.,
2005245
9 Acute left HF (inpatients), 
systolic or diastolic, 
nonobese, NS
COPD, bronchodilators, 
corticosteroids, antibiotics
77 ± 7 22 NA 43 ± 
15
0 NA** NA** NA 44** 22** NA
Faggiano et al., 
1993287
13 Severe chronic CoHF 
(admitted), LVEF < 30%, no 
BB agents, physical findings 
of pulmonary and systemic 
congestion without acute 
pulmonary edema and/or 
pleural effusion
History of smoking or lung 
disease 
59 ± 10 100 IV NA NA ATS (1981) ATS (1981) NA 46*** 46*** NA
Siegel et al., 
1990305
34 CoHF with LVEF < 40%, 13 
admitted with CoHF, 21 with 
known CoHF evaluated for 
chronic arrhythmias
Pneumonia, pleural effusion, 
overt pulmonary edema, 
underlying lung disease, 
clinical or radiographic 
evidence of neoplasm, 
previous lung resection or a 
history of drugs that could 
result in pulmonary toxicity
65 ± 10 71 NA 25 ± 7 100 NA NA Diffusing 
capacity 
corrected for 
hemoglobin 
< lower  
95 confidence 
limit
NA NA 35
Pison et al.,
1989242
12 Chronic left HF during 
acute decompensation 
and after intensive 
diuretic treatment, 
hemodynamically stable, 
none with BB, 8 subjects 
with signs of right HF
NA 60 ± 10 83 III-IV NA 100 FEV1 ≤ 80% 
and FEV1/FVC  
< 85% pred.
Significantly 
reduced TLC, 
VC, and FRC
NA 50
25†
17
8†
NA
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1.5  Different definitions of COPD and pulmonary 
function impairment: the lower limit of normal 
versus conventional cutoff values
As mentioned before, spirometry is required for the diagnosis of COPD by measuring 
persistent airflow limitation. However, there is still no consensus on the most 
appropriate threshold of FEV1/FVC for diagnosing airflow limitation.
10-20 The GOLD 
guidelines recommend the use of the fixed ratio of FEV1/FVC < 0.70 for the sake of 
simplicity.1 However, a growing body of literature indicates that considering the 
physiological decline of the FEV1/FVC ratio with age (the FEV1 declines more rapidly 
with age than the FVC in normal subjects) the use of the fixed ratio may lead to 
overdiagnosis of COPD in elderly subjects5, 306-321 and underdiagnosis of COPD in 
young adults.314-323 To avoid misclassification, the American Thoracic Society/European 
Respiratory Society (ATS/ERS) recommends the use of statistically derived LLN 
values for FEV1/VC that are based on the normal distribution and that classify the 
bottom 5% of the healthy population as abnormal.249 This is particularly important in 
patients with HF, given that HF is most prevalent among elderly individuals.32 Thus, 
previously reported COPD prevalence rates may have been overestimated in prior 
studies that have used the fixed ratio of 0.7 to define COPD in patients with HF (Table 1). 
Although population-based studies have shown that the application of different criteria to 
define airflow obstruction dramatically changes the prevalence of COPD,5, 309, 310, 324-327 
it is less well understood to what extent this occurs in patients with HF.169, 215
Table 3   Continued.
Author, 
Yr
No. Population Exclusion of  
pulmonary disease
Age,
yrs
Men,
%
NYHA LVEF,
%
FS/CS, 
%
Definition Prevalence, %
O R D O R D
Light and George,
1983281
28 Admitted with CoHF, most 
with both right and left HF
History of chronic 
obstructive lung disease
62 ± ? 71 NA NA 46 FEV1/FVC 
outside 
normal range 
 (pred-1.65 SEE)
NA NA 61‡ NA NA#
Data are presented as mean ± standard deviation (SD) and percentages unless stated otherwise. Abbreviations: ATS, 
American Thoracic Society; BB, beta-blockers; CoHF, congestive heart failure; CS, current smokers; D, diffusion 
impairment; FEV1, forced expiratory volume in 1 second; FRC, functional residual capacity; FS; former smokers; FVC, 
forced vital capacity; HF, heart failure; LVEF; left ventricular ejection fraction; NA, not available; No., number of patients; 
NS, non-smokers; NYHA, New York Heart Association; O, airway obstruction; post-BD, post-bronchodilator; R, restriction; 
SEE, standard error of the estimate; SVC, slow vital capacity; TLC, total lung capacity; yr(s), year(s). ^ Median 
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An incorrect diagnosis of COPD may result in unnecessary treatment for COPD with 
possible side-effects and adverse cardiovascular events associated with pharmaco-
logical treatment for COPD and undertreatment with life-saving beta-blockers.12, 81, 82 
Moreover, an incorrect diagnosis and interventions for COPD may have a considerable 
psychological impact on the subject and his/her family and may lead to unnecessary 
costs.12 Conversely, misclassifying a number of young adults already affected by 
COPD as healthy, prevents early interventions that could limit disease progression. 
Therefore, there is a need for clear diagnostic criteria for COPD to avoid diagnostic 
confusion, incorrect diagnosis, and inappropriate treatment.   
PFTs are also used for the diagnosis of other pulmonary function abnormalities than 
airflow limitation, such as diffusion impairment and restriction. Similarly, there is no 
consensus on how to define these pulmonary function abnormalities. Traditionally, 
the 80% predicted value (i.e. diffusing capacity or TLC < 80% predicted) has been 
used. This frequently used 80% predicted value has, however, neither statistical nor 
physiological validity249, 328 and may misclassify more than 20% of patients leading to 
false-positive diagnosis in the elderly and underdiagnosis in younger patients.314 
Limits of normal as the predicted ± 20% can only be accurate when the variance 
above and below the predicted regression line is proportional with the predicted 
value (i.e. heteroscedastic: large variance with large values and small variance with 
small values).314, 328 However, since this is not the case, as the scatter around the 
predicted regression line is constant (homoscedastic) in pulmonary function 
measurements, the 80% predicted rule of thumb may lead to false-positive diagnosis 
in the elderly and shorter individuals with smaller predicted values and underdiagnosis 
Table 3   Continued.
Author, 
Yr
No. Population Exclusion of  
pulmonary disease
Age,
yrs
Men,
%
NYHA LVEF,
%
FS/CS, 
%
Definition Prevalence, %
O R D O R D
Light and George,
1983281
28 Admitted with CoHF, most 
with both right and left HF
History of chronic 
obstructive lung disease
62 ± ? 71 NA NA 46 FEV1/FVC 
outside 
normal range 
 (pred-1.65 SEE)
NA NA 61‡ NA NA#
(interquartile range). * Airway obstruction had resolved in 48% of patients 6 months after discharge. ** No definition for 
pulmonary function impairment was provided in the article. Prevalence data were extracted using the following definitions: 
airway obstruction, FEV1/FVC < 0.7; restriction, FVC < 80% predicted with FEV1/FVC ≥ 0.7. *** Isolated airway 
obstruction: 31%; isolated restriction: 31%; mixed pulmonary function abnormalities: 15%. † After treatment for HF. ‡ Both 
during initial assessment and at the time that the pulmonary function of the patients was the best. # Mean diffusing 
capacity for carbon monoxide was within normal range.
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in younger and taller patients with larger predicted values.314, 328 Misinterpretation of 
PFT results may lead to incorrect diagnosis of disease in elderly patients with HF and 
as a consequence unnecessary treatment. Moreover, results may be interpreted as 
having more severe or unstable HF due to the effects of HF on pulmonary function 
and as a result unnecessary intensified treatment for HF. Finally, misdiagnosis may 
interfere with interpretation of research aiming to understand the impact of HF and 
several clinical variables on pulmonary function.329, 330 To avoid misclassification, ATS/
ERS guidelines249 again recommend the use of the fifth percentile LLN values, which 
are calculated by subtracting 1.64 times the residual standard deviation (RSD) from 
the predicted value. However, studies using the LLN values to assess the prevalence 
of pulmonary function abnormalities and their predictors in patients with HF are 
lacking.      
1.6 Outline of this thesis 
Given the gaps in current knowledge as described in the general introduction, the 
aim of this thesis is to provide more insight in the occurrence of COPD and pulmonary 
function abnormalities using different definitions in patients with CHF. 
The main objectives of this thesis are:
1.  To determine the prevalence of COPD in patients with CHF according to two 
definitions of airflow obstruction: the LLN versus the fixed ratio of FEV1/FVC < 0.70. 
2.  To assess the extent of underdiagnosis and overdiagnosis of COPD in patients 
with CHF.
3.  To examine whether serial PFTs are necessary for the correct diagnosis of COPD 
in patients with stable non-congested CHF. 
4.  To determine the prevalence of pulmonary function abnormalities in patients with 
CHF according to recent ATS/ERS guidelines using the LLN compared to 
conventional cutoff values. 
5.  To assess predictors of pulmonary function impairment in patients with CHF 
according to the LLN in comparison to conventional cutoff values.
6.  To evaluate the effect of inhaled bronchodilators on pulmonary function and 
dyspnea in patients with CHF.
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After a general introduction in chapter 1, the 2nd chapter of this thesis describes the 
prevalence of COPD, including over- and underdiagnosis of COPD, in patients with 
CHF according to the widely used GOLD criteria. In addition, it provides an answer to 
the question whether serial PFTs are necessary for the correct diagnosis of COPD in 
patients with stable non-congested CHF. Chapter 3 compares two definitions of 
airflow limitation, namely the LLN versus the fixed ratio of FEV1/FVC < 0.70, regarding 
the prevalence of COPD in patients with CHF. Chapter 4 provides prevalence rates 
of pulmonary function abnormalities in patients with CHF according to the LLN versus 
conventional cutoff values. Chapter 5 describes several predictors of these 
pulmonary function abnormalities and the effect of using different diagnostic criteria, 
namely the LLN versus the conventional cutoff values. Chapter 6 evaluates the effect 
of inhaled bronchodilators on pulmonary function and dyspnea in patients with CHF. 
Finally, chapters 7 and 8 of this thesis provide a summary and discussion of all 
studies and the main findings. Subsequently, a perspective on the future is provided. 
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Abstract
Background: It is unknown whether serial pulmonary function tests are necessary 
for the correct diagnosis of chronic obstructive pulmonary disease (COPD) in patients 
with stable non-congested chronic heart failure (CHF). The aim of this study was to 
determine the prevalence of COPD in outpatients with stable CHF without pulmonary 
congestion using initial as well as confirmatory spirometry three months after treatment 
for COPD.
Methods: Spirometry was performed in 187 outpatients with stable CHF without 
pulmonary congestion on chest radiograph who had a left ventricular ejection fraction 
< 40% (mean age 69 ± 10 years, 78% men). COPD was defined according to the 
Global Initiative for Chronic Obstructive Lung Disease guidelines. The diagnosis of 
COPD was confirmed three months after treatment with tiotropium in newly diagnosed 
COPD patients.
Results: Using a three month follow-up spirometry to confirm initial diagnosis of de 
novo COPD did not change COPD prevalence significantly: 32.6% initially versus 
32.1% after three months of follow-up. Only 1 of 25 (4%) patients with newly diagnosed 
COPD was not reproducibly obstructed at follow-up. COPD was greatly under- (19%) 
and overdiagnosed (32%). 
Conclusions: Spirometry should be used under stable and euvolemic conditions to 
decrease the burden of undiagnosed or overdiagnosed COPD in patients with CHF. 
Under these conditions, a confirmatory spirometry is unnecessary, as it does not 
change a newly established diagnosis of COPD in the vast majority of patients with 
CHF.
Keywords: chronic obstructive pulmonary disease, chronic heart failure, prevalence, 
serial pulmonary function tests, underdiagnosis, overdiagnosis.
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Background
Heart failure (HF) is a common clinical condition with high mortality and morbidity 
rates.1 Chronic obstructive pulmonary disease (COPD) frequently coexists with HF, 
leading to poor prognosis as well as diagnostic and therapeutic challenges.2-17 
Estimates of COPD prevalence in patients with HF vary substantially between 9% and 
52% in earlier reports that relied on clinical data, disease codes, or self-reported 
COPD for establishing the diagnosis.2 Spirometry is considered to be the gold 
standard for the diagnosis of COPD,18 but is unfortunately still underutilised.19 Studies 
that used spirometry have also reported varying prevalence rates of COPD (9 - 44%) 
depending on study design, population, and diagnostic criteria.14-17, 20-23 Airway 
obstruction is a dynamic phenomenon in HF, as it may be present in congestive HF 
and may disappear with treatment of HF.14 Therefore, a careful timing and interpretation 
of pulmonary function tests (PFTs) is required to avoid misdiagnosis and inappropriate 
treatment.2 Ideally, serial PFTs should be used under stable conditions when clinically 
euvolemic to establish a valid diagnosis of COPD by confirming persistent airway 
obstruction. However, data on the need of serial pulmonary function measurements 
are scarce and even lacking in patients with stable chronic HF (CHF). It is therefore 
unknown whether a confirmatory spirometry is necessary for the correct diagnosis of 
COPD in patients with stable non-congested CHF. 
The present study determined the prevalence of COPD in outpatients with stable 
CHF without pulmonary congestion using initial as well as confirmatory spirometry 
three months after treatment with tiotropium in patients with newly diagnosed COPD. 
Methods
Study design and participants
All patients attending two outpatient cardiology departments of a large general 
hospital in The Netherlands were screened for inclusion in this prospective study 
between October 2009 and December 2010. In addition, existing patient lists were 
used to ensure that the majority of HF population had been examined for eligibility. 
Inclusion criteria were CHF1 with left ventricular ejection fraction (LVEF) < 40%, New 
York Heart Association (NYHA) class I-IV, and age of ≥ 18 years. CHF was defined 
according to European Society of Cardiology guidelines.1 Echocardiography was 
performed in patients without a recent (≤ 6 months) echocardiography to confirm 
persisting left ventricular systolic dysfunction (LVSD). Patients were classified as 
having stable HF in the absence of hospitalization due to progression of HF within 3 
months, change in diuretics within 1 month, 3% or more weight gain within 3 days, 
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and more than 50% increase of N-terminal pro-B natriuretic peptide (NT-pro-BNP) 
within 1 month when the baseline NT-pro-BNP was 100 pmol/L or higher or more than 
100 pmol/L increase of NT-pro-BNP within 1 month when baseline NT-pro-BNP was 
below 100 pmol/L.24 Pulmonary congestion was evaluated on standard posterior- 
anterior and lateral chest radiographs for the presence or absence of alveolar edema, 
pleural effusion, Kerley-B lines, and/or the redistribution of pulmonary blood flow by 
independent radiologists who qualitatively assessed the chest radiographs with an 
overall clinical impression. We excluded patients who were not able to cooperate or 
undergo spirometry or who had asthma according to their medical chart. Other 
exclusion criteria were malignancy with a poor prognosis (survival < 6 months) and 
participation in another cardiology study. Patients who had been hospitalized in the 
pulmonary department in the past six weeks were included six weeks after discharge 
to ensure that their pulmonary function was stable at the time of spirometry testing.   
Measurements and data collection 
At baseline, a first blood sample was taken for the measurement of NT-pro-BNP 
according to the standard methods used at the hospital laboratory. One month later, 
the participants visited the hospital for an interview with the investigator and several 
examinations, including height and weight measurement, spirometry, and a chest 
radiograph. In addition, a second blood sample (NT-pro-BNP) was taken to determine 
the stability of HF. The Minnesota Living with Heart Failure Questionnaire,25 modified 
Medical Research Council dyspnea scale,26 and 10-point Borg score27 were used to 
evaluate quality of life, effect of breathlessness on daily activities, and dyspnea at 
rest, respectively. Additional data were collected from medical records and personal 
interviews. Arterial blood gas analysis was carried out in patients with severe airway 
obstruction to determine whether they had chronic respiratory failure.18 
Patients with newly diagnosed COPD were followed up three months after standard 
treatment for COPD with once-daily 18 μg tiotropium. A third blood sample (NT-pro-BNP) 
was taken and spirometry was repeated to confirm persistent airway obstruction 
characteristic of COPD and exclude asthma as much as possible. Thus only patients 
with persistent airway obstruction on three months of follow-up were classified as 
having COPD. 
Spirometry testing
Spirometry (MasterLab Pro; Jaeger; Würzburg, Germany) was performed by trained 
and certified operators using standard techniques and according to European 
Respiratory Society standards for acceptability and reproducibility.28 The reference 
values of the European Community for Coal and Steel were used.28 Subjects with 
airway obstruction underwent post-bronchodilator spirometry 30 minutes after 
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inhalation of four doses of 100 μg aerosolised salbutamol and four doses of 20 μg 
aerosolised ipratropium via Volumatic spacer. Participants were instructed not to take 
bronchodilators 6-24 hours before the tests, depending on the type of bronchodilator 
used. At follow-up, salbutamol and ipratropium were used, as previously described, 
when patients discontinued the use of tiotropium > 24 hours prior to spirometry. Care 
was taken to match the timing of the second spirometry testing to the first to reduce 
variations that may occur over a 24-hour period. 
Definitions
COPD was defined according to the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) guidelines as post-bronchodilator ratio of forced expiratory volume 
in one second to forced vital capacity (FEV1/FVC) < 0.7.
18 COPD severity staging was 
determined on the basis of FEV1 percent predicted according to GOLD criteria: FEV1 
≥ 80% predicted (stage I, mild), 50% ≤ FEV1 < 80% predicted (stage II, moderate), 
30% ≤ FEV1 < 50% predicted (stage III, severe), and FEV1 < 30% predicted or FEV1 
< 50% predicted plus chronic respiratory failure (stage IV, very severe).18       
Smoking status was defined as never (< 100 cigarettes in a lifetime), former (≥ 3 months 
ago), or current smoker (< 3 months). Smoking pack-years (PY) were based only on 
the tobacco cigarette history and one PY was defined as smoking 20 cigarettes a day 
for 1 year. 
Dyspnea was defined as resting dyspnea or dyspnea at any level of exertion, chronic 
cough as cough ≥ 3 months prior to the study, chronic sputum production as regular 
production of sputum for ≥ 3 months in 2 consecutive years, and aspecific bronchial 
hyperreactivity (ABHR) as respiratory symptoms in response to perfumes, scent of 
baking or paint, fog, cold air, or temperature changes. 
Ethical considerations
The study was approved by the regional Research Ethics Committee Arnhem-Nijmegen 
in The Netherlands (2009/101, NL27798.091.09, ClinicalTrials.gov Identifier NCT01429376) 
and complies with the Declaration of Helsinki. All participants gave written informed 
consent. 
Statistical analysis
Descriptive data are presented as mean ± standard deviation (SD) or as number (%). 
Baseline characteristics of patients with and without COPD were compared using the 
independent t-test or Mann-Whitney U test for continuous variables and the chi-square 
or Fisher’s exact test for categorical variables, as appropriate. Correlations between 
COPD and LVEF and between COPD and NT-pro-BNP were examined using the 
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Pearson’s and Spearman’s correlation coefficient tests, respectively. Association between 
COPD and NYHA class was examined using the chi-square test. Statistical analyses 
were performed using the Statistical Package for Social Science (SPSS, version 15.0). 
All statistical tests were two-sided and a p-value < 0.05 was considered significant. 
Results
Patient characteristics
After screening of the entire HF population, a cohort of 337 patients with CHF was 
initially enrolled in this study. Thirty-eight patients withdrew informed consent and 65 
patients were excluded due to several other reasons as specified in Figure 1. The 
remaining 234 patients were finally included of whom 187 had stable CHF without 
signs of pulmonary congestion. The characteristics of these patients are shown in 
Tables 1 and 2. Mean age and LVEF were 69 ± 10 years and 29 ± 7%, respectively, 
and 78% were men. The majority of patients (72%) had NYHA class II, while only 16% 
and 12% had NYHA class I and III/IV, respectively. Almost 60% had an ischemic 
etiology of HF. Other causes of HF were idiopathic (24%), hypertension (6%), valve 
disease (6%), tachycardiomyopathy (3%), and other (2%). Most patients were former 
or current smokers (83%) and reported symptoms of dyspnea (82%). Other respiratory 
symptoms were less common (cough 36%, sputum 23%, ABHR 29%). The patients 
received optimized, individually tailored drug treatment as maintenance therapy for 
their CHF. 
COPD prevalence 
Initially, 61 (32.6%) CHF patients were diagnosed with COPD based on spirometry of 
whom 34 had a history of obstructive lung disease (OLD). Subsequently, 27 patients 
with newly diagnosed COPD were followed up three months after standard treatment 
for COPD. Two patients were lost to follow-up; one deceased and the other withdrew 
informed consent. One of the remaining 25 patients no longer had airway obstruction 
at follow-up, which was classified as mild upon initial assessment. Thus, COPD 
prevalence was 32.1% [25.4-38.8%] after three months of follow-up. 
COPD prevalence tended to be higher in men than women (p = 0.051). It was also 
higher in former (36%) and current smokers (43%) than in non-smokers (9%), with no 
significant differences between current and former smokers (Figure 2A). None of the 
9 patients aged between 31 and 50 years were diagnosed with COPD. COPD 
prevalence according to other age categories is shown in Figure 2B. Most patients 
had mild (46.7%) or moderate (40.0%) COPD, while only 8.3% and 5.0% had severe 
or very severe COPD, respectively. 
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Underdiagnosis and overdiagnosis of COPD
COPD was both over- and underdiagnosed (Figure 2 and Table 3). In terms of 
overdiagnosis, 32% (16/50) of patients with a history of OLD failed to demonstrate 
airway obstruction. In terms of underdiagnosis, 19% (26/137) of patients without a 
history of OLD were newly diagnosed with COPD based on spirometry. A history of 
OLD was defined as COPD (n = 43) or not further specified airway obstruction (n = 7) 
based on patient charts and/or general practitioner diagnosis.
Determinants of COPD
Table 1 shows characteristics of patients with and without COPD based on spirometry. 
Pulmonary symptoms and the results of questionnaires, laboratory tests, and 
spirometry are presented in Table 2. In univariate analysis patients with COPD were 
generally men who smoked more, used more pulmonary medication, had more 
respiratory symptoms of cough, ABHR, and dyspnea according to Borg score, and 
Figure 1  Flow-diagram of screening and final inclusion of study participants. 
Abbreviations: HF, heart failure; LVEF, left ventricular ejection fraction; LVSD, left 
ventricular systolic dysfunction; PFT, pulmonary function tests.
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Table 1 Characteristics of patients with and without COPD based on spirometry.
All  
(n = 187)
No COPD  
(n = 127)
COPD  
(n = 60)
p-value
Age, years 69 ± 10 68 ± 11 70 ± 9 0.173
Male sex, n (%) 146 (78) 94 (74) 52 (87) 0.051
BMI, kg/m2 28 ± 5 29 ± 5 28 ± 5 0.064
LVEF, % 29 ± 7 29 ± 7 29 ± 7 0.401
NYHA class, %
   NYHA I-II 164 (88) 114 (90) 50 (83) 0.211
   NYHA III-IV 23 (12) 13 (10) 10 (17) 0.211
Ischemic etiology 110 (59) 71 (56) 39 (65) 0.238
Smoking history, n (%) 0.008
   Non-smoker 32 (17) 29 (23) 3 (5)
   Current smoker 23 (12) 13 (10) 10 (17)
   Former smoker 132 (71) 85 (67) 47 (78)
   PY, years 24 ± 24 21 ± 21 30 ± 28 0.016
Co-morbidity, n (%)
   Myocardial infarction 109 (58) 71 (56) 38 (63) 0.336
   Atrial fibrillation 54 (29) 38 (30) 16 (27) 0.647
   Hypertension 80 (43) 51 (40) 29 (48) 0.291
   Diabetes mellitus 46 (25) 33 (26) 13 (22) 0.522
PCI/CABG 76 (41) 48 (38) 28 (47) 0.249
CRT/ICD 64 (34) 49 (39) 15 (25) 0.068
Medication, n (%) 
   ACE-I/ARB 174 (93) 119 (94) 55 (92) 0.759
   β-blockers 172 (92) 116 (91) 56 (93) 0.778
         Selective 99 (58) 66 (57) 33 (59) 0.801
         Non-selective 73 (42) 50 (43) 23 (41) 0.801
   Diuretics 159 (85) 107 (84) 52 (87) 0.666
   Aldosterone-antagonists 65 (35) 47 (37) 18 (30) 0.348
   ICS/OCS 26 (14) 9 (7) 17 (28) 0.000
   β-agonists 29 (16) 7 (6) 22 (37) 0.000
   Anticholinergics 29 (16) 6 (5) 23 (38) 0.000
Data are presented as mean ± SD and number (%). Abbreviations: ACE-I/ARB, angiotensin-converting 
enzyme inhibitor/angiotensin receptor blocker; BMI, body mass index; COPD, chronic obstructive pulmonary 
disease; CRT/ICD, cardiac resynchronization therapy/implantable cardioverter defibrillator; ICS/OCS, 
inhalation/oral corticosteroids; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; 
PCI/CABG, percutaneous coronary intervention/coronary artery bypass grafting; PY, pack-years.
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tended to have a lower body mass index. In addition, they had worse lung function 
test results except for FVC. Other variables studied did not significantly vary between 
patients with and without COPD based on spirometry.
COPD was not associated with a higher NYHA class (p = 0.130). Also, there were no 
significant correlations between COPD and LVEF (p = 0.401) or NT-pro-BNP (p = 0.251). 
Table 2  Pulmonary symptoms and results of questionnaires, laboratory tests, and 
spirometry of patients with and without COPD based on spirometry.
 All  
(n = 187)
No COPD  
(n = 127)
COPD  
(n = 60)
p-value
Symptoms, n (%)
   Cough 67 (36) 38 (30) 29 (48) 0.014
   Sputum 43 (23) 26 (20) 17 (28) 0.233
   Dyspnea 153 (82) 101 (80) 52 (87) 0.237
   ABHR 55 (29) 29 (23) 26 (43) 0.004
Questionnaires
   MLHFQ 20 ± 17 19 ± 17 21 ± 18 0.568
   MRC 1.5 ± 1.3 1.4 ± 1.3 1.7 ± 1.4 0.149
   Borg 0.9 ± 1.2 0.8 ± 1.2 1.1 ± 1.3 0.036
Laboratory data
   NT-pro-BNP1, pmol/L 201 ± 289  184 ± 273 236 ± 321 0.290
   NT-pro-BNP2, pmol/L 198 ± 308 179 ± 289 239 ± 345 0.250
Spirometry 
   FEV1, L 2.5 ± 0.8 2.7 ± 0.8 2.1 ± 0.7 0.000
   FEV1, % predicted 88 ± 21 96 ± 15 72 ± 22 0.000
   FVC, L 3.7 ± 1.0 3.7 ± 1.0 3.8 ± 1.0 0.699
   FVC, % predicted 102 ± 19 102 ± 17 101 ± 23 0.602
   FEV1/FVC, % 68 ± 11 74 ± 5 55 ± 10 0.000
Data are presented as mean ± SD and number (%). Only pre-bronchodilator lung function test results 
are presented to make comparison between groups possible. Laboratory data 1 and 2 refer to first (at 
baseline) and second (one month later) blood samples, respectively. Abbreviations: ABHR, aspecific 
bronchial hyperreactivity; COPD, chronic obstructive pulmonary disease; FEV1/FVC, ratio of forced 
expiratory volume in one second to forced vital capacity; MLHFQ, Minnesota Living with Heart Failure 
Questionnaire; MRC, modified Medical Research Council dyspnea scale; NT-pro-BNP, N-terminal pro-B 
natriuretic peptide.
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Figure 2  COPD prevalence and underdiagnosis according to (A) gender and 
smoking status, and (B) age categories. Abbreviations: COPD, chronic obstructive 
pulmonary disease; CS, current smokers; FS, former smokers; NS, non-smokers; 
OLD, obstructive lung disease. The grey parts of the bar represent the proportion 
of patients with COPD based on spirometry who did not have a history of OLD 
(i.e. previously underdiagnosed patients). 
A
B
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Discussion
We observed a high prevalence (32.1%) of COPD in a well defined subgroup of stable 
CHF patients without pulmonary congestion who were recruited from two outpatient 
cardiology departments of a large general hospital. Using a three month follow-up 
spirometry to confirm initial diagnosis of de novo COPD did not change COPD 
prevalence significantly. The majority of patients remained obstructive at follow-up 
after three months of treatment with tiotropium.
Contrary to our results, initial airway obstruction was found in 19% of patients 
hospitalized for congestive systolic HF in the study of Brenner et al.,14 but had resolved 
in 47% of these patients six months after discharge. This indicates that airway 
obstruction is a dynamic phenomenon in patients with HF, which often resolves after 
re-compensation. Therefore, a careful timing and interpretation of PFTs is required to 
avoid misdiagnosis and inappropriate treatment.2 Ideally, lung function measurements 
should be obtained under stable conditions when clinically euvolemic to establish a 
valid diagnosis of COPD. Indeed, the vast majority of patients, except for one (4%), 
with stable CHF without pulmonary congestion were reproducibly obstructed at 
follow-up in the current study. There was no indication of asthma in the patient who 
was not reproducibly obstructed at follow-up.
Our results support previous findings that COPD frequently coexists with HF,15-17, 20-22 
but are in contrast to the study of Brenner et al.14 who found only 9% of patients with 
systolic HF to have concomitant COPD, probably explained by the high number of 
never smokers (45.6%) included in their study. Several factors might explain the high 
coexistence of these two diseases, including sharing of environmental (mainly 
smoking) or genetic risk factors, advanced age, systemic inflammation, and a 
relationship between a reduction in pulmonary and heart function.2, 5-7, 29-33 Also, 
Table 3  Underdiagnosis and overdiagnosis of COPD.
COPD (+) COPD (-) Total
History of OLD (+) 34 (18.2) 16 (8.6) 50 (26.7)
History of OLD (-) 26 (13.9) 111 (59.4) 137 (73.3)
Total 60 (32.1) 127 (67.9) 187 (100)
Data are presented as number (%). Abbreviations: COPD, chronic obstructive pulmonary disease; OLD, 
obstructive lung disease.
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COPD patients are at an increased risk of co-morbidities such as type 2 diabetes, 
which in turn are an important risk for cardiovascular disease.30 Furthermore, factors 
that increase stress on the cardiovascular system or precipitate arrhythmic events 
can also explain the association between COPD and cardiovascular disease, 
including hypoxemia, hyperinflation, hyperventilation, neurohumoral disturbances, 
increased work of breathing and oxygen consumption, pulmonary hypertension, and 
the use of pulmonary medication.29, 30, 32, 34 Finally, other factors, such as oxidative 
stress, endothelial dysfunction, arterial stiffness, and connective tissue degradation 
have also been suggested to play a role.32, 34
Since spirometry is still underutilized even in a tertiary-care facility,19 it seems 
reasonable to consider routine spirometry testing in patients with CHF to diagnose or 
rule out COPD, a co-morbidity with important therapeutic and prognostic implications2, 
10-16, 22 which is still greatly under- and overdiagnosed as found in this study (19% and 
32%, respectively). Indeed, diagnostic difficulties have been stressed before, 
including the overlap in signs, symptoms, and risk factors, the underuse of spirometry 
despite the fact that objective evidence of airway obstruction is mandatory for 
diagnosing COPD, and difficulties with interpreting spirometry results, especially in 
patients with decompensated HF.2, 4-7, 14 This raises concerns regarding possible 
inappropriate treatment of COPD in an already vulnerable group of patients and as a 
result possible adverse impact on health and outcome. 
Unfortunately, the current study was not large enough to find predictors of newly 
diagnosed COPD to make specific recommendations regarding which subgroup of 
patients should be tested. Also, it should be noted that a large proportion (69,2%) of 
newly diagnosed COPD patients had only mild airway obstruction that may represent 
a physiological decline of lung function with age instead of a disease.35, 36 It is 
unknown whether an additional diagnosis and treatment of COPD in these patients 
would improve health outcomes and change their prognosis. This warrants further 
research to establish the effectiveness of screening of patients with CHF for COPD 
in terms of symptomatic relief and improvement of the outcome as well as cost- 
effectiveness of such a policy. Until then, spirometry could be used in CHF patients 
with pulmonary symptoms despite an adequate treatment for their HF, especially in 
the presence of risk factors for COPD, such as a smoking history of ≥ 10 PY and 
occupational exposures. Importantly, spirometry should be used when clinically 
euvolemic to avoid both misdiagnosis and inappropriate treatment of COPD.2
The current study has some limitations that deserve further discussion. It is important 
to realize that the results may not be applicable to all patients with CHF, since we did 
not include patients with preserved systolic function. The diagnosis of HF with 
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preserved systolic function is challenging and particularly difficult to establish in 
patients with COPD.5 Thus, to avoid possible overestimation of COPD prevalence in 
our population, we only included patients with LVSD. Also, patients with more severe 
HF could have been under-represented in this study because of inability to participate. 
COPD prevalence may therefore have been somewhat underestimated. Likewise, 
there may be a recruitment bias in the cohort, given the refusal of 311 patients to 
provide informed consent. Finally, another limitation is the relatively small number of 
patients, particularly with COPD. However, included patient numbers are comparable 
to other recently published studies.16, 20-22 
Despite these limitations, our findings have potential clinical implications. Our results 
indicate that confirmatory spirometry does not change a newly established diagnosis 
of COPD in the vast majority of patients with CHF, provided that PFTs are obtained 
during stable and non-congested conditions. The results also highlight the need for 
extensive use of spirometry to decrease the burden of undiagnosed or overdiagnosed 
COPD in patients with CHF. Evidently, the frequent underdiagnosis and overdiagnosis 
of COPD is not only a concern in the general population, but also in patients who are 
regularly monitored in outpatient cardiology clinics. Physicians should bear in mind 
that both diseases often coexist with important diagnostic and therapeutic difficulties 
and prognostic implications. Thus, both conditions must be simultaneously assessed 
and collaboration between cardiologists and pulmonologists is essential. 
   
Conclusions
In conclusion, COPD is a frequent co-morbidity in patients with stable CHF without 
pulmonary congestion, but is often unrecognized or overdiagnosed. To avoid this 
and thus ensure adequate treatment of COPD in CHF, PFTs should be routinely 
obtained in a stable and non-congested condition. Under these conditions a 
confirmatory spirometry is unnecessary, as it does not change a newly established 
diagnosis of COPD in the vast majority of patients with CHF.
Acknowledgments
The authors would like to thank the participants in this study for their cooperation. 
We also would like to thank the nurse practitioners P.A. Ninaber, W.A.M. Janssen, 
W.H. van Zimmeren-Feijen, and heart failure nurse J.G. Froon-Elferink for their 
contribution to inclusion of participants and data collection. The authors owe much 
gratitude to the pulmonary function and clinical chemistry and haematology 
laboratories as well as the echocardiography and radiology departments for their 
assistance in data collection. Also, we would like to acknowledge biostatistician 
68
Chapter 2
A.R.T. Donders for his contribution to statistical analysis. Finally, we would like to 
thank GlaxoSmithKline for supporting this study by an unrestricted grant. Glaxo-
SmithKline had no involvement in study design, data collection, data analysis, 
interpretation of data, writing of the manuscript, or in the decision to submit the 
manuscript for publication.
69
Serial pulmonary function tests to diagnose COPD in chronic heart failure
2
References
1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC 
Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for 
the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of 
Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and 
endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388-442.
2. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic 
obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11:130-9.
3. Hannink JD, van Helvoort HA, Dekhuijzen PN, Heijdra YF. Heart failure and COPD: partners in crime? 
Respirology. 2010;15:895-901.
4. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive 
pulmonary disease: An ignored combination? Eur J Heart Fail. 2006;8:706-11.
5. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent 
chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2007;49:171-80.
6. Lusuardi M, Garuti G, Massobrio M, Spagnolatti L, Bendinelli S. Heart and lungs in COPD. Close 
friends in real life--separate in daily medical practice? Monaldi Arch Chest Dis. 2008;69:11-7.
7. Padeletti M, Jelic S, LeJemtel TH. Coexistent chronic obstructive pulmonary disease and heart failure 
in the elderly. Int J Cardiol. 2008;125:209-15.
8. Dahlstrom U. Frequent non-cardiac comorbidities in patients with chronic heart failure. Eur J Heart 
Fail. 2005;7:309-16.
9. Hawkins NM, Jhund PS, Simpson CR, Petrie MC, Macdonald MR, Dunn FG, et al. Primary care burden 
and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. Eur 
J Heart Fail. 2010;12:17-24.
10. Rusinaru D, Saaidi I, Godard S, Mahjoub H, Battle C, Tribouilloy C. Impact of chronic obstructive 
pulmonary disease on long-term outcome of patients hospitalized for heart failure. Am J Cardiol. 
2008;101:353-8.
11. Macchia A, Monte S, Romero M, D’Ettorre A, Tognoni G. The prognostic influence of chronic obstructive 
pulmonary disease in patients hospitalised for chronic heart failure. Eur J Heart Fail. 2007;9:942-8.
12. Staszewsky L, Wong M, Masson S, Barlera S, Carretta E, Maggioni AP, et al. Clinical, neurohormonal, 
and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in 
patients with heart failure: data from the Val-HeFT heart failure trial. J Card Fail. 2007;13:797-804.
13. De Blois J, Simard S, Atar D, Agewall S. COPD predicts mortality in HF: the Norwegian Heart Failure 
Registry. J Card Fail. 2010;16:225-9.
14. Brenner S, Guder G, Berliner D, Deubner N, Frohlich K, Ertl G, et al. Airway obstruction in systolic heart 
failure - COPD or congestion? Int J Cardiol. 2013;168:1910-6.
15. Arnaudis B, Lairez O, Escamilla R, Fouilloux A, Fournier P, Monteil B, et al. Impact of chronic obstructive 
pulmonary disease severity on symptoms and prognosis in patients with systolic heart failure. Clin Res 
Cardiol. 2012;101:717-26.
16. Mascarenhas J, Lourenco P, Lopes R, Azevedo A, Bettencourt P. Chronic obstructive pulmonary 
disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J. 2008;155:521-5.
17. Iversen KK, Kjaergaard J, Akkan D, Kober L, Torp-Pedersen C, Hassager C, et al. Chronic obstructive 
pulmonary disease in patients admitted with heart failure. J Intern Med. 2008;264:361-9.
18. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, 
management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. 
Am J Respir Crit Care Med. 2007;176:532-55.
19. Damarla M, Celli BR, Mullerova HX, Pinto-Plata VM. Discrepancy in the use of confirmatory tests in 
patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart 
failure. Respir Care. 2006;51:1120-4.
20. Steinacher R, Parissis JT, Strohmer B, Eichinger J, Rottlaender D, Hoppe UC, et al. Comparison 
between ATS/ERS age- and gender-adjusted criteria and GOLD criteria for the detection of irreversible 
airway obstruction in chronic heart failure. Clin Res Cardiol. 2012;101:637-45.
70
Chapter 2
21. Boschetto P, Fucili A, Stendardo M, Malagu M, Parrinello G, Casimirri E, et al. Occurrence and impact 
of chronic obstructive pulmonary disease in elderly patients with stable heart failure. Respirology. 
2013;18:125-30.
22. Macchia A, Rodriguez Moncalvo JJ, Kleinert M, Comignani PD, Gimeno G, Arakaki D, et al. 
Unrecognised ventricular dysfunction in COPD. Eur Respir J. 2012;39:51-8.
23. Minasian AG, van den Elshout FJ, Dekhuijzen PN, Vos PJ, Willems FF, van den Bergh PJ, et al. COPD 
in chronic heart failure: less common than previously thought? Heart Lung. 2013;42:365-71.
24. O’Hanlon R, O’Shea P, Ledwidge M, O’Loughlin C, Lange S, Conlon C, et al. The biologic variability of 
B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. 
J Card Fail. 2007;13:50-5.
25. Rector TS, Kubo SH, Cohn JN. Patients’ self-assessment of their congestive heart failure. Part 2: 
Content, reliability and validity of a new measure, the Minnesota Living with Heart Failure questionnaire. 
Heart Failure. 1987;Oct/Nov:198-209.
26. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical 
Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive 
pulmonary disease. Thorax. 1999;54:581-6.
27. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14:377-81.
28. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced 
ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community 
for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993;16:5-40.
29. Sin DD, Man SF. Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. 
Can J Physiol Pharmacol. 2005;83:8-13.
30. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor 
for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis. 2009;4:337-49.
31. Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, et al. Percent emphysema, airflow 
obstruction, and impaired left ventricular filling. N Engl J Med. 2010;362:217-27.
32. Malerba M, Romanelli G. Early cardiovascular involvement in chronic obstructive pulmonary disease. 
Monaldi Arch Chest Dis. 2009;71:59-65.
33. Malerba M, Ragnoli B, Salameh M, Sennino G, Sorlini ML, Radaeli A, et al. Sub-clinical left ventricular 
diastolic dysfunction in early stage of chronic obstructive pulmonary disease. J Biol Regul Homeost 
Agents. 2011;25:443-51.
34. Macnee W, Maclay J, McAllister D. Cardiovascular injury and repair in chronic obstructive pulmonary 
disease. Proc Am Thorac Soc. 2008;5:824-33.
35. Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O. Risk of over-diagnosis of COPD in 
asymptomatic elderly never-smokers. Eur Respir J. 2002;20:1117-22.
36. Enright P, Brusasco V. Counterpoint: should we abandon FEV/FVC < 0.70 to detect airway obstruction? 
Yes. Chest. 2010;138:1040-2 [discussion 42-4].
71
Serial pulmonary function tests to diagnose COPD in chronic heart failure
2

Armine G. Minasian 
Frank J.J. van den Elshout
P.N. Richard Dekhuijzen
Petra J.E. Vos
Frank F. Willems
Paul J.P.C. van den Bergh
Yvonne F. Heijdra
Heart Lung. 2013;42:365-71.
COPD in chronic heart failure: 
less common than previously thought?
CHAPTER 3
74
Chapter 3
Abstract 
Background: Using the fixed ratio of forced expiratory volume in 1 s to forced vital 
capacity (FEV1/FVC) < 0.70 instead of the lower limit of normal (LLN) to define chronic 
obstructive pulmonary disease (COPD) may lead to overdiagnosis of COPD in elderly 
patients with heart failure (HF) and consequently unnecessary treatment with possible 
adverse health effects. 
Objective: The aim of this study was to determine COPD prevalence in patients with 
chronic HF according to two definitions of airflow obstruction.
Methods: Spirometry was performed in 187 outpatients with stable chronic HF without 
pulmonary congestion who had a left ventricular ejection fraction < 40% (mean age 
69 ± 10 years, 78% men). COPD diagnosis was confirmed three months after standard 
treatment with tiotropium in newly diagnosed COPD patients.  
Results: COPD prevalence varied substantially between 19.8% (LLN-COPD) and 
32.1% (GOLD-COPD). Twenty-three of 60 patients (38.3%) with GOLD-COPD were 
potentially misclassified as having COPD (FEV1/FVC < 0.7 but > LLN). In contrast to 
patients with LLN-COPD, potentially misclassified patients did not differ significantly 
from those without COPD regarding respiratory symptoms and risk factors for COPD. 
Conclusions: One fifth, rather than one third, of the patients with chronic HF had 
concomitant COPD using the LLN instead of the fixed ratio. LLN may identify clinically 
more important COPD than the fixed ratio of 0.7.
Keywords: Chronic heart failure; chronic obstructive pulmonary disease; prevalence; 
fixed ratio; lower limit of normal. 
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Introduction
Chronic obstructive pulmonary disease (COPD) frequently coexists with heart failure 
(HF), leading to poor prognosis as well as diagnostic and therapeutic challenges.1 
However, estimates of COPD prevalence in patients with HF with reduced or 
preserved left ventricular ejection fraction (LVEF) vary substantially between 9% and 
52%, depending on study design, population (age, gender, smoking habits, inpatients 
versus outpatients, acute versus chronic HF, primary, secondary, or tertiary care), 
and diagnostic criteria.1 Although spirometry is considered to be the gold standard 
for the diagnosis of COPD,2 data on the prevalence of COPD based on spirometry in 
patients with HF are scarce.3-7 Moreover, even when spirometry is used, in general 
there is still no consensus on how to define COPD.8-11 The Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) guidelines recommend the use of the fixed ratio of 
forced expiratory volume in 1 s to forced vital capacity (FEV1/FVC) < 0.70 for the sake 
of simplicity.2 However, a growing body of literature indicates that considering the 
physiological decline of the FEV1/FVC ratio with age the use of the fixed ratio may 
lead to overdiagnosis of COPD in elderly subjects12-19 and underdiagnosis of COPD in 
young adults.15-17, 20 Therefore, to avoid misclassification, the American Thoracic 
Society/European Respiratory Society (ATS/ERS) recommends the use of statistically 
derived lower limit of normal (LLN) values for FEV1/VC that are based on the normal 
distribution and that classify the bottom 5% of the healthy population as abnormal.21 
This is particularly important in patients with HF, given that HF is most prevalent 
among elderly individuals.22 Thus, COPD prevalence of 30-44% may have been over - 
estimated in prior studies that used the fixed ratio of 0.7 to define COPD in patients 
with HF.3-7 Subsequently, an incorrect diagnosis of COPD may result in unnecessary 
treatment for COPD and undertreatment with beta-blockers, with possible adverse 
health effects.8, 23, 24
Although population-based studies have shown that the application of different criteria 
to define airflow obstruction dramatically changes the prevalence of COPD,18, 25-30 
it is less well understood to what extent this occurs in patients with chronic HF.6, 7 
Therefore, the primary aim of this study was to determine COPD prevalence according 
to two definitions of airflow obstruction (FEV1/FVC < 0.70 versus FEV1/FVC < LLN) in 
outpatients with stable chronic HF with left ventricular systolic dysfunction (LVSD). 
The secondary aim of this study was to determine whether patients potentially 
misclassified as having COPD (FEV1/FVC < 0.7 but > LLN) had clinical features of 
COPD or those of the healthy population.
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Methods
Study design and participants
All patients visiting two outpatient cardiology departments of a large general hospital 
in The Netherlands were screened for inclusion in this prospective observational 
study between October 2009 and December 2010. In addition, existing patient lists 
were used to ensure that the majority of the HF population had been examined for 
eligibility. Inclusion criteria were stable chronic HF with LVSD, i.e., LVEF < 40%, without 
pulmonary congestion, New York Heart Association (NYHA) class I-IV, and age ≥ 18 
years. Chronic HF was defined according to the European Society of Cardiology 
guidelines.22 Echocardiography was performed in patients without a recent (≤ 6 
months) echocardiography to confirm persisting LVSD. Patients were classified as 
having stable HF in the absence of hospitalization due to progression of HF within 3 
months, change in diuretics within 1 month, 3% or more weight gain within 3 days, 
and more than 50% increase of N-terminal pro-B natriuretic peptide (NT-pro-BNP) 
within 1 month when the baseline NT-pro-BNP was 100 pmol/L or higher or more than 
100 pmol/L increase of NT-pro-BNP within 1 month when baseline NT-pro-BNP was 
below 100 pmol/L.31 Pulmonary congestion was evaluated on standard posterior-an-
terior and lateral chest radiographs for the presence or absence of alveolar edema, 
pleural effusion, Kerley-B lines, and/or the redistribution of pulmonary blood flow by 
independent radiologists who qualitatively assessed the chest radiographs with an 
overall clinical impression. Patients who were not able to cooperate or undergo 
spirometry or who had asthma according to their medical chart were excluded. Other 
exclusion criteria were malignancy with a poor prognosis (survival < 6 months) and 
participation in another study. Patients who had been hospitalized in the pulmonary 
department in the past six weeks were included six weeks after discharge to ensure 
that their pulmonary function was stable at the time of spirometry testing.      
In conformity with the ethical guidelines of the 1975 Declaration of Helsinki, this study 
was conducted with the approval of the regional Research Ethics Committee Arnhem- 
Nijmegen in The Netherlands (2009/101, NL27798.091.09, ClinicalTrials.gov Identifier 
NCT01429376). All patients gave written informed consent.
Measurements and data collection 
At baseline, a first blood sample was taken for the measurement of NT-pro-BNP 
according to standard methods used in the hospital laboratory. One month later, the 
participants visited the hospital for an interview with the investigator and several 
examinations, including height and weight measurement, spirometry, and a chest 
radiograph. In addition, a second blood sample (NT-pro-BNP) was taken to determine 
the stability of HF. A 10-point Borg score32 was used to evaluate dyspnea at rest. 
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Additional data were collected from medical records and personal interviews. Arterial 
blood gas analysis was performed on patients with severe airflow obstruction to 
determine whether they had chronic respiratory failure.2 
Patients with newly diagnosed COPD according to either definition were followed up 
three months after standard treatment for COPD with once-daily 18 μg tiotropium. 
A third blood sample (NT-pro-BNP) was taken, and spirometry was repeated to confirm 
persistent airflow obstruction characteristic of COPD in an attempt to exclude asthma 
as much as possible. Thus only patients with persistent airflow obstruction on three 
months of follow-up were classified as having COPD.
Spirometry testing
Spirometry (MasterLab Pro; Jaeger; Würzburg, Germany) was performed by trained 
and certified operators using standard techniques and according to ERS standards for 
acceptability and reproducibility.33 The reference values of the European Community 
for Coal and Steel were used.33 Subjects with airflow obstruction according to either 
definition underwent post-bronchodilator spirometry 30 minutes after inhalation of 
four doses of 100 μg aerosolized salbutamol and four doses of 20 μg aerosolized 
ipratropium via Volumatic spacer. Participants were instructed not to take broncho-
dilators 6-24 hours before the tests, depending on the type of bronchodilator used. 
At follow-up, salbutamol and ipratropium were used, as previously described, when 
patients discontinued the use of tiotropium > 24 hours prior to spirometry. Care was 
taken to match the timing of the second spirometry testing to the first to reduce 
variations that may occur over a 24-hour period.
Definitions
COPD was defined according to two criteria: post-bronchodilator FEV1/FVC < 0.7 
(GOLD-COPD)2 and post-bronchodilator FEV1/FVC < LLN (LLN-COPD).
21 LLN was 
regarded as the lower fifth percentile of the frequency distribution of a healthy reference 
population and was calculated by subtracting 1.64 times the residual standard 
deviation from the predicted value. The investigator who identified the GOLD or LLN 
criteria was not blinded to the other rating.
Smoking status was defined as never (< 100 cigarettes in a lifetime), former (≥ 3 months 
ago), or current smoker (< 3 months). Smoking pack-years (PY) were based only on 
the tobacco cigarette history, and one PY was defined as smoking 20 cigarettes a 
day for 1 year. 
Dyspnea was defined as resting dyspnea or dyspnea at any level of exertion, chronic 
cough as cough ≥ 3 months prior to the study, chronic sputum production as the 
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regular production of sputum for ≥ 3 months in 2 consecutive years, and aspecific 
bronchial hyperreactivity (ABHR) as respiratory symptoms in response to perfumes, 
the scent of baking or paint, fog, cold air, or temperature changes. 
Variables and measures
GOLD-COPD severity staging was determined on the basis of FEV1 percent predicted 
according to GOLD criteria: FEV1 ≥ 80% predicted (stage I, mild), 50% ≤ FEV1 < 80% 
predicted (stage II, moderate), 30% ≤ FEV1 < 50% predicted (stage III, severe), and 
FEV1 < 30% predicted or FEV1 < 50% predicted plus chronic respiratory failure (stage 
IV, very severe).2 LLN-COPD severity staging was determined on the basis of FEV1 
percent predicted according to ATS/ERS criteria: FEV1 ≥ 70% predicted (mild), FEV1 
60-69% predicted (moderate), FEV1 50-59% predicted (moderately severe), FEV1 
35-49% predicted (severe), and FEV1 < 35% predicted (very severe).
Statistical analysis
Descriptive data are presented as the mean ± SD or as a number (%). Baseline 
 characteristics of patients with and without GOLD-COPD were compared using an 
independent t-test or a Mann-Whitney U test for continuous variables and a chi-square 
or Fisher’s exact test for categorical variables, as appropriate. Differences in 
continuous variables between three groups of patients (patients with LLN-COPD, 
patients with potentially misclassified COPD (FEV1/FVC < 0.7 but > LLN), and patients 
without COPD) were examined with independent analysis of variance. Post hoc 
analyses were performed using Fisher’s LSD test, and a Games-Howell test was used 
when the assumption of homogeneity of variance was not met. Log transformation 
was applied to achieve normal distribution when the assumption of normal distribution 
was not met. Differences in categorical variables between the aforementioned three 
groups of patients were analyzed with a chi-square test, and the Bonferroni correction 
was used to control for type I errors. Statistical analyses were performed using the 
Statistical Package for Social Science version 15.0. All statistical tests were two-sided, 
and a p-value < 0.05 was considered significant. 
Results
Patient characteristics
A cohort of 337 patients with chronic HF was initially included in this study. Thirty-eight 
patients withdrew informed consent, and 65 patients were excluded for several 
reasons, as specified in Fig. 1. The remaining 234 patients were included in the study, 
of whom 187 had stable chronic HF without signs of congestion on chest radiograph. 
Table 1 shows the characteristics of these patients. The mean age was 69 ± 10 years, 
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the mean was LVEF 29 ± 7%, and 78% of participants were male. The majority of 
patients had NYHA class II (72%). Almost 60% had an ischemic etiology of HF. Other 
causes of HF were idiopathic causes (24%), hypertension (6%), valve disease (6%), 
tachycardiomyopathy (3%), and other causes (2%). Most patients were former or 
current smokers (83%) and reported symptoms of dyspnea (82%) (Table 2). Other 
respiratory symptoms were less common.   
COPD prevalence
COPD prevalence varied substantially according to the definition used, from 19.8% 
(LLN-COPD) to 32.1% (GOLD-COPD), after three months of follow-up (Fig. 2A). 
GOLD-COPD prevalence tended to be higher in men than women (35.6% versus 
19.5%, p = 0.051). The prevalence of LLN-COPD was not significantly different between 
men and women (21.9% versus 12.2%, p = 0.167). The lack of statistical significance 
when comparing COPD prevalence according to gender is likely a function of sample 
Figure 1  Flow-diagram of screening and final inclusion of study participants.
Abbreviations: HF, heart failure; LVEF, left ventricular ejection fraction; LVSD, left ventricular 
systolic dysfunction; PFT, pulmonary function tests.
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size. Regardless of the definition used, the prevalence of COPD was higher in current 
and former smokers than in non-smokers (GOLD-COPD: 43.5%, 35.6%, and 9.4%, 
respectively, overall p = 0.008; LLN-COPD: 26.1%, 23.5%, and 0%, respectively, 
overall p = 0.008), with no significant differences between current and former 
smokers (Fig. 2A). Interestingly, none of the non-smokers had COPD according to 
the LLN, while 3 of 32 (9.4%) non-smokers were diagnosed with COPD using the fixed 
Table 1 Characteristics of patients.
Characteristics All (n = 187)
Age, years 69 ± 10
Male sex, n (%) 146 (78)
BMI, kg/m2 28 ± 5
LVEF, % 29 ± 7
NYHA I-II, % 164 (88)
NYHA III-IV, % 23 (12)
Ischemic etiology 110 (59)
Co-morbidity, n (%)
   Myocardial infarction 109 (58)
   PCI/CABG 76 (41)
   CRT/ICD 64 (34)
   Atrial fibrillation 54 (29)
   Hypertension 80 (43)
   Diabetes mellitus 46 (25)
Medication, n (%)
   ACE-I/ARB 174 (93)
   β-blockers 172 (92)
   Diuretics 159 (85)
   Aldosterone-antagonists 65 (35)
Laboratory data
   NT-pro-BNP1, pmol/L 201 ± 289
   NT-pro-BNP2, pmol/L 198 ± 308
Data are presented as the mean ± SD and number (%). Laboratory data 1 and 2 refer to the first (at 
baseline) and second (one month later) blood samples, respectively. Abbreviations: ACE-I/ARB, angio-
tensin-converting enzyme inhibitor/angiotensin receptor blocker; BMI, body mass index; CRT/ICD, 
cardiac resynchronization therapy/implantable cardioverter defibrillator; LVEF, left ventricular ejection 
fraction; NT-pro-BNP, N-terminal pro-B natriuretic peptide; NYHA, New York Heart Association; PCI/
CABG, percutaneous coronary intervention/coronary artery bypass grafting.
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ratio. None of the 9 patients aged between 31 and 50 years were diagnosed with 
COPD using either definition. COPD prevalence according to other age categories is 
shown in Fig. 2B. Most patients had mild to moderately severe COPD, while only a 
minority had severe or very severe COPD (Table 3).
Figure 2  COPD prevalence as defined by two spirometric criteria and according 
to (A) gender and smoking status, and (B) age categories. Abbreviations: COPD, 
chronic obstructive pulmonary disease; CS, current smokers; FS, former smokers; 
GOLD, Global Initiative for Chronic Obstructive Lung Disease; LLN, lower limit of 
normal; NS, non-smokers.
A
B
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Twenty-three of 60 patients (38.3%) with GOLD-COPD were potentially misclassified 
as having COPD. The majority of these patients had only mild COPD (GOLD stage I: 
61% versus 38%, p = 0.082) in contrast to patients with true COPD (FEV1/FVC < 0.7 
and < LLN) who had more severe disease. These potentially misclassified patients 
did not differ significantly from patients without COPD, except for a lower ratio of 
FEV1/FVC (64 ± 3% versus 74 ± 5%, p < 0.001) (Table 2). On the other hand, patients 
with LLN-COPD did in fact show significant differences compared with patients 
without COPD: they smoked more (33 ± 27 PY versus 21 ± 21 PY, p < 0.001; current/
former smokers 100% versus 77%, p = 0.001); they had more symptoms of cough 
(51% versus 30%, p = 0.016), Borg dyspnea (1.5 ± 1.4 versus 0.8 ± 1.2, p = 0.026) 
and ABHR (57% versus 23%, p < 0.001); they reported a family history of asthma or 
COPD more often (43% versus 23%, p = 0.014); and they had a lower FEV1 (64 ± 18% 
predicted versus 96 ± 15% predicted, p < 0.001) and FEV1/FVC ratio (49 ± 8% 
versus 74 ± 5%, p < 0.001) (Table 2). Moreover, LLN-COPD patients also differed 
significantly from potentially misclassified patients: they had more symptoms of Borg 
dyspnea (1.5 ± 1.4 versus 0.6 ± 1.0, p = 0.019) and ABHR (57% versus 22%, p = 
0.008); more frequently, they had a family history of asthma or COPD (43% versus 
13%, p = 0.014); they had a lower FEV1 (64 ± 18% predicted versus 85 ± 22% 
predicted, p = 0.010) and FEV1/FVC ratio (49 ± 8% versus 64 ± 3%, p = 0.002); and 
they tended to be more likely current/former smokers (100% versus 87%, p = 0.052). 
Table 3  Distribution of COPD patients according to GOLD and ATS/ERS  
severity stages.
Severity class GOLD-COPD (n = 60) LLN-COPD
All
(n = 60)
Potentially 
misclassified:
< 0.7 but  
> LLN  
(n = 23)
True COPD:  
< 0.7 and  
< LLN  
(n = 37)
(n = 37)
Mild, n (%) 28 (47) 14 (61) 14 (38) 21 (57)
Moderate, n (%) 24 (40) 7 (30) 17 (46) 7 (19)
Moderately severe, n (%) - - - 4 (11)
Severe, n (%) 5 (8) 2 (9) 3 (8) 3 (8)
Very severe, n (%) 3 (5) 0 (0) 3 (8) 2 (5)
Data are presented as number (%). Abbreviations: ATS/ERS, American Thoracic Society/European 
Respiratory Society. Other abbreviations are identical to those in the Table 2 legend.
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Patients with GOLD-COPD differed significantly from patients without COPD on 
corresponding variables as those with LLN-COPD, except for one variable; in contrast to 
patients with LLN-COPD who had a family history of asthma or COPD significantly more 
often than those without COPD, this was not true for patients with GOLD-COPD (Table 2). 
Thirty-four of 60 patients (56.7%) with GOLD-COPD had previously been diagnosed 
with obstructive lung disease, compared with 25 of 37 patients (67.6%) with LLN-COPD. 
On the other hand, 16 of 50 (32.0%) patients with a history of obstructive lung disease 
did not have GOLD-COPD according to their spirometry. The corresponding figure 
was 25/50 (50.0%) for LLN-COPD.
Discussion
This is one of the few studies to determine the prevalence of COPD in patients with 
chronic HF using two definitions of COPD, namely, the fixed ratio of 0.7 and the LLN.6, 7 
Our results support previous findings that COPD frequently coexists with chronic HF.3-7 
However, the exact definition of airflow obstruction alters COPD prevalence substantially; 
one fifth, rather than one third, of the patients with chronic HF had concomitant COPD 
using the LLN instead of the fixed ratio. LLN may identify clinically more important 
COPD than the fixed ratio of 0.7 as patients who were potentially misclassified as having 
COPD, in contrast to patients with LLN-COPD, did not differ significantly from those 
without COPD in terms of respiratory symptoms and risk factors for COPD. 
As expected, using the fixed ratio of 0.7 resulted in a considerably higher prevalence 
of COPD compared with using the LLN (32.1% versus 19.8%, respectively). This 
finding is in line with the results of Steinacher et al.7 who reported COPD prevalence 
rates of 43.8% according to the GOLD criteria (fixed ratio) and 24.7% according to 
ATS/ERS criteria (LLN) in 89 outpatients with stable chronic HF. However, this finding 
was not as well supported in another study of 118 elderly (≥ 65 years) patients with 
stable chronic HF, most likely because of the selection of patients with ≥ 10 PY (COPD 
prevalence 30.5% versus 28.8%).6 
Given the physiological decline of the FEV1/FVC ratio with age, using the fixed ratio 
instead of the LLN may result in a diagnosis of COPD in elderly individuals who may 
not actually have COPD12-19 which is of particular concern in patients with HF, given 
that most patients affected by HF are elderly22 (80.2% of the patients in the current 
study were older than 60 years). Almost 40% of the patients who were diagnosed with 
GOLD-COPD based on spirometry were potentially misclassified as having COPD 
because their FEV1/FVC ratio was above the LLN. 
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In clinical practice, decisions are not made on the basis of a single test. Clinical 
findings, including history and exposure to risk factors, can facilitate the diagnosis of 
COPD,2 and the physician ultimately determines the medical significance of an 
abnormal spirometric value based on these clinical findings. However, these 
decisions are more complicated in patients with HF due to overlap in signs and 
symptoms as well as risk factors,1 which explains, at least in part, the considerable 
over- and underdiagnosis of COPD observed in this study. The majority (74%) of 
patients with potentially misclassified COPD had respiratory symptoms (dyspnea, 
cough, and/or sputum production) combined with a smoking history (current or 
former smoker), which was also true for patients without COPD, of whom 64% had 
respiratory symptoms combined with a smoking history. Subsequently, an incorrect 
diagnosis of COPD and unnecessary treatment as a consequence may be associated 
with side-effects of pharmacological interventions,34 especially in elderly patients 
with HF who usually have several co-morbidities and are prone to polypharmacy. In 
addition, concerns have been raised regarding the cardiovascular safety profile of 
bronchodilators. Beta-agonists have been reported to increase the risk for adverse 
cardiovascular events in patients with obstructive airway disease, with a significant 
increase in sinus tachycardia and a non-significant trend toward an increase in major 
cardiovascular events, including ventricular tachycardia, atrial fibrillation, syncope, 
congestive heart failure, myocardial infarction, cardiac arrest, and sudden death.35 
Moreover, observational studies have shown worse outcomes with bronchodilator 
use in patients with HF, including increased risk of HF hospitalization, increased 
mortality rates, in-hospital mechanical ventilation, intravenous vasodilator use, and 
major cardiovascular events associated with the use of beta-agonists, although 
further investigation is warranted.23, 36 Furthermore, inhaled anticholinergics have 
been reported to be associated with an increased risk of cardiovascular death, 
myocardial infarction, or stroke among patients with COPD,37 although recently 
reassuring cardiovascular safety data have been reported on the long-acting an-
ticholinergic bronchodilator tiotropium (HandiHaler).38, 39 Nevertheless, bronchodila-
tors, in particular beta-agonists, must be used with caution in patients with underlying 
cardiac condition such as HF. 
Aside from the possible side-effects and adverse cardiovascular events associated 
with pharmacological treatment for COPD, incorrect diagnosis and interventions for 
COPD may have a considerable psychological impact on the subject and his/her 
family and may cause an unnecessary financial burden on society.8 Furthermore, 
incorrect diagnosis of COPD may lead to undertreatment with life-saving beta-
blockers.23, 24 Therefore, there is a need for clear diagnostic criteria for COPD to avoid 
diagnostic confusion, incorrect diagnosis, and inappropriate treatment.
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Unfortunately, there is no gold standard for the diagnosis of COPD. The hallmark of 
the disease is the presence of airflow limitation that is not fully reversible and is usually 
progressive in nature.2 However, there is no consensus on the spirometric criteria for 
the diagnosis of COPD.8-11 Considering the physiological decline of the FEV1/FVC 
ratio with age, the application of statistically derived LLN values for FEV1/FVC that are 
based on the normal distribution and that classify the bottom 5% of the healthy 
population as abnormal should be preferred to avoid overdiagnosis of COPD in 
elderly subjects12-19 and underdiagnosis in young adults.15-17, 20 However, little is known 
about the clinical impact of these different criteria and contrasting results have been 
reported.12, 20, 40-47 More longitudinal studies are needed to determine which criterion is 
better and clinically more relevant.48 
In the current study, patients who were potentially misclassified as having COPD did 
not differ significantly from those without COPD in terms of respiratory symptoms and 
risk factors for COPD. On the contrary, patients with LLN-COPD did in fact show 
significant differences when they were compared with patients without COPD in 
terms of respiratory symptoms (cough, Borg dyspnea, and ABHR) and risk factors for 
COPD (smoking history and a family history of asthma or COPD). Moreover, patients 
with LLN-COPD more frequently had respiratory symptoms (Borg dyspnea and 
ABHR) and a family history of asthma or COPD compared with patients with potentially 
misclassified COPD, and they more frequently tended to be current or former 
smokers. Although this study is not longitudinal in nature, these findings imply that 
using the LLN may identify clinically more important COPD than the fixed ratio of 0.7. 
In support of this implication, 67.6% of the patients with LLN-COPD were previously 
diagnosed with obstructive lung disease, compared to only 39.1% of patients with 
potentially misclassified COPD.
A limitation of the LLN criterion is its dependence on the prediction equations and on 
the reference population from which the prediction equations have been drawn. In 
the USA, ethnically appropriate National Health and Nutrition Examination Survey 
(NHANES) III reference equations are recommended for those aged 8-80 years.49 In 
Europe, the combined reference equations published in the 1993 ERS statement are 
often used for people aged 18-70 years, with a height range of 155-195 cm in males, 
and 145-180 cm in females.33 Recent ATS/ERS guidelines do not recommend any 
specific set of equations to be used in Europe, but they do suggest the need for a 
new Europe-wide study to derive updated reference equations.21 Recently, 
multi-ethnic spirometric prediction equations for the 3-95 years age range that 
include appropriate age-dependent lower limits of normal and that can be applied 
globally have become available.50
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A limitation to our study is the lack of follow-up to determine how the different 
spirometric definitions of COPD relate to outcomes such as pulmonary function 
decline, hospitalization, and mortality. Furthermore, it is important to realize that the 
prevalence of COPD found in this study may not be applicable to all patients with 
chronic HF because we did not include patients with preserved systolic function. 
Additionally, patients with more severe HF could have been under-represented in this 
study because of their inability to participate. 
Clinical implications and implications for future research
Despite these limitations, our findings have potential clinical implications and 
implications for future research. The results stress the need for a clear definition of 
COPD, especially in patients with HF in whom the diagnosis of COPD is already 
complicated due to overlap in signs, symptoms, and risk factors and who are prone 
to the adverse effects of pharmacological treatment for COPD. Using the LLN results 
in considerably lower COPD prevalence rates when compared with using the fixed 
ratio of 0.7: one fifth, rather than one third, of the patients with chronic HF had 
concomitant COPD. Moreover, LLN may identify clinically more important COPD than 
the fixed ratio. More longitudinal studies are needed to determine which criterion is 
better and clinically more relevant in terms of morbidity (symptoms, exercise 
tolerance, health-related quality of life, exacerbations, hospitalization, pulmonary 
function decline, use of health recourses, systemic effects such as co-morbidities 
and systemic biomarkers) and mortality. Finally, future research should focus on the 
clinical benefit of treating COPD according to either definition in patients with HF and 
the cardiovascular safety profile of bronchodilators, especially in patients with 
underlying cardiac condition such as HF.
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Abstract 
Objective: To determine the prevalence of pulmonary function abnormalities in patients 
with chronic heart failure (HF) according to recent American Thoracic Society/European 
Respiratory Society (ATS/ERS) guidelines using the lower limit of normal (LLN) compared 
to conventional cutoff values.
Background: Recent ATS/ERS guidelines recommend the use of the LLN instead 
of the conventional cutoff values to define pulmonary function impairment to avoid 
 misclassification of patients. However, studies addressing the prevalence of pulmonary 
function abnormalities according to both definitions in patients with chronic HF are 
lacking. 
Results: Diffusion impairment and airway obstruction were found in 44-58% and 
26-37% of the patients, respectively, depending on the definition used (LLN versus 
conventional cutoff values, p < 0.05). However, restriction was infrequent, irrespective 
of the definition used (7% versus 5%, respectively, p > 0.05). The LLN identified 
fewer patients with abnormal lung function, whereas the conventional cutoff values 
classified more patients with diffusion impairment, airway obstruction, or a mixed 
category. Twenty-seven percent of patients were misclassified by the conventional 
cutoff values.
Conclusion: Pulmonary function abnormalities, especially diffusion impairment and 
airway obstruction, were highly prevalent in patients with chronic HF. Conventional 
cutoff values classified more patients with diffusion impairment, airway obstruction, 
or a mixed category compared to the LLN.
Keywords: Chronic heart failure, conventional cutoff values, lower limit of normal, 
prevalence, pulmonary function impairment.
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Introduction
Isolated or combined pulmonary function abnormalities, such as restriction, diffusion 
impairment, and to a lesser extent airway obstruction are common in patients with 
chronic heart failure (HF)1-7 and can contribute to the perception of dyspnea8 and 
exercise intolerance.8-12 Reported prevalence rates vary between 41% and 93% for 
diffusion impairment,13-19 between 21% and 55% for restriction,13-17, 20 and between 14% 
and 60% for airway obstruction.13-18, 20, 21 These varying rates across the studies can 
be partly explained by the usually small number of patients included and differences 
in study population as well as diagnostic criteria used to define pulmonary function 
abnormalities. All studies except for one20 have used conventional cutoff values to 
define an abnormality. However, the 80% predicted value (i.e. diffusing capacity or 
total lung capacity < 80% predicted) and the fixed ratio of 0.7 (i.e. forced expiratory 
volume in 1s to forced vital capacity (FEV1/FVC) < 0.7) that are traditionally used may 
misclassify more than 20% of patients leading to false-positive diagnosis in the 
elderly and underdiagnosis in younger patients.22 This is explained by the physiological 
decrease of the FEV1/FVC ratio with age because the FEV1 declines more rapidly with 
age than the FVC in normal subjects.23 Furthermore, the frequently used 80% 
predicted value has neither statistical nor physiological validity.24 To avoid misclassifi-
cation, recent American Thoracic Society/European Respiratory Society (ATS/ERS) 
guidelines25 recommend the use of statistically derived lower limit of normal (LLN) 
values that are based on the normal distribution and that classify the bottom 5% of 
the healthy population as abnormal. However, studies using the LLN values to assess 
the prevalence of pulmonary function abnormalities in patients with HF are lacking. 
Therefore, the purpose of this study was to determine the prevalence of pulmonary 
function abnormalities according to recent ATS/ERS guidelines using the LLN in 
comparison to conventional cutoff values in outpatients with chronic HF. 
Methods
Study design and participants
This study was part of a larger prospective cross-sectional study evaluating the 
prevalence of chronic obstructive pulmonary disease (COPD) in patients with chronic 
HF (ClinicalTrials.gov Identifier NCT01429376). All patients visiting two outpatient 
cardiology departments of a large hospital in The Netherlands were screened for 
inclusion between October 2009 and December 2010. Inclusion criteria were chronic 
HF26 with left ventricular systolic dysfunction (LVSD), i.e. left ventricular ejection fraction 
(LVEF) < 40%, and New York Heart Association class (NYHA) I-IV. Chronic HF was 
defined according to the European Society of Cardiology guidelines as a clinical 
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syndrome with symptoms and signs typical of HF and objective evidence of a 
structural or functional abnormality of the heart at rest.26 Echocardiography was 
performed in patients without a recent (≤ 6 months) echocardiography to confirm 
persisting LVSD. Patients who were not able to cooperate or undergo reliable spirometry 
according to ERS standards for acceptability and reproducibility27 or who had a 
history of asthma were excluded. Other exclusion criteria were malignancy with a 
poor prognosis (survival < 6 months) and participation in another study. For the 
current study we also excluded patients with known pulmonary, pleural (with exception 
of pleural effusion due to HF), neuromuscular, collagen vascular, or other diseases 
that could affect pulmonary function. Patients with a body mass index (BMI) above 35 
were excluded from the restriction prevalence analysis. 
Patients were classified as having stable HF in the absence of hospitalization due to 
progression of HF within 3 months, change in diuretics within 1 month, 3% or more 
weight gain within 3 days, and more than 50% increase of N-terminal pro-B natriuretic 
peptide (NT-pro-BNP) within 1 month when the baseline NT-pro-BNP was 100 pmol/L 
or higher or more than 100 pmol/L increase of NT-pro-BNP within 1 month when 
baseline NT-pro-BNP was below 100 pmol/L.28
Measurements and data collection 
At baseline, a first blood sample was taken for the measurement of NT-pro-BNP. One 
month later, the participants visited the hospital for an interview with the investigator 
and several examinations, including height and weight measurement, pulmonary 
function tests (PFTs), a chest radiograph, and a second blood sample (hemoglobin, 
NT-pro-BNP). Additional data were collected from medical records and personal 
interviews. Smoking status was defined as never (< 100 cigarettes in a lifetime), former 
(≥ 3 months ago), or current smoker (< 3 months). Smoking pack-years (PY) were 
based only on the tobacco cigarette history and one PY was defined as smoking 
twenty cigarettes a day for one year. 
Pulmonary function tests
All participants underwent pre-bronchodilator spirometry (MasterLab Pro, Jaeger, 
Würzburg, Germany) and measurement of the transfer factor of the lungs for carbon 
monoxide (TLCO). TLCO was measured with standard single-breath technique and 
was corrected for the subject’s hemoglobin concentration (TLCOc). Body plethys-
mography was only performed in patients with airway obstruction and/or signs of 
restriction on spirometry including FVC and/or largest VC < LLN and/or < 80% 
predicted, since patients with normal spirometry results were not expected to have 
abnormal findings of body plethysmography. PFTs were performed by trained and 
certified operators using standard techniques and according to the ERS standards 
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for acceptability and reproducibility.27 The European Community for Coal and Steel 
(ECCS) reference equations were used to calculate predicted values.27 
Diffusion impairment was defined as TLCOc < LLN (ATS/ERS)25 and < 80% predicted 
(conventional cutoff value). Restriction was defined as total lung capacity (TLC) < 
LLN (ATS/ERS)25 and < 80% predicted (conventional cutoff value). Airway obstruction 
was defined as FEV1/VC < LLN (ATS/ERS)
25 and FEV1/FVC < 0.7 (conventional cutoff 
value).29 LLN was regarded as the lower fifth percentile of the frequency distribution 
of a healthy reference population and it was calculated by subtracting 1.64 times the 
residual standard deviation from the predicted value based on the ECCS reference 
equations. Severity of diffusion impairment and airway obstruction using the LLN 
criteria was categorized according to ATS/ERS guidelines25 and severity of airway 
obstruction using the fixed ratio of 0.7 was categorized according to the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.29
Chest radiographs
Standard posterior-anterior and lateral chest radiographs were performed and evaluated 
for the presence or absence of cardiomegaly (cardiothoracic ratio > 0.5), congestion 
(alveolar edema, pleural effusion, Kerley-B lines, and/or redistribution of pulmonary 
blood flow) and conditions that belonged to the exclusion criteria. Independent 
radiologists qualitatively assessed the chest radiographs with an overall clinical 
impression.
Ethical considerations
The study was approved by the regional Research Ethics Committee Arnhem-Nijmegen 
in The Netherlands (ClinicalTrials.gov Identifier NCT01429376) and complies with the 
Declaration of Helsinki. All patients gave written informed consent. 
Statistical analysis
Descriptive data are presented as the mean ± SD or as a number (%). Differences in 
prevalence of pulmonary function abnormalities according to different definitions 
were analyzed with McNemar’s test that compares paired proportions. Differences 
between groups were analyzed using an independent t-test for continuous variables 
and a chi-square or Fisher’s exact test for categorical variables, as appropriate. 
Statistical analyses were performed using the Statistical Package for Social Science 
version 21.0. All statistical tests were two-sided, and a p-value < 0.05 was considered 
significant. 
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Results
Patient characteristics
After screening of the entire HF population, a cohort of 164 chronic HF patients was 
selected for the current study of whom 78% were men (Table 1). The mean age was 
68 ± 10 years and the mean LVEF was 28 ± 7%. Seventeen percent were in NYHA 
class I, 71% in NYHA class II, and 12% in NYHA class III. The majority had stable 
chronic HF (86%) without signs of congestion on chest radiograph (89%). Other 
patient characteristics and results of PFTs are presented in Table 1 and Table 2, 
respectively. 
Reliable diffusion measurement could not be obtained in eleven patients due to 
inability to meet ERS standards for acceptability and reproducibility. These patients 
were included only in the airway obstruction and restriction prevalence analysis. 
Similarly, reliable body plethysmography results could not be obtained in three 
patients. Two of these patients were consequently excluded from the restriction 
prevalence analysis, because suspected restriction on spirometry could not be 
confirmed by reliable body plethysmography results. Nine patients had a BMI above 
35 and were subsequently excluded from the restriction prevalence analysis.
Pulmonary function impairment
The most noted pulmonary function abnormality was diffusion impairment, which 
was more prevalent using the conventional cutoff value of 80% instead of the LLN 
(57.5% versus 44.4%, respectively, p < 0.05). The second most prevalent abnormality 
was airway obstruction, which was more frequent using the fixed ratio of 0.7 instead 
of the LLN (37.2% versus 25.6%, respectively, p < 0.05). In contrast to the high 
occurrence of diffusion impairment and airway obstruction, restriction was less 
common, irrespective of the definition used (5.2% versus 7.2%, respectively, p > 
0.05). This was also true when the two patients with suspected restriction on 
spirometry but without a reliable body plethysmography result to confirm this were 
regarded as having restriction (6.5% versus 8.4%, respectively, p > 0.05). The 
frequency of pulmonary function abnormalities according to either definition was not 
significantly different between current/former smokers and non-smokers. However, 
patients who had smoked ≥ 10 PY had diffusion impairment and airway obstruction 
more often compared to those with < 10 PY using the LLN (50.5% versus 34.5% and 
31.0% versus 17.2%, respectively, p-value ≤ 0.05). This relationship was lost when 
using conventional cutoff values (62.1% versus 50.0%, p = 0.142, and 40.0% versus 
32.8%, p = 0.353, respectively). 
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Table 1  Characteristics of the patients.
Characteristics n = 164
Age, years 68 ± 10
Male sex, n (%) 128 (78)
BMI, kg/m2 28 ± 5
LVEF, % 28 ± 7
NYHA class, n (%)
   NYHA I 28 (17)
   NYHA II 117 (71)
   NYHA III 19 (12)
Stable heart failure, n (%) 141 (86)
Congestion, n (%) 18 (11)
Pleural effusion, n (%) 12 (7)
Cardiomegaly, n (%) 97 (59)
Ischemic etiology 98 (60)
Smoking history, n (%)
   Non-smoker 35 (21)
   Current smoker 23 (14)
   Former smoker 106 (65)
   PY, years 19 ± 20
Dyspnea, n (%)  132 (80)
Co-morbidity, n (%)
   Myocardial infarction 99 (60)
   Atrial fibrillation 57 (35)
   Hypertension 66 (40)
   Diabetes mellitus 40 (24)
PCI/CABG 67 (41)
CRT/ICD 52 (32)
Medication, n (%)
   ACE-I/ARB 153 (93)
   β-blockers 149 (91)
   Diuretics 135 (82)
   Aldosterone-antagonists 63 (38)
   Digoxin 20 (12)
Laboratory data
   NT-pro-BNP1, pmol/L 236 ± 316
   NT-pro-BNP2, pmol/L 250 ± 375
   Hemoglobin, mmol/L 8.6 ± 1.0
Data are presented as the mean ± SD or as a number (%). Abbreviations: ACE-I/ARB, angiotensin-con-
verting enzyme inhibitor/angiotensin receptor blocker; BMI, body mass index; CRT/ICD, cardiac resyn-
chronization therapy/implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; 
NT-pro-BNP, N-terminal pro-B natriuretic peptide; NYHA, New York Heart Association; PCI/CABG, 
percutaneous coronary intervention/coronary artery bypass grafting; PY, pack-years.
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Table 3 shows the prevalence of pulmonary function abnormalities in non-obese 
(BMI ≤ 35) patients who had complete PFT results (n = 143). More patients had 
normal pulmonary function using the LLN criteria versus the conventional cutoff 
values (43% versus 31%). On the other hand, combined diffusion impairment and 
airway obstruction was more prevalent using the conventional cutoff values compared 
to the LLN criteria (23% versus 11%). One third of the patients had an isolated diffusion 
impairment and 10% had isolated airway obstruction. Restriction, either isolated or 
combined with other abnormalities, was uncommon. Comparable results were noted 
in a subgroup of stable chronic HF patients without signs of congestion on chest 
radiograph (n = 113).  
Table 4 shows the cross-tabulation of how the patients were classified according to 
the LLN criteria and the conventional cutoff values. The LLN identified fewer patients 
with abnormal lung function, whereas the conventional cutoff values classified more 
patients with diffusion impairment, airway obstruction, or a mixed category. Three 
patients were classified as obstructive by the FEV1/VC < LLN criterion and as normal 
by the FEV1/FVC < 0.7 criterion. However, all of these patients were obstructive using 
the FEV1/VC < 0.7 criterion determined by the largest VC instead of the FEV1/FVC 
< 0.7 criterion which contains the VC obtained from a forced expiratory maneuver. 
Table 2   Pulmonary function test results.
Pulmonary function tests
Spirometry, n = 164
   FEV1, L (% pred.) 2.7 ± 0.8 (93 ± 18)
   VC, L (% pred.) 4.0 ± 1.0 (104 ± 17)
   FEV1/VC, % 68 ± 8.0 -
   PEF, L/s (% pred.) 8.2 ± 2.3 (108 ± 24)
   IC, L (% pred.) 3.0 ± 0.8 (104 ± 21)
   FEF50, L/s (% pred.) 2.5 ± 1.1 (62 ± 25)
Diffusing capacity, n = 153
   TLCOc, mmol.min-1.kPa-1 (% pred.) 6.7 ± 1.9 (76 ± 16)
   TLCOc/VA, mmol.min-1.kPa-1.L-1 (% pred.) 1.2 ± 0.3 (90 ± 20)
   VA, L (% pred.) 5.7 ± 1.3 (88 ± 13)
Data are presented as the mean ± SD. Pulmonary function data, with exception of FEV1/VC, are expressed 
as absolute values and as percent predicted, based on age, height, and sex. Abbreviations: FEF50, 
forced expiratory flow at 50% of forced vital capacity; FEV1, forced expiratory volume in 1s; IC, inspiratory 
capacity; PEF, peak expiratory flow; % pred., percent predicted; VC, largest vital capacity; TLCOc, 
transfer factor for carbon monoxide corrected for hemoglobin concentration; VA, alveolar volume.
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Indeed, the ratio of FEV1 to VC is capable of accurately identifying more obstructive 
patterns than its ratio to FVC, because FVC is more dependent on flow and volume 
histories.25 A total of 39 (27.3%) patients were classified into discordant cells and were 
thus misclassified by the conventional cutoff values. Twenty-two of 61 (36.1%) patients 
with airway obstruction according to the conventional cutoff values were misclassified 
as having airway obstruction (i.e. < 0.7 but > LLN). Moreover, 20 of 88 (22.7%) 
patients with diffusion impairment were misclassified as having diffusion impairment 
(i.e. < 80% predicted but > LLN). Patients false-positive for airway obstruction were 
significantly older than patients with or without airway obstruction according to both 
definitions (74.9 ± 8.3 versus 66.3 ± 12.0 and 66.7 ± 9.7 years, respectively, p < 0.01). 
Patients false-positive for diffusion impairment were significantly older than patients 
without diffusion impairment according to both definitions (71.8 ± 10.7 versus 66.0 ± 
9.0 years, p = 0.018), but not significantly older compared to those with true-positive 
Table 3   Prevalence of pulmonary function abnormalities according to the LLN 
criteria and the conventional cutoff values in non-obese (BMI ≤ 35) 
patients with complete pulmonary function test results.
Total group Subgroup*
Definition n = 143 n = 113
Normal pulmonary function LLN 61 (43) 49 (43)
Cutoff value 44 (31) 36 (32)
Isolated diffusion impairment (D) LLN 41 (29) 36 (32)
Cutoff value 44 (31) 36 (32)
Isolated restriction (R) LLN 4 (3) 1 (1)
Cutoff value 2 (1) 0 (0)
Isolated airway obstruction (O) LLN 15 (10) 14 (12)
Cutoff value 15 (10) 13 (12)
D + R LLN 3 (2) 1 (1)
Cutoff value 2 (1) 1 (1)
R + O LLN 1 (1) 1 (1)
Cutoff value 0 (0) 0 (0)
D + O LLN 16 (11) 11 (10)
Cutoff value 33 (23) 27 (24)
R + D + O LLN 2 (1) 0 (0)
Cutoff value 3 (2) 0 (0)
Data are presented as number (%). Abbreviations: LLN, lower limit of normal. * Subgroup of patients with 
stable chronic HF without signs of pulmonary congestion on chest radiograph.
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Table 5   Distribution of patients according to ATS/ERS and GOLD severity stages.
Severity class
(ATS/ERS)
Diffusion impairment
(LLN)
n (%) Airway obstruction
(LLN)
n (%)
Mild TLCOc > 60% pred. 47 (69) FEV1 ≥ 70% pred. 33 (79)
Moderate TLCOc 40-60% pred. 20 (29) FEV1 60-69% pred. 5 (12)
Moderately severe - - FEV1 50-59% pred. 3 (7)
Severe TLCOc < 40% pred. 1 (2) FEV1 35-49% pred. 1 (2)
Very severe - - FEV1 < 35% pred. 0 (0)
Severity class
(GOLD)
Airway obstruction
(0.7 fixed ratio)
n (%)
Mild (GOLD I) FEV1 ≥ 80% pred. 40 (66)
Moderate (GOLD II) 50% ≤ FEV1 < 80% pred. 19 (31)
Severe (GOLD III) 30% ≤ FEV1 < 50% pred. 2 (3)
Very severe (GOLD IV) FEV1 < 30% pred. 0 (0)
Data are presented as number (%). Abbreviations: ATS/ERS, American Thoracic Society/European 
Respiratory Society; FEV1, forced expiratory volume in 1s; GOLD, Global Initiative for Chronic Obstructive 
Lung Disease; LLN, lower limit of normal; % pred., percent predicted; TLCOc, transfer factor for carbon 
monoxide corrected for hemoglobin concentration.
Table 4   Grouping of patients in different diagnostic categories according to  
the LLN criteria and the conventional cutoff values.
Grouping by LLN
Grouping by 
cutoff values
Normal Diffusion 
impairment
Restriction Obstruction Mixed Total
Normal 40 0 1 3 0 44
Diffusion impairment 10 33 1 0 0 44
Restriction 0 0 2 0 0 2
Obstruction 6 0 0 8 1 15
Mixed 5 8 0 4 21 38
Total 61 41 4 15 22 143
Data are presented as numbers. The concordant cells are shaded gray. Abbreviations: LLN, lower limit 
of normal.
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diffusion impairment (71.8 ± 10.7 versus 67.5 ± 11.4 years, p = 0.135).  There were no 
significant differences between these groups regarding the gender. 
The majority of patients had mild to moderate severity of diffusion impairment and 
airway obstruction (Table 5). Only 2 patients with restriction had a TLC between 55% 
and 64%, whereas the TLC of the remaining patients was between 76% and 83%.     
Discussion
The current study defined pulmonary function impairment in patients with chronic HF 
according to different diagnostic criteria, namely the LLN versus the conventional 
cutoff values. Our results demonstrate that the LLN identifies fewer HF patients with 
abnormal lung function, whereas the conventional cutoff values classify more patients 
as having diffusion impairment, airway obstruction, or a mixed pulmonary impairment. 
Using the conventional cutoff values instead of the LLN led to misclassification of 
27% of the patients. Importantly, the cutoff values failed to identify correctly 34% of 
patients with normal lung function placing them falsely within a pulmonary dysfunction 
category. This is explained by the physiological decrease of the FEV1/FVC ratio with 
age. The FEV1 declines more rapidly with age than the FVC in normal subjects.
23 As 
a result, the fixed ratio of 0.7, that is traditionally used because of its simplicity, may 
lead to overdiagnosis in the elderly and underdiagnosis in younger patients. 
Furthermore, the frequently used 80% predicted value has neither statistical nor 
physiological validity.24 Limits of normal as the predicted ± 20% can only be accurate 
when the variance above and below the predicted regression line is proportional with 
the predicted value (i.e. heteroscedastic: large variance with large values and small 
variance with small values). However, since this is not the case as the scatter around 
the predicted regression line is constant (homoscedastic) in pulmonary function 
measurements, the 80% predicted rule of thumb may lead to false-positive diagnosis 
in the elderly and shorter individuals with smaller predicted values and underdiagnosis 
in younger and taller patients with larger predicted values.22, 24
Misinterpretation of pulmonary function test results may lead to incorrect diagnosis of 
disease in elderly patients with HF, such as chronic obstructive pulmonary disease, 
and as a consequence unnecessary treatment with possible side effects, detrimental 
psychological impact, and unnecessary financial burden on society. Moreover, 
results may be interpreted as having more severe or unstable HF due to the effects of 
HF on pulmonary function and as a result unnecessary intensified treatment for HF. 
Finally, misdiagnosis may interfere with interpretation of research aimed at under -
standing the impact of heart failure and several clinical variables on pulmonary 
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function. For example, patients who had smoked ≥ 10 PY in our study had diffusion 
impairment and airway obstruction significantly more often compared to those with 
< 10 PY using the LLN. This relationship was, however, lost when using conventional 
cutoff values and implies that inclusion of patients who are incorrectly labelled as 
having pulmonary dysfunction distorted the effect of smoking on pulmonary function 
by adding noise to our data. 
To avoid misclassification, recent ATS/ERS guidelines25 recommend the use of 
statistically derived LLN values that are based on the normal distribution and that 
classify the bottom 5% of the healthy population as abnormal, thus limiting the 
chance of false-positive diagnosis to a maximum of 5%. However, studies using the 
LLN values to assess the prevalence of pulmonary function abnormalities in patients 
with HF are lacking and pulmonary function abnormalities may have been over -
estimated in previous studies that have used conventional cutoff values. Indeed, in 
this population of mainly old patients with chronic HF significantly higher prevalence 
rates of diffusion impairment and airway obstruction were noted with the 80% 
predicted criterion and the fixed ratio of 0.7, respectively, compared to the LLN. Thus, 
a substantially number of mainly older patients were misclassified as having airway 
obstruction and diffusion impairment using the conventional cutoff values instead of 
the LLN. 
Even though we used the LLN to better account for age, the occurrence of diffusion 
impairment and airway obstruction was still high (44% and 26%, respectively). This 
was also true for patients in a stable clinical condition who did not have signs of 
pulmonary congestion. Prevalence rates of diffusion impairment and airway 
obstruction were 41-93%13-19 and 14-60%,13-18, 20, 21 respectively, in prior studies that 
have often included heart transplant recipients. Our results extend these studies by 
demonstrating that these abnormalities are also highly prevalent in patients with less 
severe heart failure who were mainly in NYHA class II. However, in contrast to previous 
reports that have demonstrated high prevalence rates of restriction (21-55%),13-17, 20 
this was quite infrequent in the current study, independent of the definition used. 
Contrasting results are not explained by the fact that body plethysmography was 
performed only in patients with an abnormal spirometry result and not in the entire 
study population, as the chance of missing a restrictive defect is less than 3% when 
the VC is within the normal range using spirometry. Spirometry is therefore very useful 
at excluding a restrictive defect.30 Contrasting results can, however, be attributed to 
differences in patient characteristics as less severe and mainly stable chronic HF 
patients without signs of congestion on chest radiograph were enrolled in the current 
study. In addition, we excluded other diseases that could affect pulmonary function, 
including obesity. Finally, in contrast to some studies,16 we have confirmed suspected 
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restriction on spirometry with body plethysmography, as a reduced VC with normal 
FEV1/VC ratio does not prove a restrictive ventilatory defect.
25     
Several factors have been implied to play a role in the etiology of pulmonary function 
impairment in patients with HF, including the effects of HF itself on pulmonary function 
in addition to (previously undiagnosed) underlying pulmonary disease and 
confounding influences such as smoking, coronary artery bypass grafting (CABG), 
and obesity.4-7, 31 Irrespective of the causes, pulmonary function abnormalities 
associated with chronic HF may explain part of the symptoms and functional disability 
encountered in these patients.8-12  Moreover, pulmonary function impairment 
increases with the severity of HF,9, 11 provides important prognostic information,32, 33 
and may ameliorate or normalize with several treatment modalities, such as pharma-
cological and non-pharmacological treatment of HF 2, 14, 18, 34-36 and anti-obstructive 
therapy with bronchodilators.20, 37-42 Pulmonary function might thus be used as a 
guide for the evaluation of patients with chronic HF, with respect to severity of disease, 
prognosis, and response to treatment. More studies involving therapeutic approaches 
to improve pulmonary function in chronic HF are warranted to determine whether 
treatment directed at correcting pulmonary function impairment may lead to 
symptomatic relief, increased exercise capacity, and improvement of the outcome. 
Furthermore, since little is known about the clinical impact of different criteria of 
pulmonary dysfunction, longitudinal studies are needed to determine which criterion 
is clinically more relevant in terms of morbidity (symptoms, exercise tolerance, 
health-related quality of life, hospitalization, use of health resources) and mortality.
Some limitations of this study deserve further discussion. It is important to realize that 
these results may not be applicable to all patients with chronic HF, since we did not 
include patients with preserved systolic function, who seem to have less impaired 
pulmonary function.43 The diagnosis of HF with preserved systolic function is 
challenging and only few patients met our pre-defined criteria of HF with preserved 
systolic function. Consequently, only patients with LVSD were enrolled in the current 
study. Furthermore, patients with more severe HF could have been underrepresented 
in this study because of inability to participate and thus pulmonary function 
abnormalities might have been underestimated. Finally, since we did not follow the 
patients prospectively, it remains unknown whether pulmonary function impairment 
had prognostic implications in our study population and whether this is influenced by 
different definitions of pulmonary dysfunction. However, pulmonary function did 
provide significant prognostic information in patients with HF in other studies.32, 33 
In conclusion, pulmonary function impairment, especially diffusion impairment and 
airway obstruction, was highly prevalent in patients with chronic HF with LVSD, even 
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in a stable and non-congested condition and even though we used the LLN to better 
account for age. The LLN identifies fewer HF patients with abnormal lung function, 
whereas the conventional cutoff values classify more patients as having diffusion 
impairment, airway obstruction, or a mixed pulmonary impairment, leading to mis-
classification of 27% of the patients. In contrast to previous reports, restriction was 
found to be infrequent in this population of less severe chronic HF, irrespective of the 
definition used.
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Abstract 
Introduction: Using the newer lower limit of normal (LLN) criterion instead of the 
conventional cutoff values to define pulmonary function abnormalities may result in 
different predictors of pulmonary function impairment in patients with heart failure 
(HF). Therefore, we assessed predictors of pulmonary function impairment in 
subjects with chronic HF according to the LLN in comparison to conventional cutoff 
values.
Methods: In this prospective cross-sectional study, 164 chronic HF subjects (age 68 
± 10 years, 78% men, 88% New York Heart Association class I-II) with left ventricular 
ejection fraction < 40% underwent pulmonary function tests. Predictors of pulmonary 
function impairment were assessed using the LLN and conventional cutoff values 
(i.e. 80% predicted value and the fixed ratio of forced expiratory volume in 1s to forced 
vital capacity < 0.7).
Results: The LLN criterion identified an extra independent predictor of diffusion 
impairment compared to the 80% predicted value; in addition to body mass index, 
pack-years (PY), and alveolar volume, female gender also turned out to be an 
independent predictor. A smoking history of ≥ 10 PY was a significant predictor of 
diffusion impairment and airway obstruction using the LLN criterion, but not using the 
conventional cutoff values. However, lowering the cutoff points of conventional criteria 
to match the more stringent LLN and thus avoid overdiagnosis of diffusion impairment 
and airway obstruction in the elderly, produced similar results as the LLN.
Conclusion: The LLN identifies more predictors of diffusion impairment and airway 
obstruction compared to conventional cutoff values in subjects with chronic HF with 
left ventricular systolic dysfunction. However, lowering the conventional cutoff points 
yielded similar results as the LLN.
Keywords: Chronic heart failure, conventional cutoff values, lower limit of normal, 
predictors, pulmonary function impairment.
Trial registration: ClinicalTrials.gov Identifier NCT01429376.
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Introduction
Isolated or combined pulmonary function abnormalities, such as restriction, diffusion 
impairment, and to a lesser extent airway obstruction are common in patients with 
chronic heart failure (HF)1-7 and can contribute to the perception of dyspnea8 and 
exercise intolerance.8-12 Several factors have been implied to play a role in the etiology 
of pulmonary function impairment in patients with HF, including the effects of HF itself 
on pulmonary function in addition to (previously undiagnosed) underlying pulmonary 
disease and confounding influences such as smoking, coronary artery bypass 
grafting (CABG), and obesity.4-7, 13 However, results are not consistent across the 
studies. For example, although smoking and a history of CABG was associated with 
more impaired pulmonary function in the study of Johnson et. al.13 with also weak 
associations between left ventricular function and both lung volumes as well as 
diffusing capacity, none of the described pulmonary function abnormalities were 
found to be related to either smoking status, use of cardiac drugs, chest radiographic 
changes, hemodynamic findings, or clinical features, including the duration of HF in 
the study of Wright et. al.14 Misdiagnosis of pulmonary function abnormalities may 
have interfered with the interpretation of prior research aiming to investigate the 
impact of HF and several clinical variables on pulmonary function in this group of 
patients. Traditionally, the 80% predicted value and the fixed ratio of forced expiratory 
volume in 1s to forced vital capacity (FEV1/FVC) < 0.7 have been used to define 
pulmonary function abnormalities. However, these conventional cutoff values have 
neither statistical nor physiological validity15-17 and may misclassify more than 20% of 
patients leading to false-positive diagnosis in the elderly and underdiagnosis in 
younger patients.18 To avoid misclassification, recent American Thoracic Society/
European Respiratory Society (ATS/ERS) guidelines16 recommend the use of 
statistically derived lower limit of normal (LLN) values that are based on the normal 
distribution and that classify the bottom 5% of the healthy population as abnormal. 
However, studies using the LLN to assess predictors of pulmonary function 
impairment in patients with chronic HF are lacking. Therefore, the purpose of this 
study was to assess predictors of pulmonary function impairment in subjects with 
chronic HF according to the LLN in comparison to conventional cutoff values (percent 
predicted and the fixed ratio of FEV1/FVC). 
Methods
Study design and participants
This study was part of a larger prospective cross-sectional study evaluating the 
prevalence of chronic obstructive pulmonary disease in subjects with chronic HF. All 
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patients visiting two outpatient cardiology departments of a large hospital in The 
Netherlands were screened for inclusion between October 2009 and December 
2010. Inclusion criteria were chronic HF19 with left ventricular systolic dysfunction 
(LVSD), i.e. left ventricular ejection fraction (LVEF) < 40%, and New York Heart 
Association class (NYHA) I-IV. Chronic HF was defined according to the European 
Society of Cardiology guidelines.19 Echocardiography was performed in subjects 
without a recent (≤ 6 months) echocardiography to confirm persisting LVSD. Subjects 
who were not able to cooperate or undergo spirometry or who had a history of asthma 
were excluded. Other exclusion criteria were malignancy with a poor prognosis 
(survival < 6 months) and participation in another study. For the current study we 
also excluded subjects with known pulmonary (including chronic obstructive 
pulmonary disease (COPD)), pleural (with exception of pleural effusion due to HF), 
neuromuscular, collagen vascular, or other diseases that could affect pulmonary 
function. Subjects with a body mass index (BMI) above 35 were excluded from the 
restriction prevalence analysis.
Subjects were classified as having stable HF in the absence of hospitalization due to 
progression of HF within 3 months, change in diuretics within 1 month, 3% or more 
weight gain within 3 days, and more than 50% increase of N-terminal pro-B natriuretic 
peptide (NT-pro-BNP) within 1 month when the baseline NT-pro-BNP was 100 pmol/L 
or higher or more than 100 pmol/L increase of NT-pro-BNP within 1 month when 
baseline NT-pro-BNP was below 100 pmol/L.20
Measurements and data collection 
At baseline, a first blood sample was taken for the measurement of NT-pro-BNP. One 
month later, the participants visited the hospital for an interview with the investigator 
and several examinations, including height and weight measurement, pulmonary 
function tests (PFTs), a chest radiograph, and a second blood sample (hemoglobin, 
NT-pro-BNP). Additional data were collected from medical records and personal 
interviews. Smoking status was defined as never (< 100 cigarettes in a lifetime), 
former (≥ 3 months ago), or current smoker (< 3 months). Smoking pack-years (PY) 
were based only on the tobacco cigarette history, and one PY was defined as smoking 
twenty cigarettes a day for one year. Dyspnea was defined as resting dyspnea or 
dyspnea at any level of exertion.
Pulmonary function tests
All participants underwent pre-bronchodilator spirometry (MasterLab Pro, Jaeger, 
Würzburg, Germany) and measurement of the transfer factor of the lungs for carbon 
monoxide (TLCO). TLCO was measured with standard single-breath technique and 
was corrected for the subject’s hemoglobin concentration (TLCOc). During the 
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measurement of TLCO the alveolar volume (VA) was also obtained and the TLCOc 
was corrected for the VA (TLCOc/VA, i.e. transfer coefficient for carbon monoxide). 
Body plethysmography was performed in subjects with airway obstruction according 
to either definition to assess the presence of hyperinflation. In addition, it was 
performed in subjects with signs of restriction on spirometry, i.e. (F)VC < LLN and/or 
< 80% predicted with normal FEV1/(F)VC ratio, to confirm suspected restriction by 
measuring the total lung capacity (TLC). In other cases body plethysmography was 
omitted since abnormal findings of body plethysmography were not expected with 
normal spirometry results. PFTs were performed by trained and certified operators 
using standard techniques and according to the ERS standards for acceptability and 
reproducibility.21 The European Community for Coal and Steel reference equations 
were used to calculate predicted values.21 
Diffusion impairment was defined as TLCOc < LLN (ATS/ERS)16 and < 80% predicted 
(conventional cutoff value). Restriction was defined as TLC < LLN (ATS/ERS)16 and < 
80% predicted (conventional cutoff value). Airway obstruction was defined as FEV1/
VC < LLN (ATS/ERS)16 and FEV1/FVC < 0.7 (conventional cutoff value).
22 VC was 
regarded as the largest vital capacity (either slow, forced, inspiratory or expiratory) 
and FVC as the forced vital capacity obtained during a forced expiratory maneuver. 
LLN was regarded as the lower fifth percentile of the frequency distribution of a 
healthy reference population and it was calculated by subtracting 1.64 times the 
residual standard deviation (RSD) from the predicted value (Table 1). Hyperinflation 
was defined as the absolute ratio of residual volume (RV) to TLC > 40%.23 
Chest radiographs
Standard posterior-anterior and lateral chest radiographs were performed and 
evaluated for the presence or absence of cardiomegaly (cardiothoracic ratio > 0.5), 
congestion (alveolar edema, pleural effusion, Kerley-B lines, and/or redistribution of 
pulmonary blood flow) and conditions that belonged to the exclusion criteria. 
Independent radiologists qualitatively assessed the chest radiographs with an overall 
clinical impression.
Statistical analysis
Descriptive data are presented as the mean ± SD or as a number (%). Differences in 
prevalence of pulmonary function abnormalities according to different definitions 
were analysed with McNemar’s test that compares paired proportions. Differences 
between groups were analyzed using an independent t-test for continuous variables 
and a chi-square or Fisher’s exact test for categorical variables, as appropriate. 
Differences in pulmonary function between groups of subjects according to NYHA 
class were analyzed with an independent analysis of variance. Post hoc analyses 
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were performed using Fisher’s least-significant difference (LSD) test when the 
assumption of homogeneity of variance was met. The LSD pairwise comparison is 
equivalent to performing multiple t-tests on the data. However, it requires the overall 
ANOVA to be significant and therefore the Type I error is limited to a maximum of 5%. 
The Games-Howell test was used when the assumption of homogeneity of variance 
was not met and it was chosen because of unequal sample sizes. Univariate and 
multivariate logistic regression analysis was performed to identify independent 
predictors of diffusion impairment according to different definitions. All variables of 
interest with a univariate p-value < .05 were included in the multivariate analysis. 
Statistical analyses were performed using the Statistical Package for Social Science 
version 21.0. All statistical tests were two-sided, and a p-value < .05 was considered 
significant. 
Table 1   Regression equations for calculation of predicted values and lower limit 
of normal for adult men and women.
Variable Regression equation 1.64 RSD
FEV1/FVC, %
   Men -0.18A + 87.21 11.8
   Women -0.19A + 89.10 10.7
TLC, liters
   Men 7.99H – 7.08 1.15
   Women 6.60H – 5.79 0.99
RV/TLC, %
   Men 0.39A + 13.96 9.0
   Women 0.34A + 18.96 9.6
TLCO, mmol.min-1.kPa-1
   Men 11.11H – 0.066A – 6.03 2.32
   Women 8.18H – 0.049A – 2.74 1.92
The lower limit of normal (LLN) is calculated by subtracting 1.64 times the residual standard deviation 
(RSD, figure in the last column) from the predicted value. A, age; FEV1, forced expiratory volume in 1s; 
FVC, forced vital capacity; H, height; RV, residual volume; TLC, total lung capacity; TLCO, transfer factor 
for carbon monoxide. 
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Results
Subject characteristics
After screening of the entire HF population, a cohort of 164 chronic HF subjects was 
selected for the current study of whom 78% were men (Table 2). The mean age was 
68 ± 10 years and the mean LVEF was 28 ± 7%. Seventeen percent were in NYHA 
class I, 71% in NYHA class II, and 12% in NYHA class III. The majority had stable 
chronic HF (86%) without signs of congestion on chest radiograph (89%). Other 
subject characteristics and results of PFTs are presented in Table 2 and Table 3, 
respectively. 
Reliable diffusion measurement could not be obtained in eleven subjects. These 
subjects were included only in the airway obstruction and restriction prevalence 
analysis. Similarly, reliable body plethysmography results could not be obtained in 
three subjects. Two of these subjects were consequently excluded from the restriction 
prevalence analysis, because suspected restriction on spirometry could not be 
confirmed by reliable body plethysmography results. Nine subjects had a BMI above 
35 and were subsequently excluded from the restriction prevalence analysis.
Pulmonary function impairment
Prevalence rates of pulmonary function impairment are shown in Table 4. The most 
noted pulmonary function abnormality was diffusion impairment, which was more 
prevalent using the conventional cutoff value of 80% predicted instead of the LLN 
(58% versus 44%, respectively, p-value < .001). The second most prevalent abnormality 
was airway obstruction, which was more frequent using the fixed ratio of 0.7 instead 
of the LLN (37% versus 26%, respectively, p-value = .002). In contrast to the high 
occurrence of diffusion impairment and airway obstruction, restriction was infrequent, 
irrespective of the definition used (5% versus 7%, respectively, p-value = .25). This 
was also true when the two patients with suspected restriction on spirometry but 
without a reliable body plethysmography result to confirm this were regarded as 
having restriction (7% versus 8%, respectively, p-value = .25). Hyperinflation was 
present in 46% of 65 patients with airway obstruction or signs of mixed pulmonary 
dysfunction on spirometry who performed body plethysmography. The definition 
used to define airway obstruction did not impact the occurrence of hyperinflation. 
The frequency of pulmonary function abnormalities according to either definition was 
not significantly different between current/former smokers and non-smokers. 
However, subjects who had smoked ≥ 10 PY had diffusion impairment and airway 
obstruction more often compared to those with < 10 PY using the LLN (51% versus 35% 
and 31% versus 17%, respectively, p-value = .05). The significance of this relationship 
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Table 2   Characteristics of the subjects.
Characteristics n = 164
Age, years 68 ± 10
Male sex, n (%) 128 (78)
BMI, kg/m2 28 ± 5
LVEF, % 28 ± 7
NYHA class, n (%)
   NYHA I 28 (17)
   NYHA II 117 (71)
   NYHA III 19 (12)
Stable heart failure, n (%) 141 (86)
Congestion, n (%) 18 (11)
Pleural effusion, n (%) 12 (7)
Cardiomegaly, n (%) 97 (59)
Ischemic etiology 98 (60)
Smoking history, n (%)
   Non-smoker 35 (21)
   Current smoker 23 (14)
   Former smoker 106 (65)
   PY, years 19 ±  20
Dyspnea, n (%)  132 (80)
Co-morbidity, n (%)
   Myocardial infarction 99 (60)
   Atrial fibrillation 57 (35)
   Hypertension 66 (40)
   Diabetes mellitus 40 (24)
PCI/CABG 67 (41)
CRT/ICD 52 (32)
Medication, n (%)
   ACE-I/ARB 153 (93)
   β-blockers 149 (91)
   Diuretics 135 (82)
   Aldosterone-antagonists 63 (38)
   Digoxin 20 (12)
Laboratory data
   NT-pro-BNP1, pmol/L 236 ± 316
   NT-pro-BNP2, pmol/L 250 ± 375
   Hemoglobin, mmol/L 8.6 ± 1.0
 
Data are presented as the mean ± SD or as a number (%). ACE-I/ARB, angiotensin-converting enzyme 
inhibitor/angiotensin receptor blocker; BMI, body mass index; CRT/ICD, cardiac resynchronization 
therapy/implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; NT-pro-BNP, 
N-terminal pro-B natriuretic peptide; NYHA, New York Heart Association; PCI/CABG, percutaneous 
coronary intervention/coronary artery bypass grafting; PY, pack-years.
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was lost when using conventional cutoff values (62% versus 50%, p-value = .14, and 
40% versus 33%, p-value = .35, respectively). On the other hand, lowering the 
conventional cutoff value to 75% for diffusion impairment (TLCOc < 75% predicted) 
and 0.65 for airway obstruction (FEV1/FVC ratio < 0.65) yielded significant differences 
in the occurrence of diffusion impairment and airway obstruction when comparing 
groups of patients who had smoked  ≥ 10 PY versus < 10 PY (51% versus 33%, 
p-value = .03, and 27% versus 9%, p-value = .01, respectively). The frequency of 
airway obstruction according to either definition was not significantly different 
between men and women (LLN: 27% versus 19%, respectively, p-value = .34; fixed 
ratio of 0.7: 41% versus 25%, respectively, p-value = .09). However, although the 
frequency of diffusion impairment according to the 80% predicted value was not 
Table 3   Pulmonary function test results.
Pulmonary function tests
Spirometry, n = 164
   FEV1, liters (% pred.) 2.7 ± 0.8 (93 ± 18)
   VC, liters (% pred.) 4.0 ± 1.0 (104 ± 17)
   FEV1/VC, % 68 ± 8.0 -
Diffusing capacity, n = 153
   TLCOc, mmol.min-1.kPa-1 (% pred.) 6.7 ± 1.9 (76 ± 16)
   TLCOc/VA, mmol.min-1.kPa-1/L (% pred.) 1.2 ± 0.3 (90 ± 20)
   VA, L (% pred.) 5.7 ± 1.3 (88 ± 13)
Body plethysmography, n = 70*
   TLC, liters (% pred.) 6.7 ± 1.3 (100 ± 16)
   RV, liters (% pred.) 2.7 ± 0.6 (107 ± 24)
   RV/TLC, % (% pred.) 40 ± 7 (99 ± 18)
   ITGV, liters (% pred.) 4.0 ± 0.9 (112 ± 21)
   Raw, kPa.L-1.s (% pred.) 0.4 ± 0.2 (121 ± 60)
   sGaw, kPa-1.s-1 (% pred.) 0.9 ± 0.4 (98 ± 45)
Data are presented as the mean ± SD. Pulmonary function data, with exception of FEV1/VC, are 
expressed as absolute values and percent predicted based on age, height, and sex. FEV1, forced 
expiratory volume in 1s; ITGV, intra-thoracic gas volume; % pred., percent predicted; sGaw, specific 
airway conductance; TLC, total lung capacity; TLCOc, transfer factor for carbon monoxide corrected for 
hemoglobin concentration; Raw, airway resistance; RV, residual volume; VA, alveolar volume; VC, 
largest vital capacity. * Reasons for performing body plethysmography: airway obstruction (n = 58), signs 
of restriction (n = 5); signs of mixed pulmonary dysfunction (n = 7).
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significantly different between men and women (54% versus 70%, respectively, 
p-value = .11), women had diffusion impairment significantly more often than men 
using the LLN (61% versus 40%, respectively, p-value = .04). Lowering the 
conventional cutoff value to 70% (TLCOc < 70% predicted) yielded significant 
differences between women and men in the occurrence of diffusion impairment (58% 
versus 33%, p-value = .01). 
Subjects with a higher NYHA class had lower FEV1, TLCOc, and VA (Table 5). Subjects 
who had smoked ≥ 10 PY had lower FEV1, FEV1/VC ratio and TLCOc than those 
with < 10 PY (Table 6). Subjects with pulmonary congestion, pleural effusion, or 
cardiomegaly on chest radiograph had lower lung volumes and diffusing capacity 
than those without pulmonary congestion, pleural effusion, or cardiomegaly (Table 7). 
TLCOc corrected for VA, however, was comparable between the groups. A history of 
CABG was associated with lower lung volumes. 
Univariate and multivariate logistic regression analysis
Since the most frequently observed abnormality in pulmonary function was diffusion 
impairment, we performed a univariate and multivariate logistic regression analysis 
to identify independent predictors of diffusion impairment according to different 
definitions (Table 8). All variables of interest with a univariate p-value < .05 were 
Table 5   Pulmonary function test results according to New York Heart 
Association class.
Total group NYHA I NYHA II NYHA III
n = 164 n = 28 n = 117 n = 19 p-value
FEV1, % pred. 93 ± 18 98 ± 18
† 94 ± 17 84 ± 19 .03
VC, % pred. 104 ± 17 107 ± 16 104 ± 16 97 ± 21 .12
FEV1/VC, % 68 ± 8.0 68 ± 8 68 ± 8 68 ± 9 .91
TLCOc, % pred.‡ 76 ± 16 85 ± 10*† 74 ± 16 73 ± 15 < .001
TLCOc/VA, % 
pred.‡
90 ± 20 94 ± 15 88 ± 20 92 ± 23 .33
VA, % pred.‡ 88 ± 13 94 ± 10*† 88 ± 13 83 ± 15 .03
Data are presented as mean ± SD. Abbreviations as in Table 2 and 3 legends. P-values refer to 
differences in pulmonary function between groups of subjects according to NYHA class (independent 
analysis of variance). * p-value < .05, NYHA I versus NYHA II; †p-value < .05, NYHA I versus NYHA III. 
No significant differences in pulmonary function were found between NYHA class II and III. ‡ Analysis was 
performed in a total of 153 subjects.
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included in the multivariate analysis. These included female sex, BMI, PY, NT-pro-BNP, 
and VA to identify independent predictors of diffusion impairment according to the 
LLN. In addition, BMI, cardiomegaly, PY, NT-pro-BNP, and VA were included to 
identify independent predictors of diffusion impairment according to the 80% 
predicted value. Multivariate analysis showed female gender, BMI, PY (continuous 
variable), and VA to be independent predictors of diffusion impairment according to 
the LLN. Similar variables were found to be associated with diffusion impairment 
according to the 80% predicted value, except for female gender. However, female 
gender became an independent predictor of diffusion impairment after lowering the 
conventional cutoff value to 70% (TLCOc < 70% predicted, odds ratio 3.7 [1.6 – 8.7], 
p-value = .00). PY as a dichotomous variable (< 10 or ≥ 10) was an independent 
predictor of diffusion impairment according to the LLN (multivariate odds ratio 2.3 [1.1 
- 4.9], p-value .03), but not according to the 80% predicted value (univariate odds 
ratio 1.6 [0.8 - 3.2], p-value .14). However, smoking ≥ 10 PY became an independent 
predictor of diffusion impairment after lowering the conventional cutoff value to 75% 
(TLCOc < 75% predicted, multivariate odds ratio 2.7 [1.3 – 5.9], p-value = .01).
A smoking history of ≥ 10 PY was a significant predictor of airway obstruction 
(univariate logistic analysis) using the LLN criterion (odds ratio 2.2 [1.0 - 4.7], p-value 
.05), but not using the fixed ratio of 0.7 (odds ratio 1.4 [0.7 - 2.6], p-value .35). However, 
smoking ≥ 10 PY became a significant predictor of airway obstruction after lowering 
the fixed ratio of FEV1/FVC to < 0.65 as cutoff point (odds ratio 3.6 [1.4 – 9.2], p-value 
= .01). No other predictors of airway obstruction were found using either definition 
(data not shown) and thus a multivariate logistic regression analysis could not be 
performed.
Table 6   Pulmonary function test results according to smoking status.
Total group PY < 10 PY ≥ 10
n = 164 n = 64 n = 100 p-value
FEV1, % pred. 93 ± 18 97 ± 19 91 ± 17 .05
VC, % pred. 104 ± 17 105 ± 19 103 ± 15 .39
FEV1/VC, % 68 ± 8.0 69 ± 7 67 ± 9 .04
TLCOc, % pred.* 76 ± 16 80 ± 13 74 ± 17 .02
TLCOc/VA, % pred.* 90 ± 20 93 ± 17 88 ± 21 .10
VA, % pred.* 88 ± 13 89 ± 13 88 ± 13 .49
Data are presented as mean ± SD. Abbreviations as in Table 2 and 3 legends. *Analysis was performed 
in a total of 153 subjects.
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Discussion
The current study showed that the definition used for pulmonary function impairment 
impacts the role of gender and smoking on pulmonary function in subjects with 
chronic HF with LVSD. The LLN criterion identified an extra independent predictor of 
diffusion impairment compared to the 80% predicted value; in addition to BMI, PY, 
and VA, female gender also turned out to be an independent predictor. A smoking 
history of ≥ 10 PY was a significant predictor of diffusion impairment and airway 
obstruction using the LLN criterion, but not using the conventional cutoff values. 
However, making the conventional cutoff values more stringent by lowering the cutoff 
point yielded similar results as the LLN. Lower lung volumes were found in subjects 
with pulmonary congestion, cardiomegaly, and a history of CABG.
In the current study, the conventional cutoff values classified more patients as having 
diffusion impairment and airway obstruction compared to the LLN. This is explained 
by the physiological decrease of the FEV1/FVC ratio with age. The FEV1 declines 
more rapidly with age than the FVC in normal subjects.24 As a result, the fixed ratio of 
0.7, that is traditionally used because of its simplicity, may lead to overdiagnosis in the 
elderly and underdiagnosis in younger patients.24 Furthermore, the frequently used 
80% predicted value has neither statistical nor physiological validity.15-17 Limits of 
normal as the predicted ± 20% can only be accurate when the variance above and 
below the predicted regression line is proportional with the predicted value (i.e. het-
eroscedastic: large variance with large values and small variance with small values). 
However, since this is not the case as the scatter around the predicted regression line 
is constant (homoscedastic) in pulmonary function measurements, the 80% predicted 
rule of thumb may lead to false-positive diagnosis in the elderly and shorter individuals 
with smaller predicted values and underdiagnosis in younger and taller patients with 
larger predicted values.15-17
Misdiagnosis of pulmonary function abnormalities by the conventional cutoff values 
may have interfered with the interpretation of prior research aiming to investigate the 
impact of HF and several clinical variables on pulmonary function. This may explain 
part of the inconsistencies across the studies. In fact, a smoking history of ≥ 10 PY 
was a significant predictor of diffusion impairment and airway obstruction using the 
LLN criterion, but not using the conventional cutoff values. This implies that inclusion 
of subjects who are incorrectly labeled as having pulmonary dysfunction distorted 
the effect of smoking on pulmonary function. Indeed, lowering the conventional cutoff 
values to match the more stringent LLN and thus avoid overdiagnosis of diffusion 
impairment and airway obstruction in the elderly, produced similar results as the LLN. 
Similarly, female gender was an independent predictor of diffusion impairment 
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according to the LLN, but not according to the 80% predicted value. However, 
decreasing the cutoff point to define diffusion impairment showed comparable 
findings to the LLN. On the other hand, by increasing the LLN to the 10th percentile, 
the association between female gender and diffusion impairment was lost (data not 
shown). This is explained by the fact that the lower ranges of diffusing capacity 
represented relatively more women than men. In summary, the LLN criterion identified 
more predictors of diffusion impairment and airway obstruction compared to 
conventional cutoff values in subjects with chronic HF with LVSD. However, when 
conventional cutoff points were lowered to match the more stringent LLN criterion, 
the same effects were seen.
The effect of different definitions has also been put forward in the study of de Marco 
et al.,25 who have shown that the role of age, sex, former smoking, and low BMI on 
the development of COPD differs according to the definition used to define COPD. 
They suggested the need for a definition of COPD that is not exclusively based on 
spirometry.
Little is known about the clinical impact of different criteria of pulmonary dysfunction. 
Mannino and Diaz-Guzman26 followed up the mortality data of a large number of 
subjects from the NHANES III classified as normal, obstructed, or restricted using 
conventional cutoff values and the LLN. They found that subjects classified as normal 
using the LLN but obstructed or restricted using conventional cutoff values had a 
higher risk of mortality than normal subjects in up to 18 years of follow-up. This finding 
suggests that conventional criteria may identify at-risk patients who would have been 
missed using the LLN. This study was limited by the lack of post-bronchodilator 
pulmonary function test results, other outcome parameters than mortality, and the 
lack of comparison between subjects with mild airway obstruction according to 
conventional cutoff values (FEV1/FVC < 0.7 and FEV1 ≥ 80% predicted) and normal 
subjects according to the LLN (FEV1/FVC, FEV1, and FVC ≥ LLN).  More longitudinal 
studies are warranted to determine which criterion is clinically more relevant in terms of 
morbidity (symptoms, exercise tolerance, health-related quality of life, hospitalization, 
use of health recourses) and mortality. Since we did not follow our subjects 
prospectively, it remains unknown whether pulmonary function impairment had 
prognostic implications in our study population and whether this is influenced by 
different definitions of pulmonary dysfunction.
Several factors have been implied to play a role in the etiology of pulmonary function 
impairment in patients with HF, including the effects of HF itself on pulmonary function 
in addition to (previously undiagnosed) underlying pulmonary disease and confounding 
influences such as smoking, CABG, and obesity.4-7, 13
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Diffusion impairment has been thought to be related to the thickening of alveolar- 
capillary membrane due to hydrostatic mechanical injury, interstitial edema, remodeling, 
and fibrosis.1, 2, 4-6, 27 Because heart transplantation does not affect or may even worsen 
pulmonary diffusing capacity despite an improvement in hemodynamic status and 
lung volumes,28 it has been suggested that reduced diffusing capacity in CHF may be 
related to permanent damage to the alveolar-capillary membrane.2 Other possible 
causes of diffusion impairment in HF include reduced lung and pulmonary capillary 
blood volumes, ventilation-perfusion mismatch, recurrent pulmonary emboli, smoking, 
and cardiopulmonary bypass.4-6, 13 The results of our study showed a higher NYHA 
class, smoking of ≥ 10 PY, pulmonary congestion, pleural effusion, and cardiomegaly 
to be associated with more impaired diffusing capacity, the latter three probably due to 
their negative effects on lung volume. Indeed, diffusing capacity corrected for VA was 
not significantly different between the groups. Also, although VA turned out to be an 
independent predictor of diffusion impairment, pulmonary congestion and cardiomegaly 
were not. In contrast to previous reports,29-31 the use of angiotensin-converting enzyme 
inhibitors and aldosterone-antagonists was not associated with increased diffusing 
capacity. Also, diffusing capacity was not significantly different between groups of 
subjects with or without a history of CABG. Independent predictors of diffusion 
impairment were BMI, PY (continuous variable), and VA, whereas the role of gender and 
having smoked ≥ 10 PY depended on the definition used to define diffusion impairment. 
Although the underlying mechanisms are not clear, women seemed to be more 
sensitive to the detrimental effects of HF on diffusing capacity. Gender differences in 
pulmonary function have been recognized before, but not specifically in the HF 
population. Adult women have been reported to have lower resting lung diffusing 
capacity corrected for hemoglobin, smaller lung volumes, and lower maximal expiratory 
flow rates, even when corrected for age and standing height relative to men.32 It has 
been suggested that these gender differences in part can be explained by pulmonary 
structural differences (fewer total number of alveoli and smaller airway diameter relative 
to lung size) and hormonal influences  in women.32 More research is needed regarding 
the influence of gender on pulmonary function in general and specifically in the HF 
population. The protective association between a higher BMI and less likelihood of 
having diffusion impairment has to our knowledge not been described before in 
subjects with chronic HF. However, some studies in healthy obese non-smokers have 
suggested that diffusing capacity may be increased in extremely obese subjects, 
probably as a result of the increase in blood volume.33
Restriction has been linked to cardiomegaly, pleural effusion, respiratory muscle weakness, 
CABG, fibrosis from chronic congestion, and reduced lung compliance due to 
chronic vascular engorgement, interstitial/alveolar fluid accumulation, and chronic 
remodeling of the pulmonary vasculature due to elevated left atrial pressure.1, 4-6, 13, 34, 35 
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In line with expectations, we found lung volumes to be lower in subjects with pulmonary 
congestion, pleural effusion, cardiomegaly, and a history of CABG.  
Airway obstruction has been attributed to alveolar fluid accumulation, bronchial 
mucosal swelling, peribronchial edema and fibrosis, squamous metaplasia of 
bronchial epithelial cells induces by transforming growth factor-ß from the failing 
heart, geometric decrease in airway size from reduction in lung volume, abnormalities 
of autonomic control, neurohumoral bronchoconstriction, bronchial hyperrespon-
siveness, and smoking,4-7, 13, 36 although results are not consistent.14 Our study showed 
more impaired FEV1/VC ratio in patients who had smoked ≥ 10 PY. Also, having 
smoked ≥ 10 PY was a significant predictor of airway obstruction, but this depended 
on the definition used to define airway obstruction. Although we have excluded 
patients with known COPD or other obstructive lung disease, we cannot rule out 
the possibility that some of the patients with airway obstruction had previously 
undiagnosed COPD, as most patients were current or former smokers. In fact, 16% 
(LLN) to 24% (conventional cutoff values) of the patients had post-bronchodilator 
airway obstruction after inhaling 400 mcg salbutamol and 80 mcg ipratropium. These 
patients had more symptoms of cough and sputum than those without post- 
bronchodilator airway obstruction (data not shown). Also, patients who were current 
or former smokers tended to have more often post-bronchodilator airway obstruction 
than those who had never smoked (LLN: 19% versus 6%, p = .06; conventional cutoff 
values: 27% versus 11%, p = .05). However, hyperinflation, which has been found to 
be a valid indicator of true COPD in patients with congested HF,37 was not significantly 
different between groups of patients with persistent airway obstruction after broncho-
dilation and those with reversible airway obstruction (data not shown). Although 
airway obstruction in HF has also been attributed to pulmonary congestion, FEV1/VC 
ratio was not significantly different between groups of subjects with and without 
pulmonary congestion in our study. This, however, does not exclude the contribution 
of pulmonary congestion to small airways obstruction. 
Importantly, airway obstruction may lead to hyperinflation of the lungs due to 
expiratory flow limitation and air trapping, which was found in almost half of our 
patients with airway obstruction as defined by an increased RV/TLC ratio. This may 
contribute to symptoms of dyspnea, poor exercise tolerance, increased work of 
breathing and oxygen consumption, respiratory muscle dysfunction, and adverse 
impact on cardiac function by decreasing the preload.38 Thus, irrespective of the 
causes, pulmonary function abnormalities associated with chronic HF may explain 
part of the symptoms and functional disability encountered in these patients.8-12 
Moreover, pulmonary function impairment increases with the severity of HF,9, 11 
provides important prognostic information,39-42 and may ameliorate or normalize with 
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several treatment modalities, such as pharmacological and non-pharmacological 
treatment of HF2, 28, 43-46 and anti-obstructive therapy with bronchodilators.47-53 
Pulmonary function might thus be used as a guide for the evaluation of patients with 
chronic HF, with respect to severity of disease, prognosis, and response to treatment. 
Some limitations of this study deserve further discussion. It is important to realize that 
these results may not be applicable to all patients with chronic HF, since we did not 
include subjects with preserved systolic function, who seem to have less impaired 
pulmonary function.54 Furthermore, patients with more severe HF could have been 
underrepresented in this study because of inability to participate and thus pulmonary 
function abnormalities might have been underestimated. Finally, considering the 
relatively small number of subjects included in the current study, in particular women 
and non-smokers, further research is needed to confirm our results. 
In conclusion, the LLN identifies gender as an extra independent predictor of diffusion 
impairment and a smoking history of ≥ 10 PY as an additional predictor of both 
diffusion impairment and airway obstruction compared to conventional cutoff values 
in subjects with chronic HF with LVSD. However, when conventional cutoff points 
were lowered to match the more stringent LLN criterion, the same effects were seen. 
Our results stress the need for clear definitions of pulmonary function abnormalities. 
More longitudinal studies are warranted to determine which criterion is clinically more 
relevant. Specifically, future research should focus on better characterizing the 
potentially misclassified group of patients who are above the LLN but below the 
conventional cutoff values. Do these patients have worse outcome with higher 
morbidity and mortality rates that is amenable to treatment or do they present clinical 
features similar to those with CHF but without pulmonary dysfunction? Finally, more 
research is needed regarding the influence of gender on pulmonary function in the 
HF population and the possible underlying pathophysiologic mechanisms.
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Abstract
Objective: The aim of this study was to evaluate the effect of inhaled bronchodilators 
on pulmonary function and dyspnea in patients with chronic heart failure (HF). 
Background: Conflicting data exist on whether bronchodilators may improve pulmonary 
function and dyspnea in patients with chronic HF.  
Methods: In this retrospective observational study we analyzed data of 116 chronic 
HF outpatients with systolic dysfunction who underwent spirometry and Borg 
dyspnea measurements before and after inhalation of 400 μg salbutamol and 80 μg 
ipratropium. Patients with chronic obstructive pulmonary disease (COPD) or asthma 
were excluded. 
Results: Bronchodilators fully reversed airway obstruction (AO) in 25 of 64 (39.1%) 
patients with pre-bronchodilator AO. All spirometric measurements, except for forced 
vital and inspiratory capacities, improved significantly post-bronchodilation. Absolute 
and percent improvements in forced expiratory volume in 1 s (FEV1) were more 
pronounced in patients with persistent AO post-bronchodilation compared to those 
without AO (0.19 ± 0.18L and 8.4 ± 7.3% versus 0.11 ± 0.12L and 4.3 ± 4.0%, p < 0.05). 
Significant bronchodilator responsiveness of FEV1 (> 200 mL and > 12%) was noted 
in 12.1% and was more frequent in patients with persistent AO and fully reversible 
AO than in those without AO (23.1% and 16.0% versus 1.9%, p < 0.05). We measured 
a small, albeit significant improvement in dyspnea (0.7 ± 1.2 versus 0.9 ± 1.3, 
p = 0.002).
Conclusions: Inhaled bronchodilators may have an additional role in the management 
of patients with chronic HF because of their potential to improve pulmonary function, 
especially in those with AO. The clinical usefulness and possible adverse events of 
bronchodilators need to be further established.
Keywords: Chronic heart failure; bronchodilator responsiveness; salbutamol; ipratropium; 
airway obstruction.
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Introduction
Pulmonary function abnormalities, such as diffusion impairment, restriction, and airway 
obstruction (AO), are common in patients with heart failure (HF)1, 2 and may contribute 
to the perception of dyspnea and exercise intolerance.3 Treatment directed at 
reversing AO with bronchodilators may have an additional role in the management of 
these patients. There are, however, only few studies concerning the beneficial effects of 
bronchodilators in patients with HF. Improvements in pulmonary function,4-10 dyspnea,10 
and exercise performance7 have been reported. Some investigators have even 
observed an increase of mean forced expiratory volume in 1 s (FEV1) greater than 200 mL 
and 12% in patients with HF,6, 8, 9 especially in those with AO,8 left ventricular systolic 
dysfunction (LVSD),9 and during acute decompensation of HF.6 However, not all could 
confirm these findings.7, 10-14 Contrasting results across the studies might be attributed 
to the small number of patients studied and to the differences in study population, 
bronchodilators used, and definition of bronchodilator responsiveness (BDR). 
The purpose of this study was to evaluate the effect of maximal bronchodilation with 
combined inhaled salbutamol and ipratropium bromide on pulmonary function and 
dyspnea in patients with chronic HF. In addition, we determined the proportion of 
patients with significant BDR (i.e. responder), defined as post-bronchodilator (BD) 
increase in FEV1 greater than 200 mL and 12% from the baseline value.
15
Methods
Study design and participants
In this retrospective observational study we analyzed data of chronic HF16 outpatients 
with left ventricular ejection fraction (LVEF) below 40%, New York Heart Association 
(NYHA) class I to IV, and age ≥ 18 years. These patients were recruited prospectively in 
another study from two outpatient cardiology departments of a large general hospital in 
The Netherlands between October 2009 and December 2010 for the purpose of evaluating 
the prevalence of chronic obstructive pulmonary disease (COPD) and pulmonary 
function impairment in chronic HF (ClinicalTrials.gov Identifier NCT01429376). Only 
patients with both pre- and post-BD spirometry results were included in the current 
study. Patients who were not able to cooperate or undergo spirometry or had a history of 
asthma17 were excluded. Other exclusion criteria were malignancy with a bad prognosis 
(survival < 6 months) and participation in another study. In addition, patients with a 
history of COPD15 or not further specified obstructive lung disease (OLD) were excluded 
from the current study. Echocardiography was performed in patients without a recent 
(≤ 6 months) echocardiography to confirm persisting LVSD. 
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Patients were classified as having stable HF in the absence of hospitalization due to 
HF ≤ 3 months, change in diuretics ≤ 1 month, ≥ 3% weight gain ≤ 3 days, and > 50% 
increase of N-terminal pro-B natriuretic peptide (NT-pro-BNP) ≤ 1 month (baseline 
NT-pro-BNP ≥ 100 pmol/L) or > 100 pmol/L increase of NT-pro-BNP ≤ 1 month 
(baseline NT-pro-BNP < 100 pmol/L).18 
Measurements and data collection 
At baseline, a first blood sample was taken for the measurement of NT-pro-BNP. One 
month later, the participants visited the hospital for an interview with the investigator 
and several examinations, including height and weight measurement, spirometry and 
a 10-point Borg dyspnea score19 before and after bronchodilators, a chest radiograph, 
and a second blood sample (NT-pro-BNP). Additional data were collected from 
medical records and personal interviews. Smoking status was defined as never 
(< 100 cigarettes in a lifetime), former (≥ 3 months ago), or current smoker (< 3 months). 
Smoking pack-years (PY) were based only on the tobacco cigarette history and one 
PY was defined as smoking 20 cigarettes a day for 1 year.   
 
Pulmonary function tests
Participants performed spirometry (MasterLab Pro, Jaeger, Würzburg, Germany) 
before and 30 minutes after inhalation of four doses of 100 μg aerosolized salbutamol 
and four doses of 20 μg aerosolized ipratropium bromide via Volumatic spacer. 
Beta-blockers were not discontinued prior to testing. Spirometry was performed by 
trained and certified operators using standard techniques and according to European 
Respiratory Society standards for acceptability and reproducibility.20 Reference 
values of the European Community for Coal and Steel were used.20 AO was defined 
as the ratio of FEV1 to forced vital capacity (FEV1/FVC) < 0.7.
15 
    
Chest radiographs
Standard posteroanterior and lateral chest radiographs were performed and evaluated on 
the presence or absence of congestion: alveolar edema, pleural effusion, Kerley-B 
lines, and/or redistribution of pulmonary blood flow. 
Ethical considerations
The study was approved by the regional Research Ethics Committee Arnhem-Nijmegen 
in The Netherlands. All patients gave written informed consent. 
Statistical analysis
Descriptive data are presented as mean ± SD or as number (%). Differences between 
pre- and post-BD spirometry results were analyzed with the dependent t-test and the 
Wilcoxon signed-rank test was used to analyze the effect of bronchodilators on 
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dyspnea. Relationships between improvements in pulmonary function and LVEF, 
baseline pulmonary function, and changes in Borg score were examined using the 
Pearson’s or Spearman’s correlation coefficient tests, as appropriate. Differences in 
BDR between three groups of patients were examined with independent analysis of 
variance; group 1: patients with persistent AO after bronchodilation, group 2: patients 
with fully reversible AO, group 3: patients without AO. Post hoc analyses were 
performed using Fisher’s LSD procedure while Games-Howell procedure was used 
when the assumption of homogeneity of variance was not met. Comparisons 
between two groups of patients were analyzed using an independent t-test or 
Mann-Whitney U test for continuous variables and a chi-square or Fisher’s exact test 
for categorical variables, as appropriate (not all data shown). Statistical analyses 
were performed using the Statistical Package for Social Science version 15.0. All 
statistical tests were two-sided and a p-value < 0.05 was considered significant. 
Results
Patient characteristics
Of the 234 patients recruited in the prospective study, 154 had both pre- and post-BD 
spirometry results of whom 38 had a history of COPD or not further specified OLD. 
The remaining 116 patients (50%) were selected for the current study (Figure 1). Table 1 
shows the characteristics of these patients. Mean age was 70 ± 10 years and 83% 
were men. LVEF was 28 ± 7% and 86% had stable chronic HF. Only 14% had signs 
of congestion on chest radiograph. Over 60% had an ischemic etiology of HF. Other 
causes of HF were idiopathic (18%), hypertension (6%), valve disease (9%), tachycardio-
myopathy (2%), and other (3%). The majority had NYHA class II (72%) and most 
patients were current or former smokers (81%). Symptoms of dyspnea at rest and/or 
on exertion were present in 80%.
Bronchodilator responsiveness      
AO was present in 64 of 116 (55.2%) patients before administration of inhaled 
 bronchodilators. Of these patients, 39 (60.9%) had persistent AO after bronchodilation. 
Thus, bronchodilators fully reversed AO in 25 of 64 (39.1%) patients. 
Significant improvements in pulmonary function were noted in all spirometric indices 
except for FVC and inspiratory capacity (IC) after bronchodilation (Table 2). Mean 
absolute and percent baseline changes in FEV1 were 0.15 ± 0.14L and 6.1 ± 5.9%, 
respectively. Corresponding changes for FVC and IC were 0.04 ± 0.23L (1.4 ± 6.5%) 
and 0.06 ± 0.37L (2.5 ± 13.0%), respectively. Figure 2 shows mean absolute and 
percent baseline changes in FEV1, FVC, and IC according to three groups of patients: 
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Figure 1  Flow-diagram of screening and final selection of study participants. 
Abbreviations: COPD, chronic obstructive pulmonary disease; HF, heart failure; LVEF, 
left ventricular ejection fraction; LVSD, left ventricular systolic dysfunction; OLD, 
obstructive lung disease; PFT, pulmonary function tests; pre-/post-BD, pre-/post- 
bronchodilators.
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Table 1   Characteristics of the patients.
Characteristics n = 116
Age, years 70 ± 10
Male sex, n (%) 96 (82.8)
BMI, kg/m2 28 ± 4
LVEF, % 28 ± 7
NYHA class, n (%)
   NYHA I 21 (18.1)
   NYHA II 83 (71.6)
   NYHA III 12 (10.3)
Stable heart failure, n (%) 100 (86.2)
Congestion, n (%) 16 (13.8)
Ischemic etiology, n (%) 72 (62.1)
Dyspnea, n (%) 93 (80.2)
Smoking history, n (%)
   Non-smoker 22 (19.0)
   Current smoker 17 (14.7)
   Former smoker 77 (66.4)
   PY, years 19 ± 20
Co-morbidity, n (%)
   Myocardial infarction 73 (62.9)
   Atrial fibrillation 47 (40.5)
   Hypertension 50 (43.1)
   Diabetes mellitus 24 (20.7)
PCI/CABG 50 (43.1)
CRT/ICD 39 (33.6)
Cardiac medication, n (%)
   ACE-I/ARB 109 (94.0)
   Beta-blockers 105 (90.5)
         Selective 56 (48.3)
         Non-selective 49 (42.2)
   Diuretics 95 (81.9)
   Aldosterone-antagonists 46 (39.7)
   Digoxin 14 (12.1)
   Nitrates 14 (12.1)
   Calcium-antagonists 8 (6.9)
Laboratory data
   NT-pro-BNP1, pmol/L 271 ± 363
   NT-pro-BNP2, pmol/L 296 ± 432
Data are presented as mean ± SD and number (%). Abbreviations: ACE-I/ARB, angiotensin-converting 
enzyme inhibitor/angiotensin receptor blocker; BMI, body mass index; CRT/ICD, cardiac resynchronization 
therapy/implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; NT-pro-BNP, N-terminal 
pro-B natriuretic peptide; NYHA, New York Heart Association; PY, pack-years; PCI/CABG, percutaneous 
coronary intervention/coronary artery bypass grafting.
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those with persistent AO after bronchodilation (n = 39), those with fully reversible AO 
(n = 25), and those without AO both before and after bronchodilation (n = 52). Both 
absolute and percent baseline changes in FEV1 were more pronounced in patients 
with persistent AO compared to those without AO (p < 0.05). Absolute and percent 
baseline changes in FVC were different across the groups (p < 0.05). An increase of 
0.15 ± 0.25 mL (4.5 ± 8.1%) in mean FVC was observed in patients with persistent 
AO. On the other hand, a decrease of 0.09 ± 0.15 mL (2.4 ± 3.4%) was noted in the 
group with fully reversible AO, while patients without AO did not show a significant 
change in FVC. Changes in IC were not significantly different across the three groups.
Significant BDR of FEV1 (> 200 mL and > 12%) was noted in 12.1% of the entire study 
population (Table 3). Patients with persisting AO and those with fully reversible AO 
had significant BDR of FEV1 more often than patients without AO (23.1% and 16.0% 
versus 1.9%, respectively, p < 0.05). 
Improvement in FEV1, especially percent improvement from baseline, correlated weakly 
to moderately with pre-BD pulmonary function (Table 4). There was no significant 
correlation between improvement in FEV1 and LVEF. Patients using non-selective 
Table 2   Results of spirometry pre- and post-bronchodilator.
Spirometry Pre-BD
(n = 116)
Post-BD
(n = 116)
p-value
FEV1, L 2.6 ± 0.7 2.8 ± 0.7 <0.001
FEV1, % pred. 91 ± 18 96 ± 18 <0.001
FVC, L 3.9 ± 1.0 3.9 ± 1.0 0.066
FVC, % pred. 104 ± 18 105 ± 18 0.066
FEV1/FVC, % 68 ± 8 71 ± 8 <0.001
PEF, L/s 8.1 ± 2.3 8.6 ± 2.3 <0.001
PEF, % pred. 107 ± 24 113 ± 24 <0.001
IC, L 3.0 ± 0.8 3.1 ± 0.8 0.093
IC, % pred. 104 ± 20 106 ± 22 0.068
FEF50, L/s 2.2 ± 1.0 2.6 ± 1.2 <0.001
FEF50, % pred. 56 ± 25 66 ± 28 <0.001
Data are presented as mean ± SD. Pulmonary function data, with exception of FEV1/FVC, are expressed 
as absolute values and as percent predicted, based on age, height, and sex. Abbreviations: FEF50, 
forced expiratory flow at 50% of FVC; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; 
IC, inspiratory capacity; PEF, peak expiratory flow; pre-/post-BD, pre- or post-bronchodilators.
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beta-blockers showed less reversibility of IC and forced expiratory flow at 50% of 
FVC (FEF50) than those using selective beta-blockers (0.0 ± 9.9% versus 5.2 ± 14.1%, 
p = 0.034, and 13.5 ± 17.3% versus 23.8 ± 23.9%, p = 0.014, respectively). The 
reversibility of other pulmonary function variables were similar between the groups. 
Also, baseline pulmonary function measurements and the prevalence of AO before 
Figure 2  Absolute (A) and percent baseline changes (B) in FEV1, FVC, and IC after 
bronchodilation. Data are presented as mean ± SD.  Patients with persistent airway 
obstruction (AO); Δ patients with fully reversible AO; o patients without AO. *p-value 
< 0.05. Abbreviations: FEV1, forced expiratory volume in 1 s; FVC, forced vital 
capacity; IC, inspiratory capacity.
A
B
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and after bronchodilation were not affected by the type of beta-blocker used. Stability 
of chronic HF, congestion on chest radiograph, a smoking history, and a history of 
atrial fibrillation did not impact the magnitude of BDR. However, patients with 
pulmonary congestion did have more impaired pulmonary function (Table 5) and 
were more obstructed after bronchodilation than those without pulmonary congestion 
Table 3   Patterns of bronchodilator responsiveness.
Patient groups No. Significant BDR, n (%)
All 116 14 (12.1)
Persistent AO 39 9 (23.1)
Fully reversible AO 25 4 (16.0)
No AO 52 1 (1.9)*†
Data are presented as number (%). Abbreviations: AO, airway obstruction; BDR, bronchodilator responsiveness. 
*p-value < 0.05 versus patients with persistent AO. †p-value < 0.05 versus patients with fully reversible AO.
Table 4   Relationship between improvement in FEV1 after bronchodilation and 
pre-bronchodilator pulmonary function.
 Absolute improvement  
in FEV1 (n = 116)
% Baseline improvement  
in FEV1 (n = 116)
 Correlation  
coefficient
p-value Correlation  
coefficient
p-value
FEV1, L 0.025 0.794 -0.234 0.012
FEV1, % pred. -0.216 0.020 -0.402 <0.001
FVC, L 0.152 0.103 -0.083 0.374
FVC, % pred. -0.083 0.376 -0.232 0.012
FEV1/FVC, % -0.248 0.007 -0.325 <0.001
PEF, L/s -0.085 0.364 -0.310 0.001
PEF, % pred. -0.243 0.008 -0.432 <0.001
IC, L 0.240 0.009 0.028 0.762
IC, % pred. 0.036 0.704 -0.080 0.394
FEF50, L/s -0.111 0.236 -0.301 0.001
FEF50, % pred. -0.176 0.058 -0.337 <0.001
Abbreviations: FEF50, forced expiratory flow at 50% of FVC; FEV1, forced expiratory volume in 1 s; FVC, 
forced vital capacity; IC, inspiratory capacity; PEF, peak expiratory flow.
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(56.3% versus 30%, p = 0.039). Current and former smokers had significantly lower 
pre- and post-BD FEV1/FVC ratio than non-smokers (67 ± 8% versus 72 ± 7%, p = 0.022, 
and 70 ± 8% versus 75 ± 7%, p = 0.011, respectively), but the prevalence of pre- and 
post-BD AO was not significantly different between the groups (pre-BD 57.4% 
versus 45.5%, p = 0.309, and post-BD 37.2% versus 18.2%, p = 0.089, respectively). 
Also, the proportion of patients with completely reversible airway obstruction after 
bronchodilation was not significantly different between current/former smokers and 
non-smokers (35% versus 60%, p = 0.170).
Clinically small, albeit statistically significant improvements in the Borg dyspnea 
score were observed after bronchodilation in the entire group (0.7 ± 1.2 versus 
0.9 ± 1.3, p = 0.002). Improvement in Borg score was not significantly different 
between responders or non-responders and it was not correlated to the improvement 
of FEV1. Also, the type of beta-blocker used, congestion on chest radiograph, a 
smoking history, and a history of atrial fibrillation did not impact the magnitude of 
Borg score improvement. 
Discussion
The results of this study confirm that inhaled bronchodilators have the potential to 
improve pulmonary function in patients with chronic HF, especially in those with AO. 
Importantly, full reversal of AO was seen in approximately 40% of patients who had 
pre-BD AO. However, improvement in dyspnea at rest after bronchodilation was 
small and did not correlate to improvement in pulmonary function.  
Our findings agree with the notion that airway narrowing associated with HF has a 
reversible component, as almost 40% of patients without a history of COPD or asthma 
who had pre-BD AO fully recovered after bronchodilation. The bronchodilatory effect 
is most probably explained by a reduction in the increased bronchial tone which may 
contribute to AO in patients with HF. Also, acutely delivered beta-agonists may act by 
improving cardiovascular hemodynamics and resorption of pulmonary edema.21 
However, considering the speed with which bronchodilation took place and the fact 
that most patients were not congested on chest radiograph, this was likely not the 
main mechanism of action.
Similar rates of fully reversible AO after bronchodilator testing were reported in a 
 population-based survey with reductions in AO prevalence between 32% and 39%, 
depending on the definition used to describe airflow obstruction.22 Consistent with 
the findings of that study we observed an increase in mean FEV1 and a decrease in 
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mean FVC in the fully reversible group of patients while the group with persistent AO 
did in fact show an increase in both parameters. This may explain why the group with 
persistent AO maintains a low ratio of FEV1/FVC after bronchodilation while this ratio 
normalizes in the group with reversible AO. We cannot exclude the possibility that 
some of the patients with complete reversal of AO in our study may have had 
previously undiagnosed asthma, as new-onset asthma may occur at any age and is 
often underrecognised or misdiagnosed in the elderly.23 However, there was no 
indication of asthma based on symptoms and physical examination in these patients 
except for one patient who was diagnosed with asthma after having participated in 
our study. Excluding this patient from the analysis still yielded similar rates of fully 
reversible AO (38.1%).
The incomplete reversal of AO in other patients may be due to irreversible anatomical 
alterations of the bronchial wall. In fact, AO in HF has been attributed to increased 
thickness of the airway wall due to bronchial mucosal swelling, peribronchial edema, 
and fibrosis. In addition, alveolar fluid accumulation may have contributed.2 Although 
most patients were not congested on chest radiograph and pulmonary congestion 
did not influence the magnitude of BDR, occult congestion with small airways 
compression may still have been present. In support, although pulmonary function 
improved with treatment for cardiac decompensation in the study of  Light and 
George,13 a great number of patients without a history of chronic obstructive lung 
disease still had evidence of airway obstruction. In the same study, airway obstruction 
did not improve after the administration of nebulized bronchodilators in the majority 
of the patients. Another plausible explanation for the persistent AO could be previously 
undiagnosed pulmonary disease, such as COPD, which is underrecognized in 
patients with HF.14 In support of this explanation, our patients with persistent AO 
without a previous diagnosis of COPD had comparable BDR to 38 chronic HF 
patients with known COPD of similar age, gender, and LVEF (data not shown). Thus, 
patients with post-BD AO, irrespective of a previous diagnosis of COPD, might 
similarly benefit from bronchodilators. On the other hand, although smoking, which is 
a major risk factor for COPD, was associated with lower FEV1/FVC ratio, the prevalence 
of post-BD AO was not significantly different between current/former smokers and 
non-smokers. This may be, however, the result of a small number of non-smokers 
included in our study. Other differential diagnosis of fixed AO should also be 
considered, such as bronchiectases and late-onset asthma.23 Finally, considering 
the physiological decline of the FEV1/FVC ratio with age, the low ratio of FEV1/FVC 
below 0.7 may still be normal for the age of the patients when using the lower limit of 
normal to define AO.24 
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An interesting finding of our study was that the use of non-selective beta-blockers 
instead of selective beta-blockers resulted in less reversibility of IC and FEF50. This 
finding is in line with prior evidence that non-selective beta-blockers may antagonize 
beta-agonists.25 In contrast, baseline pulmonary function, the prevalence of AO, and 
improvement of dyspnea were not affected by the type of beta-blocker used.
Prior research concerning the beneficial effects of bronchodilators in patients with HF is 
scarce. Improvements in pulmonary function,4-10 dyspnea,10 and exercise performance7 
have been reported. Some investigators have even observed an increase of mean 
FEV1 greater than 200 mL and 12% in patients with HF,
6, 8, 9 especially in those with 
AO,8 LVSD,9 and during acute decompensation of HF.6 However, contrasting results 
have also been published. In the study of Witte et al.10 nebulized salbutamol (5 mg) 
and ipratropium bromide (0.5 mg) reduced peripheral airways resistance and 
breathlessness during exercise in twelve patients with stable chronic HF and increased 
measures of compliance. However, spirometry was not altered significantly and 
exercise capacity did not improve with bronchodilation. Similarly, treatment with three 
weeks of salbutamol (slow-release 8 mg twice daily) did not improve exercise 
capacity or spirometric measurements in a randomized placebo-controlled trial of 
twelve chronic HF patients, although respiratory muscle strength did increase.11 
Furthermore, there were no improvements in symptom scores as measured with the 
Minnesota living with HF questionnaire and fatigue dyspnea index in the same study. 
In addition, pre-treatment with nebulized albuterol (2.5 mg) and ipratropium bromide 
(0.5 mg) had only minor effects on spirometric values at rest and did not influence 
exercise performance and visual analogue score for dyspnea at peak exercise in a 
randomized, double-blind crossover study of nine patients with HF.12 Furthermore, 
although a small but significant increase in maximal exercise capacity and spirometric 
indices was seen after pre-treatment with nebulized salbutamol (5 mg) and with 
ipratropium bromide (0.5 mg) in a randomized double-blind study of ten patients with 
chronic HF, both bronchodilators had no effect on the perception of dypnoea, as 
measured by a visual analogue scale.7 Finally, significant reversibility, defined as 
more than 400 mL increase in FEV1 after inhalation of 0.2 mg fenoterol and 40 μg 
ipratropium, could not be demonstrated in 131 patients admitted with HF in a 
prospective substudy,14 whereas only four of eighteen patients with congestive HF 
had greater than 10% improvement in FEV1 after bronchodilation in another study.
13 
Contrasting results across the studies might be attributed to the small number of 
patients studied and to the differences in study population, bronchodilators used, 
and definition of BDR. 
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There is no consensus about the drug, dose, or mode of administering a bronchodilator 
to test BDR.24 Since BDR may differ with the bronchodilator used, we sought to obtain 
maximal bronchodilation by combining two bronchodilators with different mechanisms 
of action. In addition, we used the most recent criteria to define significant BDR.15 
Whether the presence or absence of significant BDR in patients with chronic HF 
predicts prognostic outcome and clinical response to bronchodilators has not been 
investigated before and needs further research. The small improvement in dyspnea 
after bronchodilation was not significantly different between responders or non- 
responders in our patients with chronic HF. Similarly, BDR status did not predict 
clinical benefit of bronchodilators in patients with COPD in the UPLIFT trial.26   
       
Clinical implications
Based on our results, inhaled bronchodilators may have an additional role in the 
management of patients with chronic HF because of their potential to improve 
pulmonary function, especially in those with AO. This may contribute to decrease in 
perceived dyspnea and exercise limitation as demonstrated by others.7, 10 Although 
post-BD improvements in resting dyspnea were clinically small and not related to 
improvements in pulmonary function in this study, greater symptomatic relief might 
be possible in more symptomatic patients and with longer duration of treatment. 
Further randomized-control trials are needed to examine the clinical benefits as well 
as potential adverse events of bronchodilators in the treatment of chronic HF.27 
Concerns have been raised regarding the cardiovascular safety profile of these 
drugs.25, 27-30 Recently, reassuring cardiovascular safety data have been reported on 
long-acting anticholinergic bronchodilator tiotropium (HandiHaler) in patients with 
COPD.31, 32 However, HF patients are usually excluded from clinical trials and the 
impact of bronchodilators on outcomes has never been prospectively evaluated in 
patients with HF.27 Observational studies showed worse outcomes with bronchodilator 
use in patients with HF, including increased risk of HF hospitalization, increased 
mortality rates, in-hospital mechanical ventilation, intravenous vasodilator use, and 
major cardiovascular events. Possible mechanisms for adverse cardiovascular 
outcomes are arrythmogenesis, ischemia, hypoxemia, inflammation, cardiac 
remodeling, metabolic alterations (hypokalemia), and/or attenuation of beta-blocker 
benefits.25, 27 In addition, physicians must be wary of diminished hepatic metabolism 
of beta-agonists in patients with HF, leading to prolonged plasma half-life and 
accumulation with repeated doses.5 
Methodological limitations of most studies require further investigation of reported 
adverse events.25, 27 Until then, bronchodilators, in particular beta-agonists, must be 
used with caution in patients with cardiac disease.
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Study limitations
This retrospective observational study has several limitations that need to be addressed. 
First, it is important to realize that results may not be applicable to all patients with 
chronic HF, since we did not include patients with preserved systolic function, who 
seem to have less impaired pulmonary function.9 Therefore, the bronchodilator effect 
may have been greater in our patients with decreased systolic function. Also, patients 
with more severe and unstable HF could have been under represented in this study 
because of inability to participate. There is evidence to indicate greater bronchodilator 
effect during acute exacerbation of heart failure,6 although both stability of HF and 
congestion on chest radiograph did not impact the magnitude of BDR in the current 
study. Second, since we did not measure the effects of salbutamol and ipratropium 
bromide separately, comparison between both agents was not possible. It is not 
unlikely that some patients may respond more to salbutamol than ipratropium bromide 
and vice versa. However, similar improvements in FEV1 after salbutamol or ipratropium 
were noticed by Uren et al., although peak expiratory flow rates increased more with 
salbutamol.7 Third, we did not perform spirometry following placebo inhalations. 
However, no significant changes with placebo were observed in other studies,6, 7 
suggesting genuine effect of bronchodilators. Fourth, since we did not include a control 
group, we could not establish whether improvements in pulmonary function observed 
in patients with chronic HF are a reflection of the response observed in normal subjects. 
However, one in five patients with pre-BD AO had a significant BDR of FEV1 which is 
considered to exceed spontaneous variability, response to placebo inhalations, and 
the response observed in healthy individuals. Fifth, we did not measure the effect of 
bronchodilators on airway resistance. Patients who do not improve on spirometry may 
still benefit from bronchodilators due to a decrease in airway resistance.10 Also, we did 
not measure the effect of bronchodilators on heart rate and blood pressure. However, 
no cardiac adverse effects of broncho dilators such as palpitations and angina were 
reported during the study. Finally, it is important to realize that our findings are based 
on a single measurement of BDR and results may differ with serial measurements.26
Conclusion
In conclusion, inhaled bronchodilators may have an additional role in the management 
of patients with chronic HF because of their potential to improve pulmonary function, 
especially in those with AO. Despite excluding patients with a history of COPD or 
asthma, more than half of the chronic HF population studied had pre-BD AO that was 
fully reversible in approximately 40% of these patients. However, the clinical usefulness 
and potential adverse events of bronchodilators in the treatment of chronic HF need 
to be further established in randomized placebo-controlled trials.
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Reply to letter to the editor
We thank Dr. Alkhuja and colleagues for their comments on our recent article 
‘Bronchodilator responsiveness in patients with chronic heart failure’.1 They stressed 
the presence of airway obstruction (AO) and the role of bronchial hyperreactivity / 
hyperresponsiveness in patients with pulmonary congestive changes secondary to 
heart failure (HF) in the absence of chronic obstructive pulmonary disease (COPD). 
They suggested a lower threshold to the administration of inhaled bronchodilators in 
patients with heart failure without COPD, because of their potential to completely 
reverse the bronchial obstruction. Finally, they mentioned that the high prevalence of 
current or former smokers (81%) in our study may explain the presence of AO and the 
bronchodilator response found in our group of patients.
Several factors have been implied to play a role in the etiology of AO in patients with 
HF, including the effects of HF itself on pulmonary function as well as confounding 
influences such as smoking which may lead to COPD. In addition, a careful history 
taking, physical examination, and additional investigation should be carried out to 
exclude other co-morbidities that may be the cause of AO, such as bronchial asthma 
and bronchiectasis. 
AO due to HF itself has been attributed to several factors such as alveolar fluid 
accumulation, bronchial mucosal swelling, peribronchial edema and fibrosis, squamous 
metaplasia of bronchial epithelial cells induces by transforming growth factor-ß from 
the failing heart, geometric decrease in airway size from reduction in lung volume, 
abnormalities of autonomic control, neural (vagal reflex) bronchoconstriction secondary 
to pulmonary edema, and bronchial hyperresponsiveness which is thought to be 
mediated at least in part by dilatation of the bronchial vessels.2-5 Brenner et al.6 found 
transient AO to be an important clinical feature of systolic HF, as AO resolved in 24 of 
51 (47%) patients under more stable condition six months after discharge from the 
hospital. This finding is supported by other studies showing that AO due to HF may 
be partially or completely reversible by means of cardiac therapy alone.7, 8 Thus, the 
first step in treating AO in patients with HF should include optimizing treatment 
directed at the failing heart to achieve a more compensated state. Patients with 
chronic HF with persisting AO under maximal treatment for their HF may benefit from 
inhaled bronchodilators as additional treatment because of their potential to improve 
pulmonary function,1 dyspnea,1 and exercise performance.9 As an example, in our 
subgroup of patients with stable chronic HF without pulmonary congestion (n = 90) 
bronchodilators fully reversed AO in 21 of 48 patients (43.8%) who had AO before 
administration of bronchodilators. Mean absolute and percent baseline changes in 
FEV1 were 0.16 ± 0.15L and 6.4 ± 5.9%, respectively. However, contrasting results 
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have been published regarding the beneficial effect of bronchodilators in patients 
with HF1 and concerns have been raised regarding the cardiovascular safety profile 
of these drugs.10-14 Therefore, it is our belief that further randomized-control trials are 
needed to examine the clinical benefits as well as potential adverse events of bron-
chodilators in the treatment of HF before advising the routine use of bronchodilators 
in patients with HF.11 
Finally, although patients with pulmonary congestion as well as current and former 
smokers did have more impaired pulmonary function, both pulmonary congestion 
and a smoking history did not impact the magnitude of bronchodilator responsiveness 
in our study population (Table 1 and 2). In contrast,  ipratropium produced a far better 
bronchodilation during acute decompensation than after intensive treatment for heart 
failure in another study.15 The authors hypothesized that this finding could be 
explained by an increase in cholinergic bronchial tone due to lung edema or altered 
physical properties of the bronchial wall (more edematous) in HF which could explain 
why an equal smooth muscle relaxation induced by ipratropium would result in a 
greater bronchodilating effect during acute decompensation. Future research should 
focus on the value of bronchodilators in different subgroups of patients (acute 
decompensated versus chronic compensated HF, non-smokers versus current and 
former smokers, systolic HF versus patients with preserved systolic function, and so on).
Table 1   Bronchodilator responsiveness in patients with and without pulmonary 
congestion.
Bronchodilator responsiveness Congestion –  
(n = 100)
Congestion +  
(n = 16)
p-value
Absolute change in FEV1, L 0.15 ± 0.14 0.12 ± 0.16 0.427
% Baseline change in FEV1 6.1 ± 5.7 5.8 ± 6.8 0.844
Absolute change in FVC, L 0.05 ± 0.22 -0.02 ± 0.26 0.255
% Baseline change in FVC 1.6 ± 6.4 -0.1 ± 6.7 0.319
% Baseline change in FEV1/FVC 3.0 ± 3.6 3.9 ± 3.4 0.387
Data are presented as mean ± SD. Abbreviations: FEV1, forced expiratory volume in 1 s; FVC, forced 
vital capacity.
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Table 2   Bronchodilator responsiveness in non-smokers versus current or former 
smokers.
Bronchodilator responsiveness NS  
(n = 22)
CS/FS  
(n = 94)
p-value
Absolute change in FEV1, L 0.16 ± 0.13 0.15 ± 0.15 0.841
% Baseline change in FEV1 6.9 ± 6.0 5.9 ± 5.9 0.474
Absolute change in FVC, L 0.04 ± 0.18 0.04 ± 0.24 0.931
% Baseline change in FVC 2.0 ± 7.4 1.2 ± 6.3 0.627
% Baseline change in FEV1/FVC 3.5 ± 4.1 3.1 ± 3.5 0.567
Data are presented as mean ± SD. Abbreviations: CS, current smokers; FEV1, forced expiratory volume 
in 1 s; FS, former smokers; FVC, forced vital capacity; NS, non-smokers.
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Reply to letter to the editor
We thank Dr. Aydogan and colleagues for their comments on our recent article 
‘Bronchodilator responsiveness in patients with chronic heart failure’.1 Main results of 
our study were the improvement in almost all spirometric measurements of pulmonary 
function with inhaled bronchodilators in patients with chronic heart failure (HF) with 
left ventricular systolic dysfunction (LVSD), especially in those with airway obstruction. 
Importantly, full reversal of airway obstruction was seen in approximately 40% of 
patients who had pre-bronchodilator airway obstruction. However, improvement in 
Borg dyspnea scores at rest after bronchodilation was small (0.7 ± 1.2 versus 0.9 ± 
1.3, p = 0.002) and did not correlate to improvement in pulmonary function. Dr. 
Aydogan and colleagues suggested that undiagnosed or untreated pulmonary 
hypertension may be the reason for this result. They also noticed that the results of 
our study may be different in HF patients with diastolic HF.
Indeed, up to 60% of patients with severe LVSD and up to 70% of patients with 
isolated LV diastolic dysfunction may present with pulmonary hypertension which 
may be one of the reasons why patients with chronic HF complain of breathlessness.2 
However, other potential factors, alone or in combination, may also explain dyspnea 
experienced by these patients, including cardiac dysfunction, pulmonary function 
impairment (airway obstruction, restriction, diffusion impairment, decreased lung 
compliance, ventilation/perfusion mismatch), respiratory muscle dysfunction, expansion 
of the chest wall leading to activation of chest wall position sensors, direct stimulation 
of nerve endings by vascular distention and interstitial edema, and co-morbidities 
such as anemia and previously undiagnosed pulmonary disease.3, 4-5 This multi- 
factorial etiology of dyspnea in patients with chronic HF may explain the only small 
improvement in dyspnea despite significant improvement in pulmonary function in 
our study. However, we believe that the main reason for this rather small improvement 
in dyspnea and the lack of correlation with improvement in pulmonary function was 
probably the fact that the majority of our patients had stable chronic HF without signs 
of pulmonary congestions and therefore did not report symptoms of dyspnea at rest 
(67.2% had Borg scores between 0 and 0.5, mean Borg score 0.9 ± 1.3). Greater 
symptomatic relief might be possible in more symptomatic patients and with longer 
duration of treatment. In addition, selection of other outcome variables such as other 
dyspnea scales or exercise capacity may lead to different results. There is unfortunately 
no consensus on which tool should be used to measure breathlessness severity, 
despite breathlessness being an important limiting problem for patients with chronic 
HF.6 Also, since we did not measure the effect of bronchodilators on airway resistance, 
it remains unknown whether improvement in airway resistance correlates to 
improvement in dyspnea.
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Unfortunately, we do not have data on echocardiographic estimates of pulmonary 
artery pressure (PAP) in all of the patients studied. Not all patients underwent echo-
cardiography during this study, as it was performed only in patients without a recent 
(≤ 6 months) echocardiography to confirm persisting LVSD. Consequently, estimates 
of PAP obtained a few months before the study may not be representative of PAP 
during the study, as PAP depends on the actual volemic state of HF. In addition, 
echocardiography was not performed before and after bronchodilation in the current 
study and it therefore remains unknown whether bronchodilators may improve 
dyspnea by decreasing PAP. Evidence shows that acutely delivered beta-2 agonists 
in patients with chronic HF increase cardiac output/index and decrease systemic 
vascular resistance and left-sided cardiac filling pressures due to a combination of 
afterload reduction through vasodilatation and enhanced contractile state.7 Moreover, 
beta-2 agonists are known to decrease pulmonary edema in animal studies of HF 
and acute lung injury by increasing transepithelial sodium and chloride transport.7 
Thus these mechanisms, in addition to the bronchodilator effect of beta-2 agonists, 
provide a theoretical benefit of beta-2 agonists to patients with dyspnea due to HF. 
This hypothesis deserves further investigation.
Finally, as mentioned in the limitation section of our article, the results of our study 
indeed may not be applicable to all patients with chronic HF, since we did not include 
patients with preserved systolic function, who seem to have less impaired pulmonary 
function.8 Future studies should also focus on HF patients with preserved systolic 
function.
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Summary 
The aim of this thesis is to provide more insight in the occurrence of COPD and 
pulmonary function abnormalities using different definitions in patients with CHF. In 
addition, we aimed to determine under- and overdiagnosis of COPD, the necessity of 
performing serial PFTs to correctly diagnose COPD, and predictors of pulmonary 
function abnormalities using different definitions in patients with CHF. Finally, we 
aimed to evaluate the effect of inhaled bronchodilators on pulmonary function and 
dyspnea in patients with CHF.
In chapter 2 we determined the prevalence as well as over- and underdiagnosis of 
COPD according to the widely used GOLD criteria in 187 outpatients with stable 
non-congested CHF with LVSD. In addition, we investigated whether serial PFTs are 
necessary for the correct diagnosis of COPD in this group of patients by using initial 
as well as confirmatory spirometry three months after treatment with tiotropium in 
patients with newly diagnosed COPD. We found COPD to be a frequent co-morbidity 
in patients with CHF, occurring in approximately one-third of the patients. Importantly, 
it was often unrecognized (19%) or overdiagnosed (32%). Furthermore, we concluded 
that under stable and euvolemic conditions a confirmatory spirometry is unnecessary 
for the correct diagnosis of COPD, as it did not change a newly established diagnosis 
of COPD in the vast majority of patients with CHF.
In chapter 3 we determined the prevalence of COPD in 187 outpatients with stable 
non-congested CHF with LVSD according to two definitions of airflow obstruction: the 
LLN (ATS/ERS guidelines) versus the fixed ratio of FEV1/FVC < 0.70 (GOLD 
guidelines). We found that the exact definition of airflow obstruction alters COPD 
prevalence substantially; one fifth, rather than one third, of the patients with CHF had 
concomitant COPD using the LLN instead of the fixed ratio. Importantly, the LLN 
seemed to identify clinically more important COPD than the fixed ratio of 0.7; 38% of 
patients with GOLD-COPD who were potentially misclassified as having COPD 
(FEV1/FVC < 0.7 but > LLN) did not differ significantly from those without COPD in 
terms of respiratory symptoms and risk factors for COPD, whereas patients with 
LLN-COPD did. 
In chapter 4 we investigated the occurrence of pulmonary function abnormalities in 
164 outpatients with CHF with LVSD according to the LLN versus conventional cutoff 
values (i.e. FEV1/VC < LLN versus FEV1/FVC < 0.7 for airway obstruction, TLCOc < LLN 
versus < 80% predicted for diffusion impairment, and TLC < LLN versus < 80% predicted 
for restriction). We excluded patients with known pulmonary, pleural, neuromuscular, 
collagen vascular, or other diseases that could affect pulmonary function. Patients 
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with a BMI above 35 were excluded from the restriction prevalence analysis. Pulmonary 
function abnormalities, especially diffusion impairment and airway obstruction, were 
highly prevalent in patients with CHF, even in a stable and non-congested condition 
and even though we used the LLN to better account for age. However, prevalence 
rates varied significantly according to the definition used between 44% and 58% for 
diffusion impairment and between 26% and 37% for airway obstruction using the 
LLN versus conventional cutoff values, respectively. In contrast to previous reports, 
restriction was found to be infrequent in this population of less severe and mainly 
stable CHF patients without pulmonary congestion, irrespective of the definition used 
(7% versus 5%, respectively). The conventional cutoff values classified more patients 
as having diffusion impairment, airway obstruction, or a mixed category compared to 
the LLN and failed to identify correctly 34% of patients with normal lung function 
placing them falsely within a pulmonary dysfunction category. Using the conventional 
cutoff values instead of the LLN led to misclassification of 27% of the patients.
In chapter 5 we assessed predictors of pulmonary function impairment in 164 
outpatients with CHF with LVSD according to the LLN in comparison to conventional 
cutoff values. The same exclusion criteria as described in chapter 4 were applied. We 
found that the LLN criterion identified an extra independent predictor of diffusion 
impairment compared to the 80% predicted value; in addition to BMI, PY, and VA, 
female gender also turned out to be an independent predictor of diffusion impairment 
using the LLN. A smoking history of ≥ 10 PY was a significant predictor of diffusion 
impairment and airway obstruction using the LLN criterion, but not using the 
conventional cutoff values. However, lowering the cutoff points of conventional criteria 
to match the more stringent LLN and thus avoid overdiagnosis of diffusion impairment 
and airway obstruction in the elderly, produced similar results as the LLN. Lower lung 
volumes were found in patients with pulmonary congestion, cardiomegaly, and a 
history of CABG. 
Finally, in chapter 6 we evaluated retrospectively the effect of inhaled bronchodilators 
(combined 400 μg salbutamol and 80 μg ipratropium bromide) on pulmonary function 
and dyspnea in 116 outpatients with CHF and LVSD. Patients with a history of COPD 
or asthma were excluded. The results of our study confirmed that inhaled broncho-
dilators have the potential to improve pulmonary function in patients with CHF, 
especially in those with airway obstruction. Importantly, full reversal of airway 
obstruction was seen in approximately 40% of patients without a history of COPD or 
asthma who had pre-bronchodilator airway obstruction. Significant improvements in 
pulmonary function were noted in all spirometric indices except for FVC and 
inspiratory capacity (IC) in the entire study population. Significant BDR of FEV1 
(> 200 mL and > 12% from the baseline value) was noted in 12%. Patients with both 
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persisting and fully reversible airway obstruction had significant BDR of FEV1 more 
often than patients without airway obstruction (23%, 16%, and 2%, respectively). 
Improvement in dyspnea at rest after bronchodilation was, however, small and did 
not correlate to improvement in pulmonary function in this selected study population. 
174
Chapter 7
Conclusions 
§	COPD is a frequent co-morbidity in patients with stable non-congested CHF with 
LVSD, but is often unrecognized or overdiagnosed.
§	Spirometry should be used under stable and euvolemic conditions to decrease 
the burden of undiagnosed or overdiagnosed COPD in patients with CHF. Under 
these conditions, a confirmatory spirometry is unnecessary, as it does not change 
a newly established diagnosis of COPD in the vast majority of patients with CHF.
§	The exact definition of airflow obstruction alters COPD prevalence substantially; 
one fifth, rather than one third, of the patients with CHF have concomitant COPD 
using the LLN instead of the fixed ratio. 
§	LLN may identify clinically more important COPD than the fixed ratio of 0.7 as 
patients who are potentially misclassified as having COPD, in contrast to patients 
with LLN-COPD, do not differ significantly from those without COPD in terms of 
respiratory symptoms and risk factors for COPD. 
§	Pulmonary function abnormalities, especially diffusion impairment and airway 
obstruction, are highly prevalent in patients with CHF. 
§	Conventional cutoff values classify more patients as having diffusion impairment, 
airway obstruction, or a mixed category compared to the LLN, leading to mis-
classification of 27% of the patients. 
§	The LLN identifies more predictors of diffusion impairment and airway obstruction 
compared to the conventional cutoff values. However, lowering the conventional 
cutoff points to match the more stringent LLN, produces similar results as the LLN.
§	Inhaled bronchodilators may have an additional role in the management of patients 
with CHF because of their potential to improve pulmonary function, especially in 
those with airway obstruction. Improvement in dyspnea is, however, small and 
does not correlate to improvement in pulmonary function in this selected study 
population. 
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General discussion 
1. COPD in CHF 
COPD and HF are both common diseases with significant morbidity, mortality, and 
health care use.1, 2 The combination of both diseases presents many diagnostic and 
therapeutic challenges as well as adverse prognostic implications.1-13 Although the 
occurrence of HF in patients with COPD has been assessed extensively in prior 
research, the occurrence of COPD in patients with HF has received much less 
attention.4 Moreover, although spirometry is considered to be the gold standard for 
the diagnosis of COPD, data on the prevalence of COPD based on spirometry in 
patients with HF are scarce and spirometry remains widely underused.14 Furthermore, 
since airway obstruction is a dynamic phenomenon in HF, as it may be present in 
congestive HF and may disappear with treatment of HF,15 a careful timing and 
interpretation of PFTs is required to avoid misdiagnosis and inappropriate treatment 
of COPD.1 Ideally, PFTs should be used under stable conditions when clinically 
euvolemic to establish a valid diagnosis of COPD. However, data on the need of 
serial pulmonary function measurements to confirm persistent airway obstruction 
and thus COPD are lacking in patients with stable non-congested CHF. We therefore 
aimed to determine the prevalence of COPD using spirometry in outpatients with 
stable CHF without pulmonary congestion. In addition, we investigated whether serial 
PFTs are necessary for the correct diagnosis of COPD in this group of patients by 
using initial as well as confirmatory spirometry three months after treatment with 
tiotropium in patients with newly diagnosed COPD. We observed a high prevalence 
of COPD (32.1%) according to the GOLD criteria in a well defined subgroup of 187 
stable non-congested CHF outpatients with LVSD (i.e. LVEF < 40%) (chapter 2). 
Using a follow-up spirometry after three months of treatment with tiotropium to 
confirm initial diagnosis of de novo COPD did not change COPD prevalence 
significantly: 32.6% initially versus 32.1% after three months of follow-up. Importantly, 
COPD was often unrecognized (19%) or overdiagnosed (32%). Our results support 
previous findings that COPD frequently coexists with HF (chapter 1.3, Table 1), but 
are in contrast to the study of Brenner et al.15 who found only 9% of patients with 
systolic HF to have concomitant COPD, probably explained by the high number of 
never smokers (46%) included in their study. Several factors might explain the high 
coexistence of these two diseases, as described in the general introduction. Since 
spirometry is still underutilized, even in a tertiary-care facility,14 it seems reasonable to 
consider routine spirometry testing in patients with CHF to diagnose or rule out 
COPD, a co-morbidity with important therapeutic and prognostic implications,1 which 
is still greatly under- and overdiagnosed as found in our study. Indeed, diagnostic 
difficulties have been stressed before, including the overlap in signs, symptoms, and 
risk factors, underuse of spirometry, and lower diagnostic accuracy of several tests, 
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including difficulties with interpreting spirometry results.1, 10, 14, 16 This raises concerns 
regarding possible inappropriate treatment of COPD in an already vulnerable group 
of patients and as a result possible adverse impact on health and outcome. 
Unfortunately, the current study was not large enough to find predictors of newly 
diagnosed COPD to make specific recommendations regarding which subgroup of 
patients should be tested. Also, it should be noted that a large proportion (69%) of 
newly diagnosed COPD patients according to GOLD criteria had only mild airway 
obstruction that may represent a physiological decline of lung function with age 
instead of a disease.17, 18 It is unknown whether an additional diagnosis and treatment 
of COPD in these patients would improve health outcomes and change their 
prognosis. This warrants further research to establish the effectiveness of screening 
of patients with CHF for COPD in terms of symptomatic relief and improvement of the 
outcome as well as cost-effectiveness of such a policy. Until then, spirometry could 
be used in CHF patients with pulmonary symptoms despite an adequate treatment 
for their HF, especially in the presence of risk factors for COPD, such as a smoking 
history of ≥ 10 PY and occupational exposures. Importantly, spirometry should be 
used when clinically stable and euvolemic to avoid both misdiagnosis and 
inappropriate treatment of COPD.1, 15 Under these conditions, a confirmatory 
spirometry seems to be unnecessary, as it did not change a newly established 
diagnosis of COPD in the vast majority of patients with CHF in our study (chapter 2). 
Finally, awareness of the co-occurrence of both diseases is essential among 
pulmonologists and cardiologists and collaboration between the two specialists is 
crucial to ensure optimal management of these patients. A better recognition and 
treatment of the two diseases may lead to less morbidity and mortality. 
2. COPD in CHF: the LLN versus the fixed ratio of FEV1/FVC
Spirometry is required for the diagnosis of COPD by measuring persistent airflow 
limitation.19 However, there is still no consensus on the most appropriate threshold of 
FEV1/FVC for diagnosing airflow limitation.
18, 20-29 The GOLD guidelines recommend 
the use of the fixed ratio of FEV1/FVC < 0.70 for the sake of simplicity.
19 However, a 
growing body of literature indicates that considering the physiological decline of the 
FEV1/FVC ratio with age the use of the fixed ratio may lead to overdiagnosis of COPD 
in elderly subjects17, 30-45 and underdiagnosis of COPD in young adults.38-47 To avoid 
misclassification, the ATS/ERS recommends the use of statistically derived LLN 
values for FEV1/VC that are based on the normal distribution and that classify the 
bottom 5% of the healthy population as abnormal.48 This is particularly important in 
patients with HF, given that HF is most prevalent among elderly individuals.49 Thus, 
the earlier mentioned (chapter 2) and previously reported COPD prevalence rates 
(chapter 1.3, Table 1) based on the fixed ratio of 0.7 may have overestimated the true 
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prevalence of COPD in patients with HF. Although population-based studies have 
shown that the application of different criteria to define airflow obstruction dramatically 
changes the prevalence of COPD,33-35, 50-53 it is less well understood to what extent this 
occurs in patients with HF.54, 55 Therefore, the aim of the study presented in chapter 3 
was to determine COPD prevalence in patients with CHF according to two definitions 
of airflow obstruction: the LLN versus the fixed ratio of FEV1/FVC < 0.7. We performed 
additional analysis in the same study population as described in chapter 2. The LLN 
was calculated by subtracting 1.64 times the RSD from the predicted value based on 
the reference values of the European Community for Coal and Steel.56 We found that 
the exact definition of airflow obstruction altered COPD prevalence substantially; one 
fifth, rather than one third, of the patients with CHF had concomitant COPD using the 
LLN instead of the fixed ratio. This finding is in line with the results of Steinacher et al.54 
who reported COPD prevalence rates of 44% according to the GOLD criteria (fixed 
ratio) and 25% according to the ATS/ERS criteria (LLN) in 89 outpatients with stable 
CHF. However, this finding was not as well supported in another study of 118 elderly 
(≥ 65 years) patients with stable CHF, most likely because of the selection of patients 
with ≥ 10 PY (COPD prevalence 31% versus 29%).55 
Thirty-eight percent of patients with GOLD-COPD in our study (chapter 3) were 
potentially misclassified as having COPD (FEV1/FVC < 0.7 but > LLN). In contrast to 
patients with LLN-COPD, potentially misclassified patients did not differ significantly 
from those without COPD regarding respiratory symptoms and risk factors for COPD. 
LLN may therefore identify clinically more important COPD than the fixed ratio of 0.7.
An incorrect diagnosis of COPD may result in unnecessary treatment for COPD with 
possible side-effects and adverse cardiovascular events associated with pharmaco-
logical treatment for COPD and undertreatment with life-saving beta-blockers.22, 57, 58 
Moreover, an incorrect diagnosis and interventions for COPD may have a considerable 
psychological impact on the subject and his/her family and may lead to unnecessary 
costs.22 Conversely, misclassifying a number of young adults already affected by 
COPD as healthy, prevents early interventions that could limit disease progression. 
Therefore, there is a need for clear diagnostic criteria for COPD to avoid diagnostic 
confusion, incorrect diagnosis, and inappropriate treatment.  
Unfortunately, there is no gold standard for the diagnosis of COPD. The hallmark of 
the disease is the presence of airflow limitation that is not fully reversible and is usually 
progressive in nature.19 However, there is no consensus on the spirometric criteria for 
the diagnosis of COPD.18, 20-29 In theory, the most appropriate threshold for FEV1/FVC 
in diagnosing COPD is the one with the best combination of sensitivity and specificity.21 
However, since there is no real gold standard for COPD calculating these numbers is 
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not possible and a true comparison of the fixed value and the LLN is not possible.21 
Considering the physiological decline of the FEV1/FVC ratio with age, the application 
of statistically derived LLN values for FEV1/FVC should be preferred to avoid 
overdiagnosis of COPD in elderly subjects17, 30-45 and underdiagnosis in young 
adults.38-47 However, when choosing appropriate cutoff values to define disease one 
should not only consider the statistical range of normality, but also clinically 
meaningful disease outcomes. An increasing number of studies have focused on the 
clinical impact of these different criteria. However, contrasting results have been 
reported and a recent review of 11 studies could not reveal a clear preference for one 
criterion over the other.20 The results of some studies are in favor of using the fixed 
ratio of FEV1/FVC < 0.7. Mannino et. al reported higher adjusted mortality risk
59, 60 
and increased risk of COPD-related hospitalizations59 in patients with FEV1/FVC ratio 
< 0.7 but > LLN (‘in-between group’) in comparison to subjects with normal lung 
function, suggesting that the fixed ratio of 0.7 identifies at-risk patients who would 
have been classified as normal according to the LLN. In addition, this in-between 
group has been reported to have a worse health-related quality of life than the 
non-COPD group in the study of Garcίa-Rio et.al.32 However, no differences between 
the two groups were found in the same study for respiratory exacerbations, 6-minute 
walk distance, daily physical activity, systemic biomarkers, and cardiovascular 
disease, whereas patients with mild COPD did have more respiratory exacerbations, 
greater risk for cardiovascular disease, and greater serum concentrations of nitrites/
nitrates than the control group.32 Another cross-sectional study found this in-between 
group to have similar consumption of health-care resources (number of emergency 
room visits, hospitalizations due to COPD exacerbation, pharmacological treatment) 
and associated cardiovascular disorders, with exception of ischemic heart disease, 
compared to patients with LLN-COPD.61 Furthermore, adopting an expert panel as 
the reference standard, the fixed ratio of FEV1/FVC < 0.7 was more accurate to detect 
COPD in a symptomatic primary care population than the LLN.62 Finally, subjects with 
airflow obstruction by fixed ratio only had a greater degree of emphysema, air wall 
thickening, and gas trapping using quantitative CT as gold standard than smoking 
controls without airflow obstruction.63, 64 In addition, they had higher TLC, lower 
diffusing capacity, and more respiratory symptoms.64 However, all of these variables 
were even more impaired in patients with airflow obstruction according to both the 
fixed ratio and the LLN.63, 64 On follow-up, the fixed ratio only group had more 
exacerbations, higher scores on St. George’s Respiratory Questionnaire, and more 
frequent initiation of oxygen therapy than smoking controls.63 
The results of other studies are more in favor of using the LLN. Patients with FEV1/FVC 
ratio < 0.7 but > LLN did not show accelerated post-bronchodilator FEV1 decline or 
more frequent exacerbations, whereas subjects with airway obstruction according to 
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the LLN did.65, 66 Also, these patients did not seem to have clinically important airway 
obstruction in terms of the presence of respiratory symptoms, although they did 
report a diagnosis of heart disease more often than subject with normal lung function, 
suggesting that they might be at risk and should be followed carefully.67 Additionally, 
the risk of death, COPD hospitalization, and the odds of having respiratory symptoms 
were only elevated amongst participants with FEV1/FVC ratio < LLN.
68, 69 Furthermore, 
COPD according to the LLN criterion showed a stronger association with cardiac and 
all-cause hospitalization than COPD according to the fixed ratio.70 Finally, misidentified 
subjects with lung function below the normal range (FEV1/FVC ratio < LLN but > 0.7) 
had a significantly higher risk of developing COPD and a higher use of health 
resources because of breathing problems than subjects without airflow obstruction.46, 71 
The results of Wollmer et. al did not favor either the LLN or the fixed ratio, but found 
the group of patients with FEV1/FVC ratio < 0.7 but > LLN to form an intermediate 
group with respect to lung function impairment and mortality rates,72 implicating that 
careful evaluation of patient history and extended PFTs may be warranted in this 
group of patients. More longitudinal studies are needed to determine which criterion 
is better and clinically more relevant.20, 21 
In clinical practice, decisions are not made on the basis of a single test and there are 
diagnostic difficulties that go beyond the discussion regarding which definition 
should be used. It is not possible to categorically separate sick from healthy 
individuals based on spirometry, since there is some overlap in FEV1/FVC ratio 
between those with and without respiratory disease, independent of the definition 
used. Therefore, there is always the risk of false positive and false negative results, 
especially in the grey area between normal and abnormal pulmonary function. 
Moreover, both definitions cannot exclude airflow obstruction with certainty because, 
in a minority of cases, FEV1 and FVC may be decreased proportionally as a result of 
an isolated increase in RV,48 which may lead to a false diagnosis of restriction instead 
of obstruction. Also, conditions that increase lung stiffness, such as interstitial edema 
in HF, may mask airflow obstruction.73Additional body plethysmography may therefore 
be necessary for the correct diagnosis. Furthermore, reduced FEV1/FVC ratio with 
normal FEV1 may represent a physiological variant possibly due to dysanaptic lung 
growth, by which lung volume is disproportionately large compared with airway 
size.73 Finally, structural lung changes (emphysema) may already be present before 
or even in the absence of airflow limitation.73 In light of these diagnostic difficulties, a 
more comprehensive approach is required, taking into account clinical features, 
pulmonary function tests, and radiological findings. Clinical findings, including history 
and exposure to risk factors, can facilitate the diagnosis of COPD,19 and the physician 
ultimately determines the medical significance of an abnormal spirometric value 
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based on these clinical findings. In support, an expert diagnosis of COPD has been 
found to better predict COPD exacerbations, hospitalizations, and mortality than 
GOLD or LLN criteria.74 However, these decisions are more complicated in patients 
with HF due to overlap in signs and symptoms as well as risk factors.1 Extended PFTs, 
including diffusion capacity and body plethysmography, may be warranted to 
facilitate correct diagnosis in this group of patients. Indeed, from all PFT variables 
(besides FEV1/FVC), FEV1, RV/TLC, and diffusing capacity performed best in 
predicting an expert diagnosis of COPD.74 Moreover, incorporating FEV1 and RV/TLC 
into the GOLD-COPD and LLN-based definition improved the diagnostic accuracy 
significantly and brought both definitions closer to expert panel diagnosis of COPD 
and to daily clinical practice.74 Finally, radiological findings (computed tomography) 
may advance further decision making.
3 Pulmonary function impairment in CHF 
Isolated or combined pulmonary function abnormalities, such as restriction, diffusion 
impairment, and to a lesser extent airway obstruction are common in patients with 
CHF75-82 and can contribute to the perception of dyspnea83 and exercise intolerance.83-
89 Reported prevalence rates of pulmonary function abnormalities in patients with 
CHF vary substantially between 41% and 93% for diffusion impairment, 21-55% for 
restriction, and 14-60% for airway obstruction (chapter 1.4, Table 2). These varying 
rates across the studies can be partly explained by the usually small number of 
patients included and differences in study population as well as diagnostic criteria 
used to define pulmonary function abnormalities. The majority of studies have used 
conventional cutoff values to define an abnormality, failing to diagnose pulmonary 
function impairment according to internationally accepted diagnostic criteria.48 These 
conventional cutoff values have neither statistical nor physiological validity48, 90 and 
may misclassify more than 20% of patients leading to false-positive diagnosis in the 
elderly and underdiagnosis in younger patients.38 Therefore, pulmonary function 
abnormalities may have been overestimated in previous studies of mainly old CHF 
patients. Moreover, some studies described a restrictive lung function defect on the 
basis of reduced FEV1 and FVC with normal FEV1/FVC ratio.
91 However, because 
FEV1 and FVC may also be proportionately reduced with a normal ratio in patients 
with severe COPD and gas trapping, the diagnosis of restriction additionally requires 
detection of reduced TLC by plethysmography. Finally, a large number of studies 
have included (potential) heart transplant recipients, who represent one extreme of 
the HF spectrum.91-97 Therefore, it is less known to what extent CHF patients who do 
not belong to the most severe category of HF have pulmonary function abnormalities 
and which of these abnormalities prevail. Given the gaps in current knowledge we 
investigated the occurrence of pulmonary function abnormalities in 164 outpatients 
with CHF with LVSD according to the LLN versus conventional cutoff values (i.e. 
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FEV1/VC < LLN versus FEV1/FVC < 0.7 for airway obstruction, TLCOc < LLN versus 
< 80% predicted for diffusion impairment, and TLC < LLN versus < 80% predicted 
for restriction) (chapter 4). We excluded patients with known pulmonary, pleural (with 
exception of pleural effusion due to HF), neuromuscular, collagen vascular, or other 
diseases that could affect pulmonary function. Patients with a BMI above 35 were 
excluded from the restriction prevalence analysis. Pulmonary function abnormalities, 
especially diffusion impairment and airway obstruction, were found to be highly 
prevalent in patients with CHF, even in a stable and non-congested condition and 
even though we used the LLN to better account for age. However, prevalence rates 
varied significantly according to the definition used between 44% and 58% for 
diffusion impairment and between 26% and 37% for airway obstruction using the LLN 
versus conventional cutoff values, respectively. In contrast to previous reports, 
restriction was found to be infrequent in this population of less severe and mainly 
stable CHF patients without pulmonary congestion, irrespective of the definition used 
(7% versus 5%, respectively). The conventional cutoff values classified more patients 
as having diffusion impairment, airway obstruction, or a mixed category compared to 
the LLN and failed to identify correctly 34% of patients with normal lung function 
placing them falsely within a pulmonary dysfunction category. Using the conventional 
cutoff values instead of the LLN led to misclassification of 27% of the patients. 
Misinterpretation of pulmonary function test results may lead to incorrect diagnosis of 
disease in elderly patients with HF, such as COPD, and as a consequence 
unnecessary treatment with possible side effects, detrimental psychological impact, 
and needless costs. Moreover, results may be interpreted as having more severe or 
unstable HF due to the effects of HF on pulmonary function and as a result 
unnecessary intensified treatment for HF. Finally, misdiagnosis may have interfered 
with the interpretation of prior research aiming to investigate the impact of HF and 
several clinical variables on pulmonary function. Therefore, the purpose of the study 
presented in chapter 5 was to assess predictors of pulmonary function impairment 
in 164 outpatients with CHF with LVSD according to the LLN in comparison to 
conventional cutoff values (percent predicted and the fixed ratio of FEV1/FVC). The 
same exclusion criteria as described in chapter 4 were applied. We found that the 
LLN criterion identified an extra independent predictor of diffusion impairment 
compared to the 80% predicted value; in addition to BMI, PY, and VA, female gender 
also turned out to be an independent predictor of diffusion impairment using the LLN. 
Furthermore, a smoking history of ≥ 10 PY was a significant predictor of diffusion 
impairment and airway obstruction using the LLN criterion, but not using the 
conventional cutoff values, implying that inclusion of patients who are incorrectly 
labeled as having pulmonary dysfunction distorted the effect of smoking on 
pulmonary function. Lowering the cutoff points of conventional criteria to match the 
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more stringent LLN and thus avoid overdiagnosis of diffusion impairment and airway 
obstruction in the elderly, produced similar results as the LLN. Finally, lower lung 
volumes were found in patients with pulmonary congestion, cardiomegaly, and a 
history of CABG. 
Several factors have been implied to play a role in the etiology of pulmonary function 
impairment in patients with HF, including the effects of HF itself on pulmonary function 
in addition to confounding influences such as smoking, CABG, and obesity.75-82, 98, 99 
Physicians should also consider the possibility that pulmonary function impairment in 
patients with HF represents previously undiagnosed pulmonary disease such as 
COPD. In fact, COPD is frequently unrecognized in patients with HF (chapter 1.3, 
Table 1). A careful evaluation of the patient and potential treatment options is therefore 
necessary before ascribing pulmonary function impairment only to the effects of HF. 
Although the underlying mechanisms are not clear, women seemed to be more 
sensitive to the detrimental effects of HF on diffusing capacity in our study. Gender 
differences in pulmonary function have been recognized before, but not specifically 
in the HF population. Adult women have been reported to have lower resting lung 
diffusing capacity corrected for hemoglobin, smaller lung volumes, and lower 
maximal expiratory flow rates, even when corrected for age and standing height 
relative to men.100 It has been suggested that these gender differences in part can be 
explained by pulmonary structural differences (fewer total number of alveoli and 
smaller airway diameter relative to lung size) and hormonal influences  in women.100 
More research is needed regarding the influence of gender on pulmonary function in 
general and specifically in the HF population.
The protective association between a higher BMI and less likelihood of having 
diffusion impairment has not been described before in patients with CHF. However, 
some studies in healthy obese nonsmokers have suggested that diffusing capacity 
may be increased in extremely obese subjects, probably as a result of the increase in 
blood volume.101 
Irrespective of the causes, pulmonary function abnormalities associated with CHF 
may explain part of the symptoms and functional disability encountered in these 
patients.83-89, 102 Moreover, pulmonary function impairment increases with the severity 
of HF,87, 88, 103 provides important prognostic information,104-107 and may ameliorate or 
normalize with several treatment modalities, such as pharmacological and non-phar-
macological treatment of HF and anti-obstructive therapy with bronchodilators as 
described in the general introduction. Pulmonary function might thus be used as a 
guide for the evaluation of patients with CHF, with respect to severity of disease, 
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prognosis, and response to treatment. More studies involving therapeutic approaches 
to improve pulmonary function in CHF are warranted to determine whether treatment 
directed at correcting pulmonary function impairment may lead to symptomatic relief, 
increased exercise capacity, and improvement of the outcome.
4. The role of inhaled bronchodilators in CHF
As mentioned before, airway obstruction may be present in patients with CHF. 
Treatment directed at reversing airway obstruction with bronchodilators may thus 
have an additional role in the management of HF. There are, however, only few studies 
concerning the beneficial effects of bronchodilators in patients with HF. Improvements 
in pulmonary function,108-114 dyspnea,111 and exercise performance114 have been 
reported. Some investigators have even observed an increase of mean FEV1 greater 
than 200 mL and 12% in patients with HF,108-110 especially in those with airway 
obstruction,109 LVSD,108 and during acute decompensation of HF.110 However, not all 
could confirm these findings.111, 114-118 Contrasting results across the studies might be 
attributed to the small number of patients studied and to the differences in study 
population, bronchodilators used, and definition of BDR. The purpose of the 
retrospective observational study presented in chapter 6 was to evaluate the effect 
of maximal bronchodilation with combined inhaled salbutamol (400 μg) and 
ipratropium bromide (80 μg) on pulmonary function and dyspnea in 116 patients with 
CHF without a history of COPD or asthma. In addition, we determined the proportion 
of patients with significant BDR (i.e. responder), defined as post-bronchodilator 
increase in FEV1 greater than 200 mL and 12% from the baseline value. Since there is 
no consensus about the drug, dose, or mode of administering a bronchodilator to 
test BDR,48 and BDR may differ with the bronchodilator used, we sought to obtain 
maximal bronchodilation by combining two bronchodilators with different mechanisms 
of action. The results of our study confirmed that inhaled bronchodilators have the 
potential to improve pulmonary function in patients with CHF, especially in those with 
airway obstruction. Importantly, full reversal of airway obstruction was seen in 
approximately 40% of patients without a history of COPD or asthma who had 
pre-bronchodilator airway obstruction. Significant improvements in pulmonary 
function were noted in all spirometric indices except for FVC and IC in the entire study 
population. Significant BDR of FEV1 was noted in 12%. Patients with persisting airway 
obstruction and those with fully reversible airway obstruction had significant BDR of 
FEV1 more often than patients without airway obstruction (23%, 16%, and 2%, 
respectively). Improvement in dyspnea at rest after bronchodilation was, however, 
small and did not correlate to improvement in pulmonary function.  
The bronchodilatory effect is most probably explained by a reduction in the increased 
bronchial tone which may contribute to airway obstruction in patients with HF. Also, 
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acutely delivered beta-agonists may act by improving cardiovascular hemodynamics 
and resorption of pulmonary edema.119 However, considering the speed with which 
bronchodilation took place and the fact that most patients were not congested on 
chest radiograph, this was likely not the main mechanism of action. Also, we observed 
an increase in mean FEV1 and a decrease in mean FVC in the fully reversible group 
of patients, while the group with persistent airway obstruction did in fact show an 
increase in both parameters. This may explain why the group with persistent airway 
obstruction maintained a low ratio of FEV1/FVC after bronchodilation while this ratio 
normalized in the group with reversible airway obstruction. Finally, we cannot exclude 
the possibility that some of the patients with complete reversal of airway obstruction 
in our study may have had previously undiagnosed asthma, as new-onset asthma 
may occur at any age and is often underrecognised or misdiagnosed in the elderly.120 
However, there was no indication of asthma based on symptoms and physical 
examination in these patients except for one patient who was diagnosed with asthma 
after having participated in our study. Excluding this patient from the analysis still 
yielded similar rates of fully reversible airway obstruction (38%).
The incomplete reversal of airway obstruction in other patients may be due to 
irreversible anatomical alterations of the bronchial wall or subclinical pulmonary 
congestion. In addition, previously undiagnosed pulmonary disease, such as COPD, 
bronchiectases, and late-onset asthma, should also be considered in the differential 
diagnosis of fixed airway obstruction. 
Another interesting finding of our study was that the use of non-selective beta-blockers 
instead of selective beta-blockers resulted in less reversibility of IC and FEF50. This 
finding is in line with prior evidence that non-selective beta-blockers may antagonize 
beta-agonists.57 In contrast, baseline pulmonary function, the prevalence of airway 
obstruction, and improvement of dyspnea were not affected by the type of beta- 
blocker used.
Although post-bronchodilator improvements in resting dyspnea were clinically small 
and not related to improvements in pulmonary function in this selected study population, 
greater symptomatic relief might be possible in more symptomatic patients and with 
longer duration of treatment. Further RCTs are needed to examine the clinical benefits 
as well as potential adverse events of bronchodilators in the treatment of CHF.121 
Concerns have been raised regarding the cardiovascular safety profile of these 
drugs.57, 121-124 Recently, reassuring cardiovascular safety data have been reported on 
long-acting anticholinergic bronchodilator tiotropium HandiHaler125-133 as well as 
Respimat.134 However, HF patients are usually excluded from clinical trials and the 
impact of bronchodilators on outcomes has never been prospectively evaluated in 
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patients with HF.121 Furthermore, methodological limitations of most studies require 
further investigation of reported adverse events.57, 121 Until then, bronchodilators, in 
particular beta-agonists, must be used with caution in patients with underlying 
cardiac condition such as HF, given the paucity of data in such patients. 
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Future perspectives
Although this thesis has provided answers to many questions, there are still many 
challenges for future research. 
Despite the close relationship between lung and heart diseases, pulmonologists and 
cardiologists often focus on their own field of specialization.8 Meanwhile, HF and 
COPD often remain an ignored combination11 and the degree of awareness is low 
among both cardiologists as well as pulmonologists.135 In view of diagnostic, 
therapeutic, and prognostic implications of the coexistence of COPD and HF, more 
attention should be paid to the concomitant presence of both diseases in clinical 
practice and research.11 A more combined and integrated approach in the diagnosis 
and treatment of concurrent COPD and HF is required. 
Although we found COPD to be frequently unrecognized in patients with CHF 
(chapter 2 and 3), it is unknown whether an additional diagnosis and treatment of 
COPD in these patients will improve health outcomes and change their prognosis. 
This warrants further research to establish the effectiveness of screening of patients 
with CHF for COPD in terms of symptomatic relief and improvement of the outcome 
as well as cost-effectiveness of such a policy. Additionally, future research should 
focus on the cardiovascular safety profile of bronchodilators, especially in patients 
with underlying cardiac condition such as HF. 
Furthermore, our findings stress the need for a clear definition of COPD, especially in 
patients with HF in whom the diagnosis of COPD is already complicated and who are 
prone to the adverse effects of pharmacological treatment for COPD. Considering 
the ongoing debate regarding the most appropriate threshold for FEV1/FVC in 
diagnosing COPD, more longitudinal studies are needed to determine which criterion 
is better and clinically more relevant in terms of morbidity (symptoms, exercise 
tolerance, health-related quality of life, exacerbations, hospitalization, pulmonary 
function decline, use of health recourses, systemic effects such as co-morbidities 
and systemic biomarkers) and mortality. The question is whether patients potentially 
misclassified as having COPD (FEV1/FVC < 0.7 but > LLN) actually show clinical 
features that justify a COPD diagnosis or whether they behave more like a healthy 
population. Until a consensus is reached, we prefer the application of statistically 
derived LLN values to avoid overdiagnosis of COPD in the elderly and underdiagnosis 
in younger patients, and advocate a more comprehensive approach, taking into 
account clinical features, the results of extended PFTs, and radiological findings.
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Similarly, little is known about the clinical impact of different criteria of pulmonary 
dysfunction and this therefore requires more longitudinal research. Although we 
found pulmonary function abnormalities to be highly prevalent in patients with CHF, it 
remains unknown, due to lack of follow-up, whether pulmonary function impairment 
had prognostic implications in our study population and whether this has been 
influenced by different definitions of pulmonary dysfunction. Also, more studies 
involving therapeutic approaches to improve pulmonary function in CHF are 
warranted to determine whether treatment directed at correcting pulmonary function 
impairment may lead to symptomatic relief, increased exercise capacity, and 
improvement of the outcome. The clinical usefulness and possible adverse events of 
bronchodilators need to be further established. The results of our retrospective 
observational study regarding the effects of inhaled bronchodilators on pulmonary 
function and dyspnea in patients with CHF (chapter 6) should be confirmed in large 
RCTs in both stable and decompensated conditions of HF and short-term as well as 
long-term treatment and follow-up. Moreover, the effects of salbutamol and 
ipratropium should also be studied separately. In addition, the effects of bronchodi-
lators on other outcomes should be investigated, including quality of life, exercise 
performance, airway resistance, hospitalization, and survival. Furthermore, whether 
the presence or absence of significant BDR in patients with CHF predicts prognostic 
outcome and clinical response to bronchodilators has not been investigated before 
and needs further research. The small improvement in dyspnea after bronchodilation 
was not significantly different between responders or non-responders in our patients 
with CHF. 
Although the underlying mechanisms are not clear, women seemed to be more 
sensitive to the detrimental effects of HF on diffusing capacity. This needs to be 
confirmed and further explored in future studies.  
Finally, since we only included patients with HF-REF, our results cannot be extended 
to patients with HF-PEF and more research is warranted in this group of patients.  
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Samenvatting 
Het doel van dit proefschrift is het verschaffen van meer inzicht in het vóórkomen van 
chronisch obstructieve longziekte (COPD) en longfunctiestoornissen, gebruikmakende 
van verschillende definities, bij patiënten met chronisch hartfalen (CHF). Daarnaast 
was ons streven om onder- en overdiagnostiek van COPD in kaart te brengen en 
de noodzaak te bepalen van het herhalen van longfunctietesten om een correcte 
diagnose van COPD te stellen. Tevens wilden wij mogelijke voorspellers van long-
functiestoornissen bij patiënten met CHF identificeren. Wederom hebben wij hiervoor 
gebruikgemaakt van verschillende definities van longfunctiestoornissen. Tenslotte 
wilden wij het effect van luchtwegverwijdende medicijnen bepalen op de longfunctie 
en kortademigheid bij patiënten met CHF. 
In hoofdstuk 2 bepaalden wij het vóórkomen van COPD alsook de over- en onder-
diagnostiek hiervan volgens de veel gebruikte GOLD definitie bij 187 poliklinische 
patiënten met stabiel CHF. Alle patiënten hadden een verminderde pompfunctie van 
de linker hartkamer zonder aanwijzingen voor longvaatovervulling. Daarnaast 
onderzochten wij of het nodig is om longfunctietesten te herhalen om daarmee een 
correcte diagnose van COPD te kunnen stellen. Hiertoe maakten wij gebruik van een 
initiële alsook een vervolgspirometrie drie maanden na behandeling met tiotropium, 
een luchtwegverwijdend medicijn, bij patiënten met een nieuw gestelde COPD 
diagnose. COPD kwam vaak voor bij patiënten met CHF; het werd gevonden bij 
ongeveer eenderde van de patiënten. Bovendien bleek COPD vaak onder- (19%) of 
juist overgediagnosticeerd (32%) te zijn. Wij concludeerden dat onder stabiele en 
niet-overvulde omstandigheden het niet noodzakelijk is om spirometrie te herhalen 
voor het stellen van een correcte diagnose van COPD, aangezien een nieuw gestelde 
COPD diagnose  gehandhaafd bleef bij de meerderheid van de patiënten met CHF.
In hoofdstuk 3 bepaalden wij het vóórkomen van COPD in dezelfde studiepopulatie 
als beschreven in hoofdstuk 2, waarbij we twee definities van luchtwegvernauwing 
vergeleken: de ‘lower limit of normal’ (LLN) (ATS/ERS richtlijn) en de vaste afkapwaarde 
van het geforceerde expiratoire volume in één seconde ten opzichte van de 
geforceerde vitale capaciteit (FEV1/FVC) < 0.7 (GOLD richtlijn). Wij vonden dat COPD 
substantieel minder vaak voorkwam volgens de LLN dan volgens de vaste 
afkapwaarde; slechts één op de vijf, in plaats van één op de drie, patiënten met CHF 
bleek tevens COPD te hebben. Bovendien bleken patiënten met COPD volgens de 
LLN definitie klinisch meer relevant COPD te hebben dan patiënten met COPD volgens 
de conventionele afkapwaarde. Achtendertig procent van de patiënten met 
GOLD-COPD die mogelijk onterecht bestempeld waren als COPD patiënt (FEV1/FVC 
< 0.7 maar > LLN) verschilden namelijk niet significant van degenen zonder COPD 
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in termen van longklachten en risicofactoren voor COPD, dit in tegenstelling tot 
patiënten met LLN-COPD. 
In hoofdstuk 4 onderzochten wij het vóórkomen van longfunctiestoornissen bij 164 
poliklinische CHF patiënten met een verminderde pompfunctie van de linker 
hartkamer. Hiertoe hebben wij gebruikgemaakt van de LLN versus de conventionele 
afkapwaarden, oftewel FEV1/VC < LLN versus FEV1/FVC < 0.7 voor het definiëren 
van luchtwegvernauwing, diffusiecapaciteit < LLN versus < 80% van voorspeld 
voor het definiëren van verminderde zuurstofopname en totale longcapaciteit 
< LLN versus < 80% van voorspeld voor het definiëren van een kleine longinhoud. 
Wij sloten patiënten uit met bekende aandoeningen aan long, longvlies, zenuw- en 
spierstelsel, bindweefsel en vaten, of andere aandoeningen die de longfunctie konden 
beïnvloeden. Patiënten met een ‘body mass index’ (BMI) boven de 35 werden 
uitgesloten van de analyse naar het vóórkomen van een kleine longinhoud. Long-
functiestoornissen, met name verminderde zuurstofopname en luchtwegvernauwing, 
kwamen vaak voor bij patiënten met CHF. Dit was zelfs het geval gedurende een 
stabiele en niet-overvulde klinische toestand en ondanks het gebruik van de LLN om 
rekening te houden met de gevorderde leeftijd van de patiënten. Echter, zowel een 
verminderde zuurstof- opname alsook luchtwegvernauwing kwamen significant 
minder vaak voor volgens de LLN dan wanneer we gebruikmaakten van de 
conventionele afkapwaarden:  respectievelijk 44% versus 58% en 26% versus 37%. 
In tegenstelling tot eerdere studies werd een kleine longinhoud weinig waargenomen, 
onafhankelijk van de gebruikte definitie, in deze populatie van minder ernstig aangedane 
en hoofdzakelijk stabiele CHF patiënten zonder longvaatovervulling (respectievelijk 7% en 
5%). De conventionele afkapwaarden classificeerden meer patiënten tot het hebben 
van een verminderde zuurstofopname, luchtwegvernauwing, of gecombineerde 
longfunctiestoornis in vergelijking met de LLN. Daarbij waren ze nalatig in het correct 
identificeren van 34% van de patiënten met een normale longfunctie, waardoor deze 
onterecht in de groep met longfunctiestoornissen  geclassificeerd werden. Het gebruik 
van de conventionele afkapwaarden in plaats van de LLN leidde tot misclassificatie 
van 27% van de patiënten.
In hoofdstuk 5 onderzochten wij voorspellers van longfunctiestoornissen volgens 
de LLN in vergelijking met de conventionele afkapwaarden bij 164 poliklinische CHF 
patiënten met een verminderde pompfunctie van de linker hartkamer. Dezelfde uit-
sluitingscriteria als beschreven in hoofdstuk 4 werden gebruikt. De LLN identificeerde 
een extra onafhankelijke voorspeller van verminderde zuurstofopname in vergelijking 
met de 80% voorspelde waarde; naast de BMI, het aantal gerookte pakjaren en het 
longvolume, bleek het vrouwelijk geslacht ook een onafhankelijke voorspeller te zijn 
van verminderde zuurstofopname op basis van de LLN. Het roken van ≥ 10 pakjaren 
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was een significante voorspeller van zowel verminderde zuurstofopname als lucht-
wegvernauwing gebruikmakende van de LLN, maar niet volgens de conventionele 
afkapwaarden. Echter, door het verlagen van de conventionele afkapwaarden om de 
meer strenge LLN te evenaren en hiermee overdiagnostiek van verminderde zuurstof- 
opname en luchtwegvernauwing bij ouderen te voorkomen, werden vergelijkbare 
resultaten verkregen als met de LLN. Lagere longvolumina werden gevonden bij 
patiënten met longvaatovervulling, hartvergroting, en een voorgeschiedenis van 
bypassoperatie aan de kransslagaders. 
Tenslotte evalueerden wij in hoofdstuk 6 retrospectief het effect van luchtwegverwij-
dende medicijnen (gecombineerd 400 μg salbutamol en 80 μg ipratropium bromide) 
op de longfunctie en kortademigheid bij 116 poliklinische CHF patiënten met 
verminderde pompfunctie van de linker hartkamer. Patiënten met een voorgeschie-
denis van COPD of astma werden uitgesloten. De resultaten van onze studie 
bevestigden dat luchtwegverwijdende medicijnen het vermogen hebben om de 
longfunctie bij patiënten met CHF te verbeteren, voornamelijk bij degenen met een 
luchtwegvernauwing. Bij ongeveer 40% van de patiënten met luchtwegvernauwing 
zonder bekend COPD of astma trad een volledig herstel op van de longfunctie na 
toediening van luchtwegverwijdende medicijnen. Alle longfunctionele waarden 
verbeterden significant in de gehele studiepopulatie, met uitzondering van de FVC en 
de inspiratoire capaciteit. Bij 12% werd een aanzienlijke verbetering van de FEV1 
waargenomen (> 200 mL en > 12% van de uitgangswaarde) na toediening van 
luchtwegverwijdende medicijnen. Patiënten met luchtwegvernauwing, zowel 
degenen met als zonder volledig herstel na toediening van luchtwegverwijdende 
medicijnen, vertoonden vaker een aanzienlijke verbetering in FEV1 dan patiënten 
zonder luchtwegvernauwing (respectievelijk 23%, 16% en 2%). Verbetering van 
kortademigheid in rust na luchtwegverwijding was daarentegen klein en bleek niet 
gecorreleerd te zijn met de verbeteringen in longfunctie in deze geselecteerde stu-
diepopulatie. 
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Conclusies
§	COPD is een veelvoorkomende aandoening bij patiënten met stabiel CHF die een 
verminderde pompfunctie van de linker hartkamer hebben zonder aanwijzingen voor 
longvaatovervulling. COPD wordt echter vaak onder- of juist overgediagnosticeerd.
§	Spirometrie dient gebruikt te worden tijdens een stabiele en gerecompenseerde 
klinische toestand om de hoge mate van onderdiagnostiek danwel overdiagnostiek 
van COPD te verminderen bij patiënten met CHF. Onder deze omstandigheden is 
het niet noodzakelijk om spirometrie te herhalen ter bevestiging van de diagnose 
COPD, aangezien dit een nieuw gestelde COPD diagnose niet verandert bij de 
overgrote meerderheid van de patiënten met CHF. 
§	De gebruikte definitie van luchtwegvernauwing verandert de mate van voorkomen 
van COPD substantieel; eenvijfde, in plaats van eenderde, van de patiënten met CHF 
heeft tevens COPD gebruikmakende van de LLN in plaats van de vaste afkapwaarde. 
§	De LLN definitie lijkt patiënten te identificeren met klinisch meer relevant COPD 
dan de vaste afkapwaarde van 0.7. Dit vloeit voort uit de bevinding dat patiënten 
die potentieel onterecht bestempeld zijn als COPD patiënt, in tegenstelling tot 
degenen met LLN-COPD,  niet significant verschillen van degenen zonder COPD 
in termen van longklachten en risicofactoren voor COPD.
§	Longfunctiestoornissen, met name verminderde zuurstofopname en luchtweg-
vernauwing, zijn veelvoorkomend bij patiënten met CHF. 
§	De conventionele afkapwaarden classificeren meer patiënten tot het hebben van 
een verminderde zuurstofopname, luchtwegvernauwing danwel gecombineerde 
longfunctiestoornis in vergelijking met de LLN, hetgeen leidt tot misclassificatie 
van 27% van de patiënten.
§	De LLN identificeert meer voorspellers van verminderde zuurstofopname en lucht-
wegvernauwing dan de conventionele afkapwaarden. Echter, lagere conventionele 
afkapwaarden resulteren in vergelijkbare uitkomsten als de strengere LLN.
§	Luchtwegverwijdende medicijnen zijn mogelijk van toegevoegde waarde bij de 
behandeling van patiënten met CHF in verband met hun vermogen om de 
longfunctie te verbeteren, voornamelijk bij degenen met luchtwegvernauwing. 
Verbetering van kortademigheid daarentegen is klein en niet gecorreleerd met de 
verbeteringen in longfunctie in deze geselecterde studiepopulatie. 
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Toekomstperspectief 
Hoewel dit proefschrift vele vragen heeft beantwoord, zijn er nog meer dan genoeg 
uitdagingen voor toekomstige studies. 
Ondanks de nauwe relatie tussen long- en hartaandoeningen richten longartsen en 
hartspecialisten zich vaak teveel op hun eigen vakgebied.1 Ondertussen blijven 
hartfalen en COPD dikwijls een onderschatte combinatie2 en de mate van besef 
hiervan is laag onder zowel hartspecialisten als longartsen.3 Aangezien het gezamenlijk 
voorkomen van COPD en hartfalen gevolgen kan hebben voor diagnostiek, behandeling 
en prognose van deze patiëntengroep, is zowel meer aandacht in de kliniek vereist 
als meer onderzoek naar de gelijktijdige aanwezigheid van beide ziektes.2 Een meer 
gecombineerde en geïntegreerde aanpak van diagnostiek en behandeling van 
COPD en hartfalen is noodzakelijk. 
Hoewel COPD dikwijls onderschat blijkt te zijn bij patiënten met CHF (hoofdstuk 2 en 3), 
is het onbekend of een additionele diagnose en behandeling van COPD in deze 
 patiëntenpopulatie hun gezondheidsuitkomsten zal verbeteren en de prognose zal 
veranderen. Dit behoeft verder onderzoek om de effectiviteit van het screenen van 
patiënten met CHF op COPD te bepalen in termen van symptoomverlichting en 
verbetering van de gezondheidsuitkomsten alsook de kosteneffectiviteit van een 
dergelijke aanpak. Daarnaast dient toekomstig onderzoek zich te richten op de 
 cardiovasculaire veiligheid van luchtwegverwijdende medicijnen, voornamelijk bij 
patiënten met een onderliggende hartziekte als hartfalen. 
Voorts benadrukken onze bevindingen de noodzaak van een duidelijke definitie van 
COPD, in het bijzonder bij patiënten met hartfalen bij wie de diagnose van COPD 
reeds bemoeilijkt is en die gevoelig zijn voor de bijwerkingen van medicamenteuze 
behandeling van COPD. Gezien de lopende discussie omtrent de meest geschikte 
afkapwaarde voor FEV1/FVC om de diagnose COPD te stellen, zijn meer lange-termijn 
studies nodig om te bepalen welke definitie beter en klinisch meer relevant is in 
termen van mortaliteit en ziektelast (symptomen, inspanningstolerantie, gezond-
heidsgerelateerde kwaliteit van leven, opvlamming van ziekte, ziekenhuisopnames, 
achteruitgang van de longfunctie, gebruik van gezondheidszorg, systemische 
effecten zoals het tegelijk voorkomen van meerdere ziektes en systemische 
biomarkers). De hamvraag is of patiënten die mogelijk onterecht bestempeld zijn als 
COPD patiënt (FEV1/FVC < 0.7 maar > LLN) daadwerkelijk klinische kenmerken 
vertonen die een diagnose van COPD rechtvaardigen of dat ze toch meer gelijkenis 
vertonen met de gezonde populatie. Totdat consensus is bereikt, geven wij de 
voorkeur aan het gebruik van statistisch afgeleide LLN om overdiagnostiek van 
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COPD te vermijden bij de ouderen en onderdiagnostiek bij de jongere patiënten. 
Tevens pleiten wij voor een meer uitgebreide aanpak, rekening houdende met 
klinische kenmerken, resultaten van uitgebreidere longfunctietesten en radiologische 
bevindingen. 
Evenzo is er slechts weinig bekend over de klinische relevantie van verschillende 
definities van longfunctiestoornissen en is dan ook meer longitudinaal onderzoek 
vereist. Ondanks onze bevinding dat longfunctiestoornissen veelvoorkomend zijn bij 
patiënten met CHF, blijft het zonder follow-up onbekend of de aanwezigheid van 
longfunctiestoornissen prognostische gevolgen had in onze studiepopulatie en of dit 
beïnvloed werd door het gebruik van verschillende definities voor longfunctiestoor-
nissen. Tevens zijn meer studies nodig gericht op de vraag of behandeling van long-
functiestoornissen bij hartfalen leidt tot symptoomverlichting, toegenomen inspan-
ningstolerantie en verbetering van de uitkomsten. De klinische toepasbaarheid en 
mogelijke bijwerkingen van luchtwegverwijdende medicijnen dienen verder te worden 
onderzocht. De resultaten van onze retrospectieve observationele studie betreffende 
de effecten van luchtwegverwijdende medicijnen op de longfunctie en kortademigheid 
bij patiënten met CHF (hoofdstuk 6) dienen te worden bevestigd in grote gerando-
miseerde en gecontroleerde studies met zowel stabiele als gedecompenseerde 
hartfalen patiënten alsook kortdurende en langdurige behandeling en follow-up. 
Bovendien dienen de effecten van salbutamol en ipratropium ook apart te worden 
onderzocht. Daarnaast dienen de effecten van luchtwegverwijdende medicijnen op 
andere uitkomstparameters te worden onderzocht, zoals kwaliteit van leven, inspan-
ningstolerantie, luchtwegweerstand, ziekenhuis opnames en overleving. Tevens is 
het onbekend of de aan- of afwezigheid van significante verbetering van de 
longfunctie bij patiënten met CHF voorspellend is voor hun prognose en klinische 
respons op luchtwegverwijdende medicatie. Dit behoeft dan ook verder onderzoek. 
De kleine verbetering in kortademigheid na luchtwegverwijdende medicijnen was 
niet significant verschillend bij onze CHF patiënten met of zonder significante 
verbetering van de longfunctie. 
Ofschoon de onderliggende mechanismen vooralsnog onbekend zijn, bleken vrouwen 
meer vatbaar te zijn voor de nadelige gevolgen van hartfalen op zuurstofopname. 
Dit dient te worden bevestigd en verder toegelicht in toekomstige studies. 
Tenslotte, aangezien we enkel hartfalen patiënten met een verminderde pompfunctie 
hebben onderzocht, zijn onze resultaten niet toepasbaar op hartfalen patiënten met 
een behouden pompfunctie. Meer onderzoek is nodig in deze patiëntengroep.
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List of abbreviations 
A Age
ABHR  Aspecific bronchial hyperreactivity
ACE-I Angiotensin-converting enzyme inhibitor
AF Atrial fibrillation
AO Airway obstruction 
ARB Angiotensin receptor blocker
ATS/ERS American Thoracic Society/European Respiratory Society 
BB Beta-blockers
BDR  Bronchodilator responsiveness  
BMI Body mass index
BNP B-type natriuretic peptide
BOLD Burden of Obstructive Lung Disease
CABG Coronary artery bypass grafting
CAD Coronary artery disease
CHF Chronic heart failure
CMP Cardiomyopathy
CoHF Congestive heart failure
COPD Chronic obstructive pulmonary disease
CRT Cardiac resynchronization therapy
CS Current smokers
CTR Cardiothoracic ratio
D Diffusion impairment
DLCO(c) Diffusion capacity of the lung for carbon monoxide (corrected for hemoglobin concentration)
ECCS European Community for Coal and Steel 
ESC European Society of Cardiology
FEF50 Forced expiratory flow at 50% of forced vital capacity
FEF25-75 Forced expiratory flow at 25-75% of forced vital capacity
FEV1 Forced expiratory volume in 1 second
FEV1/FVC Ratio of forced expiratory volume in 1 second to forced vital capacity 
FRC Functional residual capacity (= ITGV) 
FS Former smokers
FVC Forced vital capacity
GOLD Global Initiative for Chronic Obstructive Lung Disease
H Height
HF Heart failure 
HF-PEF Heart failure with preserved ejection fraction
HF-REF Heart failure with reduced ejection fraction
IC Inspiratory capacity
ICD Implantable cardioverter defibrillator 
ICS/OCS Inhalation/oral corticosteroids
ITGV Intra-thoracic gas volume (= FRC)
KCO(c)   Transfer coefficient for carbon monoxide (corrected for hemoglobin concentration)  
= TLCO(c)/VA
LLN Lower limit of normal 
LVEF Left ventricular ejection fraction 
LVSD Left ventricular systolic dysfunction 
M Months
MLHFQ Minnesota Living with Heart Failure Questionnaire
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MRC Modified Medical Research Council dyspnea scale
NA Not available
NHANES National Health and Nutrition Examination Survey 
No. Number of patients
NS Non-smokers
NT-pro-BNP  N-terminal pro-B natriuretic peptide 
NYHA  New York Heart Association
O Airway obstruction
OLD Obstructive lung disease 
P Prospective
PAP Pulmonary artery pressure 
PCI Percutaneous coronary intervention
PCWP Pulmonary capillary wedge pressure
PEF Peak expiratory flow
PEEP Positive end-expiratory pressure
PFTs Pulmonary function tests
Pre-/post-BD Pre/post-bronchodilator
% Pred. Percent predicted
PY Pack-years 
R Restriction; retrospective (Table 1)
Raw Airway resistance
RCT Randomized controlled trial
RSD Residual standard deviation
RV Residual volume
SD Standard deviation 
SE(E) Standard error (of the estimate)
sGaw Specific airway conductance
SPSS Statistical Package for Social Science
SVC Slow vital capacity
TLC Total lung capacity 
TLCO(c) Transfer factor of the lung for carbon monoxide (corrected for hemoglobin concentration)
TLCOc/VA Transfer coefficient for carbon monoxide (corrected for hemoglobin concentration) = KCOc 
VA Alveolar volume
VC Largest vital capacity
W Weeks
Yr(s) Year(s)
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Dankwoord 
Ik wil een ieder die bijgedragen heeft aan de opzet en uitvoering van mijn promotie- 
onderzoek, danwel de totstandkoming van dit proefschrift ontzettend bedanken. 
Een aantal mensen in het bijzonder.
Allereerst gaat mijn dank en waardering uit naar alle deelnemers die bereid waren om 
deel te nemen aan mijn onderzoek. Zonder hun inzet, enthousiasme en doorzettings-
vermogen om nog één goede longfunctie curve te blazen zou dit proefschrift er niet 
zijn geweest. 
Professor Dekhuijzen, beste Richard, met jouw enorme wetenschappelijke kennis, 
enthousiasme en behoud van overzicht wist je me altijd op de juiste koers te houden 
en hield je van een afstand alles nauwlettend in de gaten. Aan één woord/zin had ik 
genoeg om te weten dat ik op de juiste weg zat. 
Beste Yvonne, voor jouw passie voor het verrichten van wetenschappelijk onderzoek 
heb ik grote bewondering. Jouw inspirerende inbreng was dan ook onmisbaar voor 
mijn proefschrift en ik had je niet als mijn co-promotor willen missen. Binnen no-time 
kreeg ik waardevol commentaar met kritische noten terug op mijn artikelen en kwam 
je steeds weer met goede voorstellen voor nieuwe publicaties. Ondanks de tegen - 
slagen die ik gekend heb, m.n. in de publicatiefase van mijn artikelen, heb je me altijd 
opnieuw weten te motiveren om door te gaan. Je inzet voor promovendi buiten 
werktijd om is mij niet ontgaan en na een werkbezoek bij jou thuis kon ik telkens 
verder met mijn onderzoek en wist ik weer precies wat me te doen stond. 
Beste Frank, het verbreden van onze horizon door het doen van onderzoek naast de 
opleiding heb je altijd gepromoot. Je hebt dan ook alles in het werk gesteld voor de 
mogelijkheid om te kunnen promoveren bij de longgeneeskunde in het Rijnstate 
Ziekenhuis. Allerlei opstartproblemen door tegenwerking van de lokale toetsings-
commissie werden dan ook doeltreffend overwonnen. Tevens wist je naast je drukke 
baan als longarts en opleider wanneer nodig tijd vrij te maken voor mij en interesse 
te tonen; niet alleen op werkgebied, maar ook op privévlak. Jouw oog voor de mens 
achter de promovendus/AIOS siert jou als opleider.    
Beste Petra, jouw praktische manier van aanpak, het reduceren van moeilijke 
problemen tot iets makkelijks en alle tips en trucs betreffende het opstarten van een 
onderzoek hebben mij enorm geholpen. Je wist me te doen focussen op wat belangrijk 
was voor mijn onderzoek en te behoeden voor het afdwalen van het hoofddoel. Ook 
heb je me gewezen op goed time-management, waar ik de rest van mijn onderzoek 
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profijt van heb gehad. Jouw verhalen over de combinatie van werk en moederschap 
heb ik voor altijd in mijn hart gesloten en ik hoop een even betrokken en toegewijde 
moeder te worden als jij!
Beste Frank, hartelijk dank voor jouw bijdrage aan dit proefschift vanuit cardiologisch 
oogpunt. Samen hebben wij een degelijke definitie voor stabiel chronisch hartfalen 
kunnen opstellen, iets wat nog steeds niet makkelijk is naar ik begreep. Dank voor 
jouw steun gedurende mijn onderzoek, jouw vertrouwen in een goede afloop en 
uiteraard voor de financiële bijdrage vanuit de maatschap cardiologie. 
Beste Paul, het openzetten van de deuren voor mijn onderzoek van de destijds nog 
aparte cardiologie maatschap in Zevenaar heeft mij enorm geholpen in het vergroten 
van mijn populatie. Het werken in Zevenaar heb ik als zeer prettig ervaren en iedereen 
was altijd bereid om mij daar goed verder te helpen. Hartelijk dank ook voor het 
meebeoordelen van de moeilijk te interpreteren echo’s.   
Beste professor Quanjer, hartelijk dank voor de tijd en moeite die u genomen heeft 
om één van mijn artikelen te reviewen. Ik heb genoten en veel geleerd van onze 
e-mailwisselingen betreffende de LLN t.o.v. de conventionele afkapwaarden. Ik heb 
veel gehad aan uw advies om het vooral kort en simpel te houden, of zoals u het zelf 
zo mooi formuleerde met een Duits spreekwoord; “In der Beschränkung zeigt sich 
der Meister”.
Leden van de manuscriptcommissie, prof. de Boer, prof. Wouters en prof. Assendelft, 
hartelijk dank voor de nauwkeurige beoordeling van dit proefschrift en de goedkeuring 
ervan.
Mijn dank gaat tevens uit naar GlaxoSmithKline voor het verstrekken van een onvoor-
waardelijke opleidingssubsidie die de onderzoeken van dit proefschrift mogelijk 
hebben gemaakt. 
Patricia, Wim, Will en Joke, hartelijk dank voor jullie bijdrage aan de inclusie van de 
proefpersonen en de dataverzameling. Ik vond de samenwerking met jullie erg 
plezierig en stel jullie belangstelling en inzet voor wetenschappelijk onderzoek naast 
de drukke poli’s zeer op prijs.  
Longfunctie-laboranten, hartelijk dank voor al jullie hulp bij het afnemen van de long-
functietesten en het mij aanleren om zelf betrouwbare longfunctietesten af te nemen. 
Mark, Martijn (helaas niet meer in het Rijnstate Ziekenhuis werkzaam), Hans en 
Maurice, hartelijk dank voor het aanmaken van een persoonlijke longfunctie uitdraai 
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en het feit dat ik altijd bij jullie terecht kon voor de wat moeilijkere vragen over 
longfunctie. 
Alle echocardiografie laboranten, in het bijzonder Bob, Paul, Wim, Erik, en Maarten, 
hartelijk dank voor het verrichten van de echocardiografieën en alle uitleg en hulp die 
ik van jullie heb gehad. 
Annet, dank voor al je inspanningen en ‘geregel’ tijdens mijn onderzoek en nu ook 
tijdens mijn opleiding tot longarts. Je bent onmisbaar voor de afdeling longgenees-
kunde! Zonder jouw handige adresstickers en meer van dat soort handigheidjes had 
de ‘administratieve rompslomp’ van mijn onderzoek mij veel kostbare tijd gekost. Je 
oprechte belangstelling in mij als persoon en jouw luisterend oor betreffende mijn 
zwangerschap heb ik zeer gewaardeerd.
Maatschap longartsen te Arnhem, hartelijk dank voor de mogelijkheid om dit onderzoek 
te verrichten op jullie afdeling. Dank ook voor alle adviezen en het meedenken tijdens 
mijn praatjes. Jullie interesse in mijn onderzoek en de totstandkoming van dit 
proefschrift heb ik zeer gewaardeerd en dit motiveerde mij om door te zetten. Ik hoop 
in de toekomst nog veel van jullie te mogen leren. Toby, mijn mentor, dank voor al je 
adviezen en persoonlijke verhalen over jouw eigen promotietraject. Daar heb ik veel 
aan gehad. 
Mijn collega-AIOS en ANIOS, waarvan ik ondertussen meerdere heb zien komen en 
gaan, dank voor al jullie hulp, belangstelling, en op momenten oprechte bezorgdheid 
en medeleven (‘ben je nu alweer hier voor je onderzoek?’). Ook tijdens mijn onderzoek 
maakte ik deel uit van jullie gezellige groep en voelde ik me daardoor niet alleen, 
ondanks het feit dat ik de enige promovendus was. Gerben, dank voor al je hulp, 
adviezen en motiverende verhalen. Vaak heb je me een hart onder de riem moeten 
steken, dat heb ik enorm gewaardeerd. Safir, ik geef de wijsheid door aan jou: 
volhouden, uiteindelijk komt alles goed! 
Natasha en Monique, ik ben er trots op en heel blij dat jullie vandaag mijn paranifmen zijn. 
Natasha, onze vriendschap gaat veel verder terug dan vandaag en door al die jaren 
ben je er altijd voor mij geweest, zo ook vandaag. Mijn vriendschap met jou heeft mijn 
verhuizing naar en verblijf in Arnhem een stuk aangenamer gemaakt. Ook al zien wij 
elkaar helaas minder dan voorheen door de combinatie van werk en gezin, hebben 
wij net zoveel plezier tijdens onze ‘meiden uitjes’. Ik hoop dat we elkaar nooit uit het 
oog zullen verliezen.
Monique, voor mij ben je een voorbeeld van een menselijke, hardwerkende dokter en 
onderzoekster met een eindeloos doorzettingsvermogen. Hoe jij een zeven daagse 
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werkweek in Boston hebt volgehouden gedurende een half jaar is mij nog steeds een 
raadsel. Jouw drive om je promotietraject tot een goed einde te brengen, en de op - 
offeringen die je daarvoor over had, hebben mij gestimuleerd om ook mijn onderzoek 
succesvol af te ronden. 
Lieve vrienden en vriendinnen, bedankt voor jullie belangstelling, luisterend oor en 
bemoedigende woorden, maar bovenal voor de gezellige tijd die we samen hebben 
doorgebracht en nog zullen doorbrengen. Onze gezellige uitjes en gesprekken waren 
voor mij altijd een welkome afwisseling en maakten dat ik het e.e.a. beter kon relativeren. 
Hoe belangrijk en relevant ook; er is meer in het leven dan werk en onderzoek. 
Lieve Paul en Ellie, mijn schoonouders, bedankt voor jullie steun en belangstellling. 
Jullie staan altijd voor ons klaar met goede raad en hulp waar nodig. Dank voor jullie 
inzet in de opvoeding van Daniël. Ik had mij geen betere schoonouders kunnen 
wensen!
Lieve pap en mam, zonder jullie dappere zoektocht naar een betere toekomst elders, 
was ik nu überhaupt niet in Nederland geweest en stond ik vandaag niet te promoveren. 
Al jullie wijze adviezen heb ik voor altijd in mijn hart gesloten en ik ben door jullie de 
persoon geworden die ik nu ben. Van jullie heb ik geleerd om door te zetten, het beste 
uit mezelf te halen, te streven naar meer, maar ook tevreden te zijn met wat ik heb. 
Jullie wijze raad zal ik op mijn beurt doorgeven aan mijn eigen kinderen. Dank voor 
jullie steun, onvoorwaardelijke liefde en geloof in mij. Ik houd van jullie. 
Lieve Paul, mijn broer, het is bewonderenswaardig hoe jij, door jouw eeuwige nieuws-
gierigheid, altijd streeft naar het vergaren van meer kennis. Zoals ze zeggen, kennis 
is macht. Ook jij hebt je moeten bewijzen en boven jezelf moeten uitstijgen. Jouw 
masteropleiding en werkjaren in Londen, verwijderd van alles en iedereen, hebben je 
veel gebracht en je verder gevormd. Daar pluk je nu de vruchten van. Ik ben jaloers 
op je gemak waarmee jij aan nieuwe hoofdstukken in je leven begint en ik ben er trots 
op jouw zus te mogen zijn.      
Lieve Erik, mijn lieve man, mijn grote liefde, de vader van mijn kind, mijn maatje, mijn 
steun en toeverlaat, mijn klaagmuur, mijn held, mijn Excel expert….kortom mijn alles. 
Dank voor al je bemoedigende woorden om door te gaan, je relativeringsvermogen 
als ik het weer eens niet zag zitten, je eindeloze geduld, en je geloof en vertrouwen in 
mij en een goede afloop van dit traject. Het ‘hobbyen’ naast mijn werk is eindelijk 
afgelopen en ik hoop vanaf nu meer tijd met jou en Daniël te kunnen doorbrengen. 
Ik kan het niet vaak genoeg zeggen: es qez sirumem (oftewel ik houd van jou)!  
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Lieve Daniël, mijn allerliefste en langverwachte schat, jouw geboorte was mijn deadline 
en ‘schop-onder-de-kont’. Ik wil namelijk zoveel mogelijk tijd met jou doorbrengen. 
Ik ben heel gelukkig en trots om jouw mamma te mogen zijn. Sommige dromen 
komen dan toch echt uit! 

217
Curriculum Vitae
9
Curriculum Vitae
The author of this thesis was born on 6 July of 1983 in Yerevan, Armenia. At the age 
of 11 she emigrated with her family to The Netherlands, where she graduated from 
high school (Gymnasium Trevianum, Sittard) in 2002 cum laude. From 2002 until 
2008 she studied Medicine at the University of Maastricht with a cum laude result. 
During her Medicine study she worked as ‘student-assistant’ at the department of 
Anatomy and Embryology and she got familiar with the health care system at Malta 
(department of pulmonology, St. Luke’s Hospital). Her first research experience at 
the department of Pulmonology of Maastricht University Medical Centre under 
supervision of Prof. Dr. G. Wesseling resulted in the writing of an abstract called 
‘Psychological Functioning and Quality of Life of Cystic Fibrosis Adults and Adolescents’ 
that was presented at the 22nd Annual North American CF Conference in Orlando, 
FL., in 2008. After a short clinical experience of 3 months as an internal resident at the 
department of Pulmonology of Deventer Hospital, she started her PhD research in 
October of 2008 at the department of Pulmonology of Rijnstate Hospital in Arnhem, 
which resulted in this thesis. Hereafter she started her specialist training to become a 
pulmonologist, which consists of two years Internal Medicine (2012-2013, Rijnstate 
Hospital, Dr. Mattijssen) and four years of Pulmonology (2014-2017, Rijnstate Hospital, 
Dr. Van den Elshout). 
She is married to Erik and they have 1 son (Daniël).

1. COPD komt vaak voor bij patiënten met hartfalen, maar wordt vaak onder- of juist 
overgediagnosticeerd (dit proefschrift).
2. Verminderde zuurstofopname en luchtwegvernauwing, in tegenstelling tot een 
kleine longinhoud, zijn veelvoorkomende longfunctiestoornissen bij patiënten 
met chronisch hartfalen (dit proefschrift).
3. Het definiëren van een veelvoorkomend wereldwijd probleem zoals COPD is nog 
niet zo makkelijk (dit proefschrift).
4. Het gebruik van de ‘lower limit of normal’ in plaats van de conventionele afkap - 
waarden leidt tot het diagnosticeren van minder COPD en andere longfunctie-
stoornissen bij oudere patiënten met hartfalen (dit proefschrift).
5. Bij patiënten met hartfalen dienen longfunctietesten onder stabiele en gerecom-
penseerde omstandigheden plaats te vinden; onder die omstandigheden hoeft 
spirometrie over het algemeen niet herhaald te worden om de diagnose van 
COPD te ondersteunen (dit proefschrift).
6. Luchtwegverwijdende medicijnen kunnen van toegevoegde waarde zijn bij de 
behandeling van patiënten met hartfalen (dit proefschrift).
7. Life is not measured by the number of breaths we take, but by the moments that 
take our breath away (Vicki Corona, 1989).
8. Als je met een ernstig probleem geconfronteerd wordt, denk dan zeer goed na. 
Is er een oplossing, dan heeft het geen zin u op te winden. Is er geen oplossing, 
dan heeft het geen nut u op te winden (Dalai Lama).
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van het proefschrift 
COPD
and pulmonary function
in heart failure:
a matter of definition
op donderdag 8 oktober 2015 
om 12.30 precies in de aula van 
de Radboud Universiteit Nijmegen
Comeniuslaan 2 te Nijmegen.
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bij deze plechtigheid en de  
aansluitende receptie ter plaatse.
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Patiënten met chronisch hartfalen worden vaak 
beperkt in hun dagelijkse activiteiten door kortade­
mig heid en een verminderd inspanningsvermogen. 
Een deel van deze klachten kan echter ook het gevolg 
zijn van een bijkomende longaandoening, zoals 
chronisch obstructieve longziekte (COPD). Ook 
kunnen andere longfunctiestoornissen bijdragen aan 
de beperkingen die deze groep patiënten ervaart. 
In dit proefschrift beschrijft Armine Minasian hoe 
vaak COPD en longfunctiestoornissen nu eigenlijk 
voorkomen bij patiënten met chronisch hartfalen 
waarbij ze verschillende definities van COPD en 
longfunctiestoornissen met elkaar vergelijkt. Ook 
een aantal andere belangrijke vraagstukken komen 
aan bod. Wordt de diagnose COPD wel correct 
gesteld en is het noodzakelijk om hiervoor long­
functietesten te herhalen? Wat zijn voorspellers 
van longfunctiestoornissen en heeft de gebruikte 
 definitie van deze stoornissen daarop invloed? Zijn 
patiënten met chronisch hartfalen gebaat bij het 
inhaleren van luchtwegverwijdende medicijnen? 
De auteur hoopt met dit proefschrift meer aan­
dacht te vestigen op de gelijktijdige aanwezigheid 
van zowel long­ als hartaandoeningen en pleit voor 
een meer geïntegreerde aanpak van diagnostiek 
en behandeling van COPD en hartfalen.
Armine Minasian (1983) is geboren in Armenië en 
verblijft sinds haar elfde in Nederland. Ze is sinds 
2012 in opleiding tot longarts in het Rijnstate 
 ziekenhuis te Arnhem.
